curriculum vitae - a.i.l.m.a.g · 2017-08-22 · curriculum vitae date prepared: march 27, 2017...

Curriculum Vitae

Date Prepared: March 27, 2017 Name: Soldano Ferrone, M.D., Ph.D. Office Address: Massachusetts General Hospital Department of Surgery Harvard Medical School 55 Fruit Street Boston, MA 02114 Home Address: 37 Chestnut Street Boston, MA 02108 Work Phone: (617)-726-6087 Work E-mail: [email protected] Work FAX: (617) 726-8623 Place of Birth: Bella, Italy Education:

Year Degree Fields of Study Institution

1958 1964 1971

Maturita’ Classica M.D., summa cum laude Privat Dozent (Ph.D. equivalent)

Latin, Greek Medicine Hematology

Liceo Berchet, Milan University of Milan University of Milan

Postdoctoral Training:

mailto:ferrone@partners.

Year(s) Title Specialty/Discipline Institution

07/64 – 06/65 Research Fellow Medicine University of Milan

Faculty Academic Appointments:

Year(s) Academic Title Department Academic Institution

07/65 – 11/71 02/71 – 01/72 02/72 – 06/76 11/75 – 10/78 07/76 – 11/81 07/80 – 11/81 12/81 – 10/83 11/83 – 05/99 06/99 – 06/06 07/06 – 08/07 06/99 – 08/07 09/07 – 09/10 09/07 – 10/12 11/12-10-14 11/14-present 08/13-present

Assistant Professor Research Associate Assistant Professor Adjunct Professor Associate Professor (with tenure) Adjunct Associate Professor Professor Professor (with tenure) & Chairman Professor Member (with tenure) & Chairman Member Professor Associate Director Professor (with tenure) Lecturer Professor in Residence Member

Medicine Experimental Pathology Molecular Immunology Immunology Molecular Immunology Pathology Pathology & Surgery Microbiology & Immunology Dermatology, Medicine & Pathology Immunology Immunology Microbiology Mentoring of Junior Faculty Surgery, Immunology, & Pathology Surgery & Orthopedics Surgery & Orthopedics Cancer Center

University of Milan, Milan, Italy Scripps Clinic & Research Foundation, La Jolla, CA Scripps Clinic & Research Foundation, La Jolla, CA University of Padua, Padua, Italy Scripps Clinic & Research Foundation, La Jolla, CA University of California, San Diego, CA Columbia University, New York, NY New York Medical College, Valhalla, NY Roswell Park Cancer Institute, Buffalo, NY Roswell Park Cancer Institute, Buffalo, NY SUNY at Buffalo, Buffalo, NY University of Pittsburgh, Pittsburgh PA University of Pittsburgh, Pittsburgh, PA Massachusetts General Hospital; Harvard Medical School, Boston, MA Massachusetts General Hospital; Harvard Medical School, Boston, MA Massachusetts General Hospital,

Boston, MA

Committee Service:

Year(s) of Membership Name of Committee Institution/Organization

2001 – 2003 M.D., Ph.D. Student Admission Committee SUNY at Buffalo, Buffalo, NY

Professional Societies:

Year(s) of Membership Society Name Title of Roles

1973 – present 1973 – present 1973 – 1985

American Association of Immunologists The American Association for Cancer Research The Transplantation Society

Member Member Member

Grant Review Activities:

Year(s) of Membership Name of Committee Institution/Organization

Dates of Role(s) Title of Role(s)

1979-1982 1984-1999 1994-1998 1999-2002 1999-2003 2002-2006 2002-Present 2005 2002, 2003, 2005 2004-2005 2003-2007

Merit Review Board for Immunology 1979-1982 Fellowship Review Committee 1984-1999 Experimental Immunology Study Section 1994-1998 Branch Oversight Committee 1999-2002 Subcommittee F (Manpower & Training) 1999-2003 Merit Review Committee 2002-2006 Scientific Review Panel 2002-2009 Breast Cancer Immunological Sciences Panel 2005 Prostate Cancer Immunological Sciences Panel 2002, 2003, 2005 Cancer Biomarkers Study Section 2004-2005 Subcommittee D – Clinical Studies 2003-2007

Veterans Administration Member New York Medical College Member NIH Member Biological Resources, NCI Member NCI (Initial Review Group) Member Department of Veterans Affairs Member State of New Jersey Commission on Cancer Research Member Congressionally directed Medical Research Program Member Congressionally directed Medical Research Program Member NIH Member National Cancer Institute Member

2007-present 2009-2011 2011-2012

Special Emphasis Panel 2007-present Subcommittee I – Career Development 2009-2011 Subcommittee I – Career Development 2011-2012

National Cancer Institute Ad Hoc Reviewer National Cancer Institute Member National Cancer Institute Ad Hoc Reviewer

Advisory Boards:

Year(s) Role Board name

2001-2003

2009-present

2011-2015 2012-present 2012-present

Member

Member

Member

Member

Member

Scientific Advisory Board, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas External Scientific Advisory Board for the Program Project Grant “Biology and Therapy of High Risk Neuroblastoma”, directed by Dr. R.C. Seeger at the Children’s Hospital Los Angeles Saban Research Institute External Scientific Advisory Board for the Program Project Grant “PCR Gene Modified T Cells for Adoptive Immunotherapy”, directed by Dr. Michael Nishimura at Loyola University Medical Center, Maywood, Illinois External Scientific Advisory Board for the Program Project Grant “Innate Immunity”, directed by Dr. Michael Caligiuri at Ohio State University, Columbus , Ohio Scientific Advisory Board for the “ Antibodies for cancer therapy” conference, Cambridge Healthtech Institute, Needham, Massachusetts

Editorial Activities:

Ad Hoc Reviewer

Journal of Clinical Investigation Journal of Clinical Oncology Nature Biotechnology New England Journal of Medicine Science Translational Medicine

Other Editorial Roles

Year(s) Role Journal Name

1981-1984; 2000-Present 2001-2003; 2010-Present 2004-Present 2002-Present 2001-Present 2005-Present 2010-Present 2005-Present

Member Associate Editor Associate Editor Associate Editor

Member Member

Editorial Board Member

Cancer Immunology and Immunotherapy Cancer Research Cancer Science Clinical Cancer Research Contemporary Oncology Current Cancer Therapy Reviews Frontiers in B Cell Biology Expert Review of Dermatology

2011-Present 2011-Present 2007-Present 1994-Present 2001-Present 1981-1995 2011-Present 2010-Present 1991-1998 1986-2004 1987-Present 1987 1982-1986 1996-2003 1980-1983; 1999-2003 1997-Present 2012-Present 1992-Present 2010-Present 2003-2012 2012-Present 1991-1995 1996-Present 1981-1993 2012-Present 1986-1994 1993-Present 1991-Present 1992-Present 2010-Present

Member Member Member Member Member Member Member

Regional Editor Member Member Member Member Member

Associate Editor Member Member Member Member Member

Deputy Editor Senior Editor

Member Associate Editor

Member Member Member Member Member Member Member

Frontiers in Cancer Molecular Targets and Therapeutics Frontiers in Immunotherapies and Vaccines Human Immunology Hybridoma and Hybridomics Immunological Investigations Immunopharmacology ImmunoTargets and Therapy Inflammation and Allergy International Journal of Clinical and Laboratory Research International Journal of Immunotherapy In Vivo Journal of Clinical and Laboratory Analysis Journal of Experimental and Clinical Cancer Research Journal of Experimental and Clinical Cancer Research Journal of Immunology Journal of Immunotherapy Journal of Immune Based Therapies, Vaccines and Antimicrobials Journal of the National Cancer Institute Journal of Stem Cell Research & Therapy Journal of Translational Medicine Journal of Translational Medicine Melanoma Research Melanoma Research Monoclonal Antibody News Open Journal of Immunology The International Journal of Biological Markers The International Journal of Oncology Tissue Antigens Vaccine Research Vaccines & Vaccination

Honors and Prizes:

Year Name of Honor/Prize Awarding Organization Achievement for which awarded

1959-1963 1959 1965 1966 1967 1968 1969 1970 1971 1974-1976 1976-1981 1985 1986

Tuition Scholarship Scholarship National Brigatti Award National Piccinini Award National Luigi Mangiagalli Award Butturini Award European Ganassini Award Research award Research award Senior Fellowship #D-221 Established Investigator Award, 76-102 Guest Professor, Department of Genetics Cabrini Gold Medal Award

University of Milan University of Milan University of Milan University of Milan University of Milan University of Milan Ganassini Foundation Italian Research Council Istituto di Medicina Sociale American Cancer Society - California Division American Heart Association University of Giessen, Giessen, Germany

Research in hematology Research in immunohematology Research in hematology Outstanding research in lymphocyte biology Research on autoimmune hemolytic anemias Continuation of studies on human transplantation antigens Research on lymphocytotoxic antibodies in parous women

http://sm1.mailserv.in/omicsonlineorg/lt.php?id=eB8GUgEYUgNRV0kGBlVXBwNIBFwURV1fAUNwExJZUk9VB0Y%3D

1987 1987-1988 1988 1988 1992 1992-1993 1994 1994-1995 1995 1995-1996 1997 1997-2002 2010 2011 2012

Visiting Professor, Department of Oncology Elected to Faculty of the Year Alexander Von Humboldt Award & Senior Distinguished US Scientist Award, Germany Medical Education and Health Service Award Leonard S. Zombek, M.D. Memorial Lectureship of the Pittsburgh Cancer Institute Visiting Professor, Department of Anatomy Westchester Chemical Society Distinguished Scientist Award Visiting Professor, Department of Anatomy Visiting Professor, Department of Dermatology Visiting Professor, Department of Anatomy Alexander Von Humboldt Award & Senior Distinguished U.S. Scientist Award Chairman, HLA and Cancer Component Pitt Innovator Award Pitt Innovator Award Pitt Innovator Award

University of Reggio Calabria, Catanzaro, Italy AOA The Westchester Chapter of the American Committee on Italian Migration University of Pittsburgh, Pittsburgh, PA University G D'Annunzio, Chieti, Italy University of Bologna, Bologna, Italy Shinshu University, Matsumoto, Japan University of Bologna, Bologna, Italy Germany 13th International Histocompatibility Workshop University of Pittsburgh, Pittsburgh PA University of Pittsburgh, Pittsburgh PA University of Pittsburgh, Pittsburgh PA

Report of Local Teaching and Training:

Year(s) Course Title Location

1975-1978 1980 1984-1999 1988-1998 1988-1998 1988-1998 1999-2003 2000-2007 2009-2012

Immunology, 3rd year medical students Experimental Pathology, PhD graduate students Microbiology, 2nd year medical students Advanced Immunology, PhD graduate students Monoclonal Antibodies in Oncology, PhD graduate students Adhesion Molecules, PhD graduate students Medical Microbiology, 2nd year medical students Advanced Immunology, PhD graduate students Immunology and Human Disease, PhD graduate students

University of Padua; Padua, Italy UCSD; San Diego, CA New York Medical College; Valhalla, NY New York Medical College; Valhalla, NY New York Medical College; Valhalla, NY New York Medical College; Valhalla, NY SUNY at Buffalo; Buffalo, NY Roswell Park Cancer Institute; Buffalo, NY University of Pittsburgh; Pittsburgh, PA

Former Supervised Trainees and Faculty:

Year(s) Name and Degrees / Current Position

1976-1980 1977-1980 1977-1982 1982-1986 1983-1987 1987-1991 1989-1991 1989-1997 1990-1996 1991-1996 1999-2001 1999-2007 2000-2003 2000-2004 2002-2004 2002-2006 2000-2007 2002-2007 2003-2007 2004-2006 2005-2006 2005-2007

V. Quaranta, M.D., Professor of Cancer Biology, Vanderbilt University Medical Center – Nashville, TN K. Imai, M.D., Ph.D., President, Sapporo University – Sapporo, Japan C. Russo, M.D., Vice President, GSK – Philadelphia, PA M. Maio, M.D., Professor and Chairman, Department of Oncology, Medical School, University of Siena – Siena, Italy F. Perosa, M.D., Ph.D., Professor and Chairman, Department of Clinical Immunology, Medical School, University of Bari – Bari, Italy E. Armandola, Ph.D., Assistant Professor, Department of Molecular Immunology, German Cancer Research Center – Heidelberg, Germany S. Mariani, M.D., Associate Editor, Nature Medicine L. Li, M.D., Postdoctoral Fellow, Massachusetts General Hospital – Boston, MA Z. Wang, M.D., Assistant Professor, Harvard Medical School – Boston, MA D. Hicklin, B.S., Director of Immunology, ImClone Systems, Inc. – New York, NY S.Y. Hur, M.S., M.D., Instructor, Catholic University Medical College – Seoul, Korea W. Luo, Ph.D., Affiliate Member of Pharmacology, RPCI – Buffalo, NY T. Ogino, Ph.D., Associate Professor, Asahikawa Medical College – Asahikawa, Japan M. Campoli, M.D., Ph.D., Resident, University of Colorado Health Sciences – Denver, CO N. Bandoh, Ph.D., Instructor, Asahikawa Medical College – Asahikawa, Japan L. Peng, Research Associate, Cleveland Clinic – Cleveland, OH C.Y. Tsao, Ph.D., Postdoctoral Associate, Duke University – Durham, NC C.F. Hsu, Ph.D., Intramural Training Award for Postdoctoral Fellow, National Institutes of Health E. Ko, M.D., Ph.D., Transitional Intern, Christiana Care Health System – Newark, DE C.C. Chang, Ph.D., Assistant Professor, Institute of Molecular and Cellular Biology, National Tsing Hua University – Hsinchu, Taiwan G. Sconocchia, M.D., Assistant Professor, University of Rome Torvergata– Rome, Italy A. Katayama, Ph.D., Assistant Professor, Department of Otolaryngology, Asahikawa Medical College – Asahikawa, Japan

2005-2007 2007-2009 2008-2009 2008-2010 2007-2010 2006-2010 2008-2011 2010-2011

T. Tsuchikawa, M.D., Assistant Professor, Department of Surgery, Hokkaido University – Sapporo, Japan X. Liu, Ph.D., Professor, School of Basic Medical Sciences, Guangdong Pharmaceutical University – Guangzhou, Guangdong, China P. Miyazato, Ph.D., Postdoctoral Fellow, Kyoto University Institute for Virus Research – Kyoto, Japan K. Sakakura, M.D., Ph.D., Head, Department of Otolaryngology, National Hospital Organization, Shizuoka Medical Center – Shizuoka, Japan S.H. Yoo, Ph.D., Senior Scientific Officer, Advanced Therapy Products Research, Korea Food and Drug Administration - Chungcheongbuk-do, Korea Y. Koya, Ph.D., Team Leader/Director, Bio-databases Institute of Reproductive and Developmental Medicine – Nagoya, Japan E. Favoino, Ph.D., Research Associate, University of Bari – Bari, Italy M. Michalak, M.D., Ph.D., Surgeon, Asistant Professor, Poznan University of Medical Sciences – Polna, Czech Republic.

Current Supervised Trainees and Faculty:

Year(s) Name and Degrees / Current Position

2007-present 2011-present

Y. Wang, M.D., Postdoctoral Research Fellow, Massachusetts General Hospital and Harvard Medical School – Boston, MA F. Sabbatino, M.D., Ph.D., Postdoctoral Research Fellow, Massachusetts General Hospital and Harvard Medical School – Boston, MA

National and International Invited Presentations: Dr. Ferrone has lectured extensively on a variety of topics including the role of immunoesccape mechanisms in malignant diseases and immunotherapy of cancer at many prominent Institutions. These include Johns Hopkins University, Baltimore, MD, Scripps Research Institute, LaJolla, CA, University of California, San Francisco, CA and Sloan Kettering Cancer Institute, New York, NY, in this country and Karolinska Institute, Stockholm Sweden, University of Bonn, Bonn, Germany, University of Mainz, Mainz, Germany, University of Marburg, Marburg, Germany, Martin Luther University Halle-Wittenberg, Halle, Germany, University of Naples, Naples, Italy, Univesity of Turin, Turin, Italy, and University of Zurich, Zurich, Switzerland abroad, to name a few. In addition, he has been a Visiting Professor at the following Institutions, Department of Genetics, University of Giessen, Giessen, Germany, Visiting Professor, Department of Oncology, Medical School, University of Reggio Calabria, Catanzaro, Italy; Department of Anatomy, Medical School, University G D'Annunzio, Chieti, Italy; Department of Anatomy, Medical School, University of Bologna, Bologna, Italy, and University of Rome Torvergata, Rome, Italy. GRANTS Current

Title of Grant “Strategies to counteract resistance mechanisms in CAR + T Cell-Based Immunotherapy” Grant ID W81XWH-16-1-0500

Role PI

Supporting Agency Department of Defense

09/1/2016 - 08/31/2019

Description (Include the goals and specific aims of the project) This project is to optimize immunotherapy of triple negative (TNBC) with CSPG4-specific CAR T cells utilizing strategies which counteract the escape utilized by TNBC cells.

Title of Grant “HSP based combinatorial immunotherapy in triple negative breast cancer” Grant ID 1 R03 CA175957

Role PI

Supporting Agency NIH (NCI)

07/01/14-06/30/17 Description (Include the goals and specific aims of the project) This proposal will test the novel hypothesis that combinatorial immunotherapy with the Grp94-specific mAb W9 and the Sonic Hedgehog pathway inhibitor LDE225 is effective in eradicating triple negative breast cancer. The validity of this hypothesis will be tested utilizing immunodeficient mice orthotopically grafted with surgically removed human triple negative breast cancer tumors.

Past I have been continuously funded by NIH since 1975. In addition, I have been awarded grants by the DOD, ACS, and Juvenile Diabetes Foundation. As an example, I am listing some of the grants I have been awarded in the past.

Title of Grant “Antigen processing and HLA-peptide complexes in head and neck cancer” Grant ID RO1 CA110249

Role PI


Performance Period 05/01/06 – 09/30/14

Description (Include the goals and specific aims of the project) This project aims to test the hypothesis that lack of recognition of squamous cell carcinomas of head and neck (SCCHN) cells by HLA class I antigen restricted, tumor antigen (TA)-specific CTL, in spite of detectable expression of the restricting HLA class I allele and of the target TA, reflects defects in HLA class I allele-TA derived peptide complex.

Title of Grant “Combinatorial targeting of melanoma initiating cells” Grant ID RO1 CA138188

Role PI


Performance Period 09/08/08-07/31/15

Description (Include the goals and specific aims of the project) The goal of this proposal is to test the novel concept that targeting melanoma cells with stem cell-like properties, i.e., malignant melanoma initiating cells (MMIC), and tumor-associated pericytes with a combinatorial immunotherapy is an effective treatment for melanoma. The combinatorial therapy consists of antibody- and T cell-based immunotherapy and continuous administration of low dose cyclophosphamide (CTX), i.e., metronomic chemotherapy.

Title of Grant “Grp94 targeted therapy for pancreatic ductal adenocarcinoma”

Grant ID R21 CA164756

Role PI



Description (Include the goals and specific aims of the project) This project aims to develop a combinatorial immunotherapy of pancreatic ductal adenocarcinoma with the Grp94-specific mAb W9, the Sonic Hedgehog pathway inhibitor LDE225 and 5-FU. The therapeutic efficacy of this strategy will be tested utilizing immunodeficient mice orthotopically grafted with surgically removed human pancreatic ductal adenocarcinoma cells.

Title of Grant “Therapy of pancreatic cancer with 212Pb-labeled B7-H3 specific Ab and LDE225” Grant ID 1R21CA173120

Role Co-PI



Description (Include the goals and specific aims of the project) This proposal will test the novel hypothesis that pancreatic cancer can be eradicated by targeting not only differentiated/differentiating pancreatic cancer cells, which form the bulk of the tumor, but also pancreatic cancer initiating cells (CICs), the root of the disease, with 212Pb conjugated to the B7-H3-specific mAb 376.96, in combination with LDE225, an inhibitor of Sonic Hedgehog pathway. The validity of this hypothesis will be tested utilizing immunodeficient mice orthotopically grafted with surgically removed human pancreatic ductal adenocarcinoma cells.

Title of Grant “SPORE in Skin Cancer” Grant ID P50 CA121973-06

Role Co-leader Project 3



Description (Include the goals and specific aims of the project) This proposal will test the hypothesis that combinatorial therapy with BRAF inhibitor and with IFNa is more effective than the individual agents in the treatment of malignant melanoma with BRAF mutations. The improved therapeutic efficacy of the proposed combinatorial strategy is believed to reflect an increased sensitivity of melanoma cells to the immunomodulatory properties of IFNa.

Title of Grant “Targeting cancer initiating cells with CSPG4-specific mAbs in chordoma” Grant ID

Role PI

Supporting Agency Chordoma Foundation

Performance Period 07/01/13 -- 06/30/14

Description (Include the goals and specific aims of the project) This proposal will test the hypothesis that CSPG4-specific monoclonal antibodies in combination with the Sonic

Hedgehog pathway inhibitor LDE225 are effective in eradicating cancer initiating cells in chordoma tumors.

Title of Grant “Mechanisms and inhibition of anti-angiogenic therapy” Grant ID JSMF#220020244

Role Co-PI

Supporting Agency James S. McDonnell Foundation


PI: Bo Hu

Description (Include the goals and specific aims of the project) This project evaluates a hypothesis that inhibition of VEGF signaling in GBMs induces tumor cell invasion through up-regulation of Ang2 and CSPG4 activating unique signaling pathways. Therefore, simultaneously targeting of VEGF signaling and of the evoked glioma invasion should overcome this malignant phenotype and be effective in treatment of diffuse glioblastomas.

Title of Grant “Combinatorial immunotherapy for triple-negative breast cancer” Grant ID

Role Sponsor

Supporting Agency Susan G. Komen for the Cure


Description (Include the goals and specific aims of the project) This postdoctoral fellowship, awarded to Dr. Y. Wang, aims at developing a combinatorial immunotherapy for the treatment of triple negative breast cancer.

Title of Grant “Immune escape in human cancer: mechanisms and therapeutic implications” Grant ID P01 CA109688

Role Co-PI

Supporting Agency NIH

Performance Period 11/01/06 to 10/31/11

PI: Theresa Whiteside

Description (Include the goals and specific aims of the project) This program project grant includes three projects which characterize escape mechanisms utilized by tumors and develop therapeutic strategies to counteract these escape mechanisms in a clinical setting.

Title of Grant “Rational design of HMW-MAA peptide mimics” Grant ID R01 CA105500

Role PI



Description (Include the goals and specific aims of the project) This project aims at characterizing the structural basis of the interactions of HMW-MAA peptide mimics with anti-HMW-MAA antibodies and to use this information to improve the mimicry of HMW-MAA by peptides with the expectation that these changes will enhance the immunogenicity of HMW-MAA peptide mimics.

Title of Grant “HLA class I-peptide complex expression in breast cancer immunity” Grant ID R01 CA113861

Role Co-PI



PI: Keith Knutson

Description (Include the goals and specific aims of the project) This project aims at examining whether the affinity, avidity, and stability of scFvs, that recognize HLA-

A*0201:HER2/neupeptide complexes on breast cancer cells can be improved with molecular modeling techniques.

Title of Grant “TCR affinity and therapeutic efficacy of T cells” Grant ID R01 CA10494

Role Co-PI



PI: Michael Nishimura

Description (Include the goals and specific aims of the project) This project aims to determine if TCR affinity influences the ability of TCR transduced CD8+ T cells to prevent tumor growth and treat established tumors in vivo; determine if adoptively transferred CD4+ T cells, engineered to express a CD8 independent, HLA-A2 restricted, tyrosinase:368-376 reactive TCR, can enhance effector and memory of CD8+ T cells; determine if host APC, vaccines, and cytokines influence the persistence and function of TCR gene modified T cells leading to enhanced prevention of tumor growth and treatment of established tumors in vivo and; determine if “bifunctional” T cells are effective in reducing tumor progression due to tumor antigen loss variants.

Title of Grant “Combinatorial targeting of prostate cancer cells and tumor associated pericytes with antibody-based immunotherapy and metronomic chemotherapy” Grant ID PC061351

Role PI

Supporting Agency DOD


Description (Include the goals and specific aims of the project) This project aims to test the hypothesis that i) combinatorial targeting of prostate cancer (CaP) cells and pericytes with AN2-specific monoclonal antibodies (mAb) in combination with cyclophosphamide (CTX) metronomic chemotherapy delays tumor progression in TRAMP mice as measured by time to palpable tumor and that ii) immunological and antiangiogenic mechanisms underlie the antitumoral effects elicited by combinatorial targeting of CaP, tumor associated pericytes and endothelial cells with AN2-specific mAb in combination with CTX metronomic chemotherapy.

Report of Technological and Other Scientific Information

Internal_Case_Number Filing Date Patent Title Application Number

2346 12/2/2010 DELAYING AND PREVENTING B-RAF INHIBITOR

RESISTANCE 61/419,208

2343 5/27/2011 ANTIBODIES TO HLA-A2 ANTIGEN-MAGE-3271-279

PEPTIDE COMPLEX AND THEIR USES 61/491,118

1792 3/16/2011

MONOCLONAL ANTIBODIES FOR CSPG4 FOR THE DIAGNOSIS AND TREATMENT OF BASAL BREAST

CARCINOMA 13/119,428

1794 10/15/2009

FULLY HUMAN ANTIBODIES TO HIGH MOLECULAR WEIGHT-MELANOMA ASSOCIATED ANTIGEN AND USES

THEREOF 2011-532263

2181 6/15/2011 ANTIBODIES TO ENDOPLASMIN AND THEIR USE 13/161,432

2346 12/1/2011 METHODS FOR TREATING A TUMOR USING AN

ANTIBODY THAT SPECIFICALLY BINDS HMW-MAA PCT/US2011/062943

2348 12/1/2011 METHODS FOR TREATING A TUMOR USING AN

ANTIBODY THAT SPECIFICALLY BINDS GRP94 13/309,490

TBN 09/06/2012

UNIVERSITY OF PITTSBURGH INVENTION DISCLOSURE AND ASSIGNMENT AGREEMENT- TITLE EAF1 AND EAF2

ANTIBODIES Pitt Ref: 02877

PEER REVIEWED PUBLICATIONS 1. Sirchia G, Ferrone S, Mercuriali F. The action of two sulfydryl compounds on normal human red cells.

Relationship to red cells of paroxysmal nocturnal hemoglobinuria. Blood, 25:502-510, 1965. PMID: 14284339 2. D'Amico G, Sirchia G, Ferrone S, Romagnoni M. Cation transport in normal human red cells treated with

sulfhydryl compounds. Experientia, 22:32-33, 1966. PMID: 5915131 3. Ferrone S, Zanella A, Sirchia G. Normal human red cells treated with 2-amino-ethylisothiouroniumbromide

(AET). Acetylcholinesterase inactivation and susceptibility to acid lysis in vitro. Experientia, 22:731-732, 1966. 4. Praga C, Jean G, Ferrone S. Effet du bromure de 2-amino-ethylisothiouronium (AET) sur l'hemocoagulation.

Thromb Diath Haemorrh (Stuttg.), 15:131-142, 1966. PMID: 5919797 5. Sirchia G, Ferrone S, Milani R, Mercuriali F. Observations on certain enzyme activities of normal human red cells

treated with sulfhydryl compounds. Blood, 28:98-101, 1966. PMID: 5944266 6. Sirchia G, Ferrone S, Nocca G. Some red cell enzyme activities in paroxysmal nocturnal haemoglobinuria.

Enzymol Biol Clin, 7:145-148, 1966. PMID: 5965865 7. Ferrone S, Zanella A, Sirchia G. Red cell acetylcholinesterase in ABO haemolytic disease of the newborn.

Experientia, 24:495, 1968. PMID: 4970753 8. Ferrone S, Zanella A, Mercuriali F, Pizzi C. Some enzymatic and metabolic activities of normal human

erythrocytes treated in vitro with cephalothin. Eur J Pharmacol, 4:211-214, 1968. PMID: 5724004 9. Ferrone S and Sirchia G. Survival of cephalothin-treated erythrocytes. JAMA, 206:378, 1968. PMID: 5695620 10. Sirchia G, Mercuriali F, Ferrone S. Cephalothin-treated normal red cells: a new type of PNH-like cells.

Experientia, 24:495-496, 1968. PMID: 5674999 11. Ferrone S, Mercuriali F, Sirchia G. The positive direct Coombs test of cephalothin-treated blood. Experientia,

25:78-79, 1969. PMID: 4179729 12. Sirchia G, Ferrone S, Mercuriali F. The in vitro lysis of the red cells of paroxysmal nocturnal haemoglobinuria by

the serum of patients with cirrhosis of the liver. Brit J Haemat, 16:269-275, 1969. PMID: 4978548 13. Sirchia G, Ferrone S, Mercuriali F. In-vitro lysis of AET-treated normal red cells (PNH-like cells) by normal and

cirrhotic sera. Brit J Haemat, 17:245-249, 1969. PMID: 4979897 14. Sirchia G, Ferrone S, Mercuriali F. Sulfhydryl compounds. Blood, 33:791-792, 1969. 15. Ferrone S, Zanella A, Sirchia G. Erythrocyte glutathione-reductase activity in chronic renal disease. Scand J

Haematol, 7:409-412, 1970. PMID: 5507564 16. Ferrone S, Zanella A, Mercuriali F, Sirchia G. Normal human blood treated in vitro with cephalothin.

Relationship between serologic and metabolic abnormalities of red blood cells. Experientia, 26:1255-1257, 1970. PMID: 5485305

17. Ferrone S, Zanella A, Flores A, Sirchia G. Red cell metabolism in anaemia. The oxygen uptake in the presence of methylene blue. Acta Haematol, 44:279-286, 1970. PMID: 4994890

18. Lambertenghi G, Ferrone S, Sirchia G. Surface ultramicroscopy of paroxysmal nocturnal haemoglobinuria erythrocytes. Acta Haematol, 44:257-264, 1970. PMID: 4994888

19. Sirchia G, Ferrone S, Marubini E, Zanella A. Statistical evaluation of the determination of red cell acetylcholinesterase activity. Enzymol Biol Clin, 11:369-374, 1970. PMID: 5309722

20. Sirchia G, Ferrone S, Mercuriali F, Zanella A. Red cell acetylcholinesterase activity in autoimmune haemolytic anaemias. Brit J Haemat, 19:411-415, 1970. PMID: 5469590

21. Sirchia G, Ferrone S, Mercuriali F. Leukocyte antigen-antibody reaction and lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Blood, 36:334-336, 1970. PMID: 5311198

22. Ferrone S, Cooper NR, Pellegrino MA, Reisfeld RA. The lymphocytotoxic reaction: the mechanism of rabbit complement action. J Immunol, 107:939-947, 1971. PMID: 4999260

23. Ferrone S, Lambertenghi-Deliliers G, Ranzi T. Normal human red cells treated in vitro with cephalothin. A scanning electron microscope study. Acta Haematol, 45:245-249, 1971. PMID: 4999132

24. Ferrone S, Mercuriali F, Scalamogna M. Cephalothin positive direct Coombs test. Relationship to serum immunoglobulin concentration. Experientia, 27:193-194, 1971. PMID: 5544746

25. Ferrone S, Pellegrino MA, Reisfeld RA. A rapid method for direct HL-A typing of cultured lymphoid cells. J Immunol, 107:613-615, 1971. PMID: 5568777

26. Ferrone S, Zanella A, Scalamogna M. Red cell metabolism in positive direct Coombs test after cephalothin therapy. Experientia, 27:194-195, 1971. PMID: 5101648

27. Lambertenghi-Deliliers G, Ferrone S, Ranzi T, Sirchia G. Immune lysis of normal and AET-treated lymphocytes: a study of transmission and scanning electron microscopy. Blood, 38:759-768, 1971. PMID: 5126164

28. Lewis SM, Lambertenghi G, Ferrone S, Sirchia G. Electron microscope study of PNH red cells and AET-treated normal red cells (PNH-like cells). J Clin Pathol, 24:677-684, 1971. PMID: 5130532

29. Sirchia G, Ferrone S. Normal human lymphocytes treated in vitro with the sulfhydryl compound AET: relationship to the lymphocytes of paroxysmal nocturnal hemoglobinuria. Blood, 37:563-567, 1971. PMID: 5554214

30. Ferrone S, Del Villano BC, Pellegrino MA, Lerner RA, Reisfeld RA. Expression of HL-A antigens on the surface of cultured human lymphoid cells: effect of inhibitors of protein and nucleic acid synthesis. Tissue Antigens, 2:447-453, 1972. PMID: 4648386

31. Ferrone S, Marubini E, Mercuriali F, Sirchia G. Study of in vitro lysis of paroxysmal nocturnal haemoglobinuria (PNH) and PNH-like red cells. Brit J Haemat, 23:5-12, 1972. PMID: 5045962

32. Ferrone S, Mittal KK, Pellegrino MA, Terasaki PI, Reisfeld RA. Serologic specificity and crossreactivity of soluble HLA alloantigens. Immunol Commun, 1:77-91, 1972. PMID: 4123469

33. Ferrone S, Natali PG, Hunter A, Terasaki PI, Reisfeld RA. Immunogenicity of soluble HL-A alloantigens. J Immunol, 108:1718-1722, 1972. PMID: 4113180

34. Ferrone S, Pellegrino MA, Reisfeld RA. Typing of cultured human lymphoid cells. Lancet, 1:1237-1238, 1972. PMID: 4113220

35. Gotze D, Ferrone S. A rapid micromethod for direct H-2 typing of mouse cultured lymphoid cells. J Immunol Methods, 1:203-206, 1972. PMID: 5079999

36. Gotze D, Ferrone S, Reisfeld RA. Serologic cross-reactivity between H-2 and HL-A antigens. I. Specific reactivity of rabbit anti-HL-A sera against murine cells. J Immunol, 109:439-450, 1972. PMID: 4115540

37. Gotze D, Pellegrino MA, Ferrone S, Reisfeld RA. Expression of H-2 antigens during growth of cultured tumor cells. Immunol Commun, 1:533-544, 1972. PMID: 4680356

38. Pellegrino MA, Ferrone S, Natali PG, Pellegrino A, Reisfeld RA. Expression of HL-A antigens in synchronized cultures of human lymphocytes. J Immunol, 108:573-576, 1972. PMID: 4114956

39. Pellegrino MA, Ferrone S, Pellegrino A. A simple microabsorption technique for HL-A typing. Proc Soc Exp Biol Med, 139:484-488, 1972. PMID: 5059037

40. Pellegrino MA, Ferrone S, Safford JW Jr, Hirata AA, Terasaki PI, Reisfeld RA. Stimulation of lymphocyte transformation by streptococcal type M1 protein: relationship to HL-A antigens. J Immunol, 109:97-102, 1972. PMID: 5067822

41. Sirchia G, Zanella A, Perrella M, Mercuriali F, Ferrone S. PNH-like red cells: mechanism of action of sulfhydryl compounds on normal red cells. Experientia, 28:191, 1972. PMID: 5020354

42. Sirchia G, Ferrone S. The laboratory substitutes of the red cells of paroxysmal nocturnal haemoglobinuria (PNH): PHN-like red cells. Ser Haematol, 5:137-175, 1972. PMID: 4565711

43. Brautbar C, Pellegrino MA, Ferrone S, Reisfeld RA, Payne R, Hayflick L. Fate of HL-A antigens in aging cultured human diploid cell strains. II. Quantitative absorption studies. Exp Cell Res, 78:367-375, 1973. PMID: 4698170

44. Brautbar C, Stanbridge E, Pellegrino MA, Ferrone S, Reisfeld RA, Payne R, Hayflick L. Expression of HL-A antigens on cultured human fibroblasts infected with mycoplasmas. J Immunol, 111:1783-1789, 1973. PMID: 4127300

45. Ferrone S, Cooper NR, Pellegrino MA, Reisfeld RA. Interaction of histocompatibility (HL-A) antibodies and complement with synchronized human lymphoid cells in continuous culture. J Exp Med, 137:55-68, 1973. PMID: 4734592

46. Ferrone S, Cooper NR, Pellegrino MA, Reisfeld RA. Activation of human complement by human lymphoid cells sensitized with histocompatibility alloantisera. Proc Natl Acad Sci, USA, 70:3665-3668, 1973. PMID: 4128546

47. Mittal KK, Ferrone S, Mickey MR, Pellegrino MA, Reisfeld RA, Terasaki PI. Specificity of lymphocytotoxic anti-human antibodies in normal rabbit sera. Tissue Antigens, 3:88-94, 1973. PMID: 4203769

48. Mittal KK, Ferrone S, Mickey MR, Pellegrino MA, Reisfeld RA, Terasaki PI. Serological characterization of natural anti-human lymphocytotoxic antibodies in mammalian sera. Transplantation, 16:287-294, 1973. PMID: 4745116

49. Pellegrino MA, Ferrone S, Mittal KK, Pellegrino A, Reisfeld RA. A quantitative study of cross reactivity in the HL-A system with human cultured lymphoid cells and soluble HL-A antigens. Transplantation, 15:42-47, 1973. PMID: 4123049

50. Pellegrino MA, Ferrone S, Pellegrino A, Reisfeld RA. The expression of HL-A antigens during the growth cycle of cultured human lymphoid cells. Clin Immunol Immunopathol, 1:182-189, 1973. PMID: 4128502

51. Pellegrino MA, Pellegrino A, Ferrone S, Kahan BD, Reisfeld RA. Extraction and purification of soluble HL-A antigens from exhausted media of human lymphoid cell lines. J Immunol, 111:783-788, 1973. PMID: 4741297

52. Pellegrino MA, Ferrone S, Pellegrino A, Reisfeld RA. A rapid microtechnique for in vitro stimulation of human lymphocytes by phytohemagglutinin. Clin Immunol Immunopathol, 2:67-73, 1973. PMID: 4775047

53. Sirchia G, Marubini E, Mercuriali F, Ferrone S. Study of two in vitro diagnostic tests for paroxysmal nocturnal haemoglobinuria. Brit J Haemat, 24:751-759, 1973. PMID: 4716058

54. Dierich MP, Pellegrino MA, Ferrone S, Reisfeld RA. Evaluation of C3 receptors on lymphoid cells with different complement sources. J Immunol, 112:1766-1773, 1974. PMID: 4522461

55. Dierich MP, Ferrone S, Pellegrino MA, Reisfeld RA. Chemical modulation of cell surfaces by sulfhydryl compounds: effect on C3b receptors. J Immunol, 113:940-947, 1974. PMID: 4528467

56. Ferrone S, Pellegrino MA, Dierich MP, Reisfeld RA. Effect of inhibitors of macromolecular synthesis on HL-A antibody mediated lysis of cultured lymphoblasts. Tissue Antigens, 4:275-282, 1974. PMID: 4528542

57. Pellegrino MA, Ferrone S, Pellegrino AG, Oh SK, Reisfeld RA. Evaluation of two sources of soluble HL-A antigens: platelets and serum. Eur J Immunol, 4:250-255, 1974. PMID: 4851933

58. Pellegrino MA, Ferrone S, Mittal KK, Gotze D, Terasaki PI, Reisfeld RA. Cross-reactivity between human and murine lymphocyte antigens: III. Reactivity of H-2 allo-and xenoantisera with human lymphoid cells. Immunogenetics, 1:158-173, 1974.

59. Pellegrino MA, Ferrone S, Cooper NR, Dierich MP, Reisfeld RA. Variation in susceptibility of a human lymphoid cell line to immune lysis during the cell cycle. Lack of correlation with antigen density and complement binding. J Exp Med, 140:578-590, 1974. PMID: 4527075

60. Callahan GN, Ferrone S, Allison JP, Reisfeld RA. Detection of H-2 antigens in serum. Transplantation, 20:431-433, 1975. PMID: 174256

61. Ferrone S, Ting A, Pellegrino MA, Terasaki PI, Reisfeld RA. Utilization of cultured human lymphoid cells for detection of humoral sensitization in prospective recipients of kidney transplants. J Clin Invest, 55:388-394, 1975. PMID: 1092715

62. Ferrone S, Pellegrino MA, Billing R, Terasaki PI, Reisfeld RA. Production of anti-W24 xenoantisera in rabbits. Tissue Antigens, 5:41-47, 1975. PMID: 1138440

63. Ferrone S, Pellegrino MA, Callahan GN. Activation of the complement system by H-2 alloantisera: differential susceptibility to lysis of thymocytes and lymphocytes. Immunogenetics, 2:199-203, 1975.

64. Hoch JA, Dierich MP, Pellegrino MA, Ferrone S, Reisfeld RA. Distinction between malignant L cells and normal mouse fibroblasts by rosette formation with sheep red blood cells. J Immunol, 114:1638-1640, 1975. PMID: 164508

65. Oh SK, Pellegrino MA, Ferrone S, Sevier ED, Reisfeld RA. Soluble HL-A antigens in serum. I. Isolation and purification. Eur J Immunol, 5:161-166, 1975. PMID: 789087

66. Pellegrino MA, Ferrone S, Dierich MP, Reisfeld RA. Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol, 3:324-333, 1975. PMID: 233982

67. Pellegrino MA, Ferrone S, Dierich MP, Pellegrino A, Reisfeld RA. Inhibitory effect of normal mammalian sera on the rosette formation of human lymphocytes with sheep red blood cells. Clin Immunol Immunopathol, 4:85-95, 1975. PMID: 123840

68. Pellegrino MA, Ferrone S, Theofilopoulos AN. Rosette formation of human lymphoid cells with monkey red blood cells. J Immunol, 115:1065-1071, 1975. PMID: 809506

69. Reisfeld RA, Pellegrino MA, Dierich MP, Ferrone S. Cultured human lymphoid cells: tools for the biological and molecular characterization of antigens and their recognition systems. In Vitro, 11:173-185, 1975. PMID: 51826

70. Reisfeld RA, Sevier ED, Pellegrino MA, Ferrone S, Poulik MD. Association of HL-A antigens and β2-microglobulin at the cellular and molecular level. Immunogenetics, 2:183-197, 1975.

71. Callahan GN, Ferrone S, Poulik MD, Reisfeld RA, Klein J. Characterization of Ia antigens in mouse serum. J Immunol, 117:1351-1355, 1976. PMID: 185298

72. Ferrone S, Pellegrino MA, Mittal KK. Natural antibodies to human lymphocytes in murine strains. J Natl Cancer Inst, 56:75-78, 1976. PMID: 1255752

73. Ferrone S, Mickey MR, Terasaki PI, Reisfeld RA, Pellegrino MA. Humoral sensitization in parous women: cytotoxic antibodies to non-HL-A antigens. Transplantation, 22:61-68, 1976. PMID: 936285

74. Ferrone S, Pellegrino MA, Cooper NR. Expression of C4 on human lymphoid cells and possible involvement in immune recognition phenomena. Science, 193:53-55, 1976. PMID: 132701

75. Pellegrino MA, Ferrone S, Pellegrino AG, Reisfeld RA. Inhibition of T-lymphocyte rosetting by HL-A alloantisera and complement. Proc Soc Exp Biol Med, 151:321-325, 1976. PMID: 1082598

76. Pellegrino MA, Ferrone S, Brautbar C, Hayflick L. Changes in HL-A antigen profiles on SV40-transformed human fibroblasts. Exp Cell Res, 97:340-345, 1976. PMID: 55364

77. Pellegrino MA, Ferrone S, Theofilopoulos AN. Isolation of human T and B lymphocytes by rosette formation with 2-aminoethylisothiquronium bromide (AET)-treated sheep red blood cells with monkey red blood cells. J Immunol Methods, 11:273-279, 1976. PMID: 819587

78. Thompson JS, Braun WE, Carpenter CB, Dossetor JB, Dupont B, Falk JA, Ferrone S, Johnson AH, Shaw JF, Singal DP, Terasaki TI, Troup GM, Walford RL. Summary report on the second New World B-cell workshop. Tissue Antigens, 8:355-357, 1976. PMID: 65026

79. Ferrone S. Xenoantisera to allospecificities of human histocompatibility antigenic systems. Transplantation, 24:387-388, 1977. PMID: 72441

80. Ferrone S, Pellegrino MA. Cytotoxic antibodies to cultured melanoma cells in the sera of melanoma patients. J Natl Cancer Inst, 58:1201-1204, 1977. PMID: 67208

81. Ferrone S, Pellegrino MA, Mittal KK. Cytotoxic antibodies to cultured human lymphoid cells in polytransfused thrombocytopenic patients: association with reduced survival of allogeneic transfused platelets. Immunol Commun, 6:267-282, 1977. PMID: 142066

82. Ferrone S, Pellegrino MA, Reisfeld RA. Immunogenicity of human B cell antigens solubilized from cultured human lymphoid cells. J Immunol, 118:1036-1041, 1977. PMID: 139444

83. Ferrone S, Halasz NA, Collins G, Pellegrino MA. Humoral immunity in kidney transplant recipients. Transplantation, 23:113-118, 1977. PMID: 138228

84. Ferrone S, Mittal KK, Pellegrino MA, Allison JP, Reisfeld RA. Immunogenicity of HLA antigens purified from serum. Transplantation, 23:7-15, 1977. PMID: 65035

85. Glaser R, Lenoir G, Ferrone S, Pellegrino MA, de-The G. Cell surface markers on epithelial-Burkitt hybrid cells superinfected with Epstein-Barr virus. Cancer Res, 37:2291-2296, 1977. PMID: 193641

86. Pellegrino MA, Ferrone S, Reisfeld RA, Irie RF, Golub SH. Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma. Cancer, 40:36-41, 1977. PMID: 69483

87. Reisfeld RA, Pellegrino MA, Ferrone S. The immunologic and molecular profiles of HLA antigens isolated from urine. J Immunol, 118:264-269, 1977. PMID: 63518

88. Reisfeld RA, David GS, Ferrone S, Pellegrino MA, Holmes EC. Approaches for the isolation of biologically functional tumor-associated antigens. Cancer Res, 37:2860-2865, 1977. PMID: 301432

89. Allison JP, Belvedere M, Reisfeld RA, Pellegrino MA, Ferrone S. Serologic and immunochemical characterization of HLA-A9 xenoantisera. J Immunol, 121:579-585, 1978. PMID: 681750

90. Allison JP, Ferrone S, Walker LE, Pellegrino MA, Silver J, Reisfeld RA. Partial amino acid sequence of HLA-A9 antigen purified with a specific xenoantiserum. Transplantation, 26:451-454, 1978. PMID: 569916

91. Allison JP, Walker LE, Russell WA, Pellegrino MA, Ferrone S, Reisfeld RA, Frelinger JA, Silver J. Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci, 75:3953-3956, 1978. PMID: 99745

92. Balch CM, Dougherty PA, Vogler LB, Ades EW, Ferrone S. A new B cell differentiation antigen (BDA) on normal and leukemic human B lymphocytes that is distinct from known DR (Ia-like) antigens. J Immunol, 121:2322-2328, 1978. PMID: 102693

93. Ferrone S. The major portion of rabbit antibody to serum HLA-A9 antigens is directed to allospecificity. Tissue Antigens, 12:153-155, 1978. PMID: 81540

94. Ferrone S, Belvedere M, Pellegrino MA. Structural relationship between W4/W6 antigens and other surface markers on cultured human lymphoid cells as determined by the ‘lysostrip’ method. Immunogenetics, 6:161-169, 1978.

95. Ferrone S, Naeim F, Indiveri F, Walker LE, Pellegrino MA. Xenoantisera to human DR antigens: serological and immunochemical characterization. Immunogenetics, 7:349-358, 1978.

96. Jordan TF, Ferrone S, Pellegrino MA, Dennert G. Human lymphoblastoid cell lines as effector cells in mitogen-dependent and antibody-dependent cell-mediated lysis. Cancer Res, 38:3707-3711, 1978. PMID: 698930

97. McCabe RP, Ferrone S, Pellegrino MA, Kern DH, Holmes EC, Reisfeld RA. Purification and immunologic evaluation of human melanoma-associated antigens. J Natl Cancer Inst, 60:773-777, 1978. PMID: 75978

98. Pellegrino MA, Ferrone S. Receptors for sheep red blood cells on human B lymphoid WI-L2 cells. Clin Immunol Immunopathol, 9:277-286, 1978. PMID: 414871

99. Pellegrino MA, Belvedere M, Pellegrino AG, Ferrone S. B peripheral lymphocytes express more HLA antigens than T peripheral lymphocytes. Transplantation, 25:93-95, 1978. PMID: 341433

100. Saxton RE, Irie RF, Ferrone S, Pellegrino MA, Morton DL. Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients. Int J Cancer, 21:299-306, 1978. PMID: 204583

101. Strong DM, Pellegrino MA, Ferrone S. Human lymphoid cell lines as targets for DRw. In Vitro, 14:989-995, 1978. PMID: 310802

102. Strong DM, Ahmed A, Ferrone S, Mittal KK, Hartzman RJ, Salvatierra O, Sell KW. Detection of B cell antibodies in renal transplant recipients. Transplantation, 25:208-211, 1978. PMID: 345548

103. Belvedere M, Richiardi P, Curtoni ES, Pellegrino MA, Ferrone S. Sera from volunteers immunized by planned blood transfusions as a source of DR cytotoxic typing reagents. Immunol Commun, 8:93-106, 1979. PMID: 311335

104. Callahan GN, Pellegrino MA, Ferrone S, Haubrich L, Reisfeld RA. Expression of a sheep red blood cell receptor by a murine lymphoma. J Immunol, 123:2725-2728, 1979. PMID: 115920

105. Curry RA, Quaranta V, Pellegrino MA, Ferrone S. Serologically detectable human melanoma-associated antigens are not genetically linked to HLA-A and B antigens. J Immunol, 122:2630-2632, 1979. PMID: 448138

106. Indiveri F, Pellegrino MA, Molinaro GA, Quaranta V, Ferrone S. Rosetting of human T lymphocytes with goat red blood cells: effect of treatment with 2-aminoethylisothiouronium bromide (AET) and comparison with AET treated sheep red blood cells. J Immunol Methods, 30:317-328, 1979. PMID: 315972

107. Indiveri F, Wilson BS, Pellegrino MA, Ferrone S. Detection of human histocompatibility (HLA) antigens with an indirect rosette microassay. J Immunol Methods, 29:101-109, 1979. PMID: 479610

108. McCabe RP, Quaranta V, Frugis L, Ferrone S, Reisfeld RA. A radioimmunometric antibody-binding assay for evaluation of xenoantisera to melanoma-associated antigens. J Natl Cancer Inst, 62:455-463, 1979. PMID: 283276

109. Molinaro GA, Quaranta V, and Ferrone S. Characterization of the specificity of DR monoclonal antibodies. Transplant Proc, 11:1748-1750, 1979. PMID: 93799

110. Natali PG, Pellegrino MA, Walker L, Ferrone S, Reisfeld RA. Antibody-coated protein A-bearing Staphylococcus aureus: a versatile and stable immune reagent. J Immunol Methods, 25:255-264, 1979. PMID: 368250

111. Noguchi P, Wallace R, Johnson J, Earley EM, O'Brien S, Ferrone S, Pellegrino MA, Milstien J, Needy C, Browne W, Petricciani J. Characterization of WiDr: a human colon carcinoma cell line. In Vitro, 15:401-408, 1979. PMID: 90012

112. Richiardi P, Pellegrino MA, Ferrone S. Xenoantisera to allotypic specificities of HLA-A and B antigens: serological characterization. Transplantation, 28:333-338, 1979. PMID: 92080

113. Silver J, Walker LE, Reisfeld RA, Pellegrino MA, Ferrone S. Structural studies of murine I-E and human DR antigens. Mol Immunol, 16:37-42, 1979. PMID: 447368

114. Silver J, Ferrone S. Structural polymorphism of human DR antigens. Nature, 279:436-437, 1979. PMID: 16068184

115. Wilson BS, Indiveri F, Pellegrino MA, Ferrone S. Production and characterization of DR xenoantisera: use for detection of serum DR antigens. J Immunol, 122:1967-1971, 1979. PMID: 376728

116. Wilson BS, Indiveri F, Pellegrino MA, Ferrone S. DR (Ia-like) antigens on human melanoma cells: serological detection and immunochemical characterization. J Exp Med, 149:658-668, 1979. PMID: 429961

117. Ades EW, Ferrone S, Balch CM. Immunochemical characterization of a human B lymphocyte differentiation antigen (p65). Scand J Immunol, 12:519-523, 1980. PMID: 6972571

118. Belvedere M, Pellegrino MA, Ferrone S. Xenoantisera to DRw allospecificities. J Immunogenet, 7:167-172, 1980. PMID: 6155413

119. Belvedere M, Richiardi P, Pellegrino MA, Ferrone S. Fab2 fragments from HLA xenoantisera specifically block cytolysis mediated by HLA-A, B alloantisera. J Immunogenet, 7:215-219, 1980. PMID: 6157749

120. Callahan GN, Pellegrino MA, Ferrone S. Cross-reacting xenoantibodies to the heavy chain of H-2 and HLA-A, B antigens: serologic and immunochemical characterization. Scand J Immunol, 12:297-302, 1980. PMID: 6162196

121. Conner BR, Ferrone S, Pellegrino MA, Glaser R. Lymphoid cell line identification and the detection of cross contamination. In Vitro, 16:446-452, 1980. PMID: 6248453

122. Curry RA, Pellegrino MA, Saxton RE, Jensen F, Ferrone S. Appearance of receptors for Macaca speciosa red blood cells on human fibroblasts transformed by simian virus 40. J Immunol, 125:2017-2019, 1980. PMID: 6253561

123. Eskinazi DP, Molinaro GA, Reisfeld RA, Ferrone S. Indirect rosette microassay: comparison of protein A with purified anti-Ig antibody. Immunol Lett, 1:259-263, 1980.

124. Ferrone S, Pellegrino MA, Callahan GN. Human and murine tumours: changes in cell surface structures coded by the major histocompatibility complex region. J Immunogenet, 7:71-79, 1980. PMID: 6768809

125. Fitchen JH, Ferrone S, Lusis AJ, Cline MJ. Cytotoxicity of anti- β2-microglobulin xenoantisera to human and murine myeloid progenitor cells and lack of cross-reactivity with colony-stimulating activity. J Immunol, 124:2906-2908, 1980. PMID: 6154742

126. Fitchen JH, Ferrone S, Quaranta V, Molinaro GA, Cline MJ. Monoclonal antibodies to HLA-A, B and Ia-like antigens inhibit colony formation by human myeloid proginator cells. J Immunol, 125:2004-2008, 1980. PMID: 6159398

127. Imai K, Ferrone S. Indirect rosette microassay to characterize human melanoma-associated antigens recognized by operationally specific xenoantisera. Cancer Res, 40:2252-2256, 1980. PMID: 6966965

128. Indiveri F, Huddlestone J, Pellegrino MA, Ferrone S. Isolation of human T lymphocytes: comparison between nylon wool filtration and rosetting with neuraminidase (VCN) and 2-aminoethylisothiouronium bromide (AET)-treated sheep red blood cells (SRBC). J Immunol Methods, 34:107-115, 1980. PMID: 6966664

129. Indiveri F, Ng AK, Russo C, Quaranta V, Pellegrino MA, Ferrone S. Isolation of Ia-like antigen-bearing cells from human peripheral lymphocytes through the use of a monoclonal antibody to framework determinants of Ia-like antigens. J Immunol Methods, 39:343-354, 1980. PMID: 6161968

130. Indiveri F, Wilson BS, Russo C, Quaranta V, Pellegrino MA, Ferrone S. Ia-like antigens on human T lymphocytes: relationship to other surface markers, role in mixed lymphocyte reactions, and structural profile. J Immunol, 125:2673-2678, 1980. PMID: 6448901

131. McCabe RP, Indiveri F, Galloway DR, Ferrone S, Reisfeld RA. Lack of association of serologically detectable human melanoma-associated antigens with beta 2 microglobulin: serologic and immunochemical evidence. J Natl Cancer Inst, 65:703-707, 1980. PMID: 6158590

132. McMillan R, Pellegrino MA, Ferrone S. HLA antigens and immune thrombocytopenic purpura (ITP). Blood, 55:709, 1980.

133. Messner RP, De Horatius R, Ferrone S. Lymphocytotoxic antibodies in systemic lupus erythematosus patients and their relatives: reactivity with the HLA antigenic molecular complex. Arthritis Rheum, 23:265-272, 1980. PMID: 6153898

134. Ng AK, Indiveri F, Pellegrino MA, Molinaro GA, Quaranta V, Ferrone S. Natural cytotoxicity and antibody-dependent cellular cytotoxicity of human lymphocytes depleted of HLA-DR bearing cells with monoclonal HLA-DR antibodies. J Immunol, 124:2336-2340, 1980. PMID: 7365259

135. Quaranta V, Walker LE, Pellegrino MA, Ferrone S. Purification of immunologically functional subsets of human Ia-like antigens on a monoclonal antibody (Q5/13) immunoadsorbent. J Immunol, 125:1421-1425, 1980. PMID: 6157732

136. Quaranta V, Indiveri F, Glassy MC, Ng AK, Russo C, Molinaro GA, Pellegrino MA, Ferrone S. Serological, functional, and immunochemical characterization of a monoclonal antibody (MoAb Q2/70) to human Ia-like antigens. Hum Immunol, 1:211-223, 1980. PMID: 6790480

137. Russo C, Quaranta V, Indiveri F, Pellegrino MA, Ferrone S. Effect of polyclonal and monoclonal HLA-DR xenoantibodies on xenogeneic mixed lymphocyte reactions. Immunogenetics, 11:413-416, 1980. PMID: 6448810

138. Sarkar S, Glassy MC, Ferrone S, Jones OW. Cell cycle and the differential expression of HLA-A, B and HLA-DR antigens on human B lymphoid cells. Proc Natl Acad Sci USA, 77:7297-7301, 1980. PMID: 6971443

139. Silver J, Ferrone S. Molecular polymorphism of HLA-DR antigens isolated from Raji and Daudi lymphoblastoid cell lines. Immunogenetics, 10:295-298, 1980.

140. Walker LE, Ferrone S, Pellegrino MA, Reisfeld RA. Structural polymorphism of the beta chain of human HLA-DR antigens. Mol Immunol, 17:1443-1448, 1980. PMID: 6975425

141. Belzer MB, Fitchen JH, Ferrone S, Foon KA, Billing RJ, Golde DV. Expression of Ia-like antigens on human erythroid progenitor cells as determined by monoclonal antibodies and heteroantiserum to Ia-like antigens. Clin Immunol Immunopathol, 20:111-115, 1981. PMID: 6790211

142. Cordiali-Fei P, Natali PG, Pecci G, Pellegrino MA, Ferrone S. Levels of Ia-like antigen bearing lymphocytes in patients with solid primary tumors. J Clin Lab Immunol, 6:197-199, 1981. PMID: 6951050

143. Curry RA, Quaranta V, Pellegrino MA, Ferrone S. Lysis of cultured human melanoma M10 cells by polyclonal xenoantibodies to melanoma-associated antigens. Cancer Res, 41:463-466, 1981. PMID: 7448792

144. Curtoni ES, Pellegrino MA, Indiveri F, Borelli I, Ferrone S. Persistence of cytotoxic antibodies to HLA-A, B, C antigens and to Ia-like antigens in parous women. J Immunogenet, 8:281-285, 1981. PMID: 6944382

145. Eskinazi DP, Molinaro GA, Reisfeld RA, Ferrone S. Cellular and molecular heteroeneity of H-2Kk antigens. J Immunogenet, 8:101-106, 1981. PMID: 7229421

146. Galloway DR, McCabe RP, Pellegrino MA, Ferrone S, Reisfeld RA. Tumor-associated antigens in spent medium of human melanoma cells: immunochemical characterization with xenoantisera. J. Immunol. 126:62-66, 1981. PMID: 7451981

147. Glassy MC, Ferrone S. Ultrastructural alterations in human lymphoblastoid B cell lines treated with tunicamycin. Am J Pathol, 103:1-9, 1981. PMID: 6971575

148. Howe AJ, Seeger RC, Molinaro GA, Ferrone S. Analysis of human tumor cells for Ia-like antigens with monoclonal antibodies. J Natl Cancer Inst, 66:827-829, 1981. PMID: 6262557

149. Imai K, Ng AK, Ferrone S. Characterization of monoclonal antibodies to human melanoma-associated antigens. J Natl Cancer Inst, 66:489-496, 1981. PMID: 6162991

150. Imai K, Galloway DR, Ferrone S. Serological and immunochemical analysis of the specificity of xenoantiserum 8986 elicited with hybrids between human melanoma cells and murine fibroblasts. Cancer Res, 41:1028-1033, 1981. PMID: 6161692

151. Imai K, Ng AK, Glassy MC, Ferrone S. Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies. J Immunol, 127:505-509, 1981. PMID: 6166672

152. Imai K, Ng AK, Glassy MC, Ferrone S. ADCC of cultured human melanoma cells: analysis with monoclonal antibodies to human melanoma-associated antigens. Scand J Immunol, 14:369-377, 1981. PMID: 7336169

153. Imai K, Pellegrino MA, Ng AK, Ferrone S. Role of antigen density in immune lysis of interferon-treated human lymphoid cells: analysis with monoclonal antibodies to the HLA-A, B antigenic molecular complex and to Ia-like antigens. Scand J Immunol, 14:529-535, 1981. PMID: 6175019

154. Indiveri F, Russo C, Quaranta V, Pellegrino MA, Ferrone S. HLA-DR antigens and mitogenic factors released by PWM-stimulated T lymphocytes share the framework determinant recognized by the monoclonal antibody Q5/13. Cell Immunol, 62:406-411, 1981. PMID: 6169455

155. Lordon RE, Wilson RL, Shield CF III, Ferrone S. Humoral immunity in renal transplantation: detection of cytotoxic antibodies to lymphocyte antigens other than HLA-A, B, C and Ia-like antigens in patients with vascular graft rejection. Transplantation, 32:286-290, 1981. PMID: 7036445

156. Natali PG, De Martino C, Quaranta V, Bigotti A, Pellegrino MA, Ferrone S. Changes in Ia-like antigen expression on malignant human cells. Immunogenetics, 12:409-413, 1981. PMID: 7009419

157. Natali PG, De Martino C, Quaranta V, Nicotra MR, Frezza F, Pellegrino MA, Ferrone S. Expression of Ia-like antigens in normal human nonlymphoid tissues. Transplantation, 31:75-78, 1981. PMID: 7015604

158. Natali PG, De Martino C, Pellegrino MA, Ferrone S. Analysis of the expression of I-Ak-like antigens in murine fetal and adult tissues with the monoclonal antibody l0-2.16. Scand J Immunol, 13:541-546, 1981. PMID: 6171869

159. Natali PG, Cordiali-Fei P, Cavaliere R, Di Filippo F, Quaranta V, Pellegrino MA, Ferrone S. Ia-like antigens on freshly explanted human melanoma. Clin Immunol Immunopathol, 19:250-259, 1981. PMID: 6784988

160. Natali PG, Imai K, Wilson BS, Bigotti A, Cavaliere R, Pellegrino MA, Ferrone S. Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. J Natl Cancer Inst, 67:591-601, 1981. PMID: 6944531

161. Natali PG, Nicotra MR, Giacomini P, Pellegrino MA, Ferrone S. Ontogeny of murine I-Ak antigens in tissue of nonlymphoid origin. Immunogenetics, 14:359-365, 1981. PMID: not available

162. Natali PG, De Martino C, Marcellini M, Quaranta V, Ferrone S. Expression of Ia-like antigens on the vasculature of human kidney. Clin Immunol Immunopathol, 20:11-20, 1981. PMID: 7021026

163. Ng AK, Pellegrino MA, Imai K, Ferrone S. HLA-A, B antigens, Ia-like antigens, and tumor-associated antigens on prostate carcinoma cell lines: serologic and immunochemical analysis with monoclonal antibodies. J Immunol, 127:443-447, 1981. PMID: 6788840

164. Ng AK, Indiveri F, Russo C, Quaranta V, Pellegrino MA, Ferrone S. Characterization of human null cells isolated from peripheral lymphocytes by a simultaneous double-rosetting procedure. Scand J Immunol, 14:225-231, 1981. PMID: 6460312

165. Pellegrino MA, Ng AK, Russo C, Glassy M, Ferrone S. Immunochemical analysis of anti-HLA-A2, HLA-A3, and HLA-B27 xenoantisera elicited with hybrids between human and murine cells. Immunogenetics, 14:141-152, 1981. PMID: 7035347

166. Pellegrino MA, Richiardi P, Ferrone S. 8th International Histocompatibility Workshop analysis of a goat antiserum to HLA-B15 allospecificity. Tissue Antigens, 17:542-545, 1981. PMID: 7336416

167. Pellegrino MA, Russo C, Ng AK, Pellegrino AG, Ferrone S. An antiglobulin microcytotoxicity assay to analyze non-complement fixing monoclonal antibodies to human histocompatibility antigens. J Immunol Methods, 49:119-128, 1981.

168. Quaranta V, Pellegrino MA, Callahan GN, Ferrone S. Cross-reactivity between human and murine lymphocyte antigens. IV. Reactivity of H-2 alloantisera with HLA-A, B antigens. Immunogenetics, 13:311-317, 1981. PMID: 6168581

169. Quaranta V, Pellegrino MA, Ferrone, S. Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens. J Immunol, 126:548-552, 1981. PMID: 6161181

170. Quaranta V, Pellegrino MA, Ferrone S. The monoclonal xenoantibody Q6/64 recognizes a determinant expressed by certain gene products of the A and B loci of the HLA region. Immunogenetics, 14:403-413, 1981. PMID: 6174438

171. Quaranta V, Tanigaki N, Ferrone S. Distribution of antigenic determinants recognized by three monoclonal antibodies (Q2/70, Q5/6, and Q5/13) on human Ia-like alloantigens and on their subunits. Immunogenetics, 12:175-182, 1981. PMID: 6162791

172. Quaranta V, Walker LE, Ruberto G, Pellegrino MA, Ferrone S. The free and β2-microglobulin-associated heavy chains of HLA-A, B alloantigens share the antigenic determinant recognized by the monoclonal antibody Q1/28. Immunogenetics, 13:285-295, 1981. PMID: 6168579

173. Russo C, Indiveri F, Quaranta V, Molinaro GA, Pellegrino MA, Ferrone S. Stimulation of human T lymphocytes by PHA-activated autologous T lymphocytes: analysis of the role of Ia-like antigens with monoclonal antibodies. Immunogenetics, 12:267-274, 1981. PMID: 6451578

174. Seeger RC, Rosenblatt HM, Imai K, Ferrone S. Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies. Cancer Res, 41:2714-2717, 1981. PMID: 6166367

175. Slovin SF, Glassy MC, Dambaugh T, Catalano MA, Curry RA, Ferrone S, Kieff E, Vaughan JH, Carson DA. Discordant expression of 2 Epstein-Barr virus-associated antigens, Ebna and Rana, in man-rodent somatic cell hybrids. J Immunol, 127:585-590, 1981. PMID: 6265553

176. Tsoukas CD, Fox RI, Slovin SF, Carson DA, Pellegrino MA, Fong S, Pasquali JL, Ferrone S, Kung P, Vaughan JH. T lymphocyte-mediated cytotoxicity against autologous EBV-genome-bearing B cells. J Immunol, 126:1742-1746, 1981. PMID: 6163816

177. Wilson BS, Ferrone S. Antibodies to human Ia-like antigens and heterologous anti-human lymphocyte sera. J Immunogenet, 8:1-5, 1981. PMID: 6972978

178. Wilson BS, Imai K, Natali PG, Ferrone S. Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer, 28:293-300, 1981. PMID: 7033148

179. Wilson BS, Ruberto G, Ferrone S. Sulfation and molecular weight of fibronectin shed by human melanoma cells. Biochem Biophys Res Commun, 101:1047-1051, 1981. PMID: 7306108

180. Wilson BS, Glassy MC, Quaranta V, Ng AK, Ferrone S. Effect of tunicamycin on the assembly and antigenicity of HLA antigens: analysis with monoclonal antibodies. Scand J Immunol, 14:201-205, 1981. PMID: 6171878

181. Allen RW, Ferrone S, Hoch JA. Characterization of antigens on human lymphocytes coded by messenger RNA translated in vitro. Mol Immunol, 19:1127-1138, 1982. PMID: 7144756

182. Burchiel SW, Martin JC, Imai K, Ferrone S, Warner NL. Heterogeneity of HLA-A, B, Ia-like, and melanoma-associated antigen expression by human melanoma cell lines analyzed with monoclonal antibodies and flow cytometry. Cancer Res, 42:4110-4115, 1982. PMID: 7049355

183. Fitchen JH, Hays EF, Ferrone S. Expression of the H-2 antigenic complex on murine haematopoietic stem cells. Scand J Immunol, 15:547-551, 1982. PMID: 6981838

184. Fitchen JH, Le Fevre C, Ferrone S, Cline MJ. Expression of Ia-like and HLA-A, B antigens on human multipotential hematopoietic progenitor cells. Blood, 59:188-190, 1982. PMID: 6947831

185. Ghose T, Ferrone S, Imai K, Novell ST Jr, Luner SJ, Martin RH, Blair AH. Imaging of human melanoma xenografts in nude mice with a radiolabeled monoclonal antibody. J Natl Cancer Inst, 69:823-826, 1982. PMID: 6956760

186. Glassy MC, Ferrone S. Differential segregation patterns of human chromosomes in somatic cell hybrids constructed with human B-lymphocytes and human melanoma cells. Cancer Res, 42:3971-3973, 1982. PMID: 6980701

187. Imai K, Natali PG, Kay NE, Wilson BS, Ferrone S. Tissue distribution and molecular profile of a differentiation antigen detected by a monoclonal antibody (345.134S) produced against human melanoma cells. Cancer Immunol Immunother, 12:159-166, 1982. PMID: not available

188. Imai K, Wilson BS, Bigotti A, Natali PG, Ferrone S. A 94,000-Dalton glycoprotein expressed by human melanoma and carcinoma cells. J Natl Cancer Inst, 68:761-769, 1982. PMID: 6951087

189. Imai K, Pellegrino MA, Wilson BS, Ferrone S. Higher cytolytic efficiency of an IgG2α than of an IgG1 monoclonal antibody reacting with the same (or spatially close) determinant on a human high-molecular-weight melanoma-associated antigen. Cell Immunol, 72:239-247, 1982. PMID: 6185235

190. Natali PG, Russo C, Ng AK, Nicotra MR, Apollonj C, Pellegrino MA, Ferrone S. Ontogeny of human Ia antigens. Cell Immunol, 73:385-396, 1982. PMID: 6218895

191. Natali PG, Wilson BS, Imai K, Bigotti A, Ferrone S. Tissue distribution, molecular profile, and shedding of a cytoplasmic antigen identified by the monoclonal antibody 465.12S to human melanoma cells. Cancer Res, 42:583-589, 1982. PMID: 6173115

192. Ng AK, Zhang YH, Russo C, Ferrone S. Immunochemical and functional analysis of Ia-like antigens on human monocyte-macrophages with monoclonal antibodies. Cell Immunol, 66:78-87, 1982. PMID: 6177422

193. Ng AK, Giacomini P, Kantor R, Ferrone S. Molecular heterogeneity and shedding of a high molecular-mass melanoma-associated antigen identified with monoclonal antibodies. Clin Chem, 28:2347-2350, 1982. PMID: 6183026

194. Pellegrino MA, Ng AK, Russo C, Ferrone S. Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation, 34:18-23, 1982. PMID: 6181590

195. Pellegrino MA, Indiveri F, Fagiolo U, Antonello A, Ferrone S. Immunogenicity of serum HLA antigens in allogeneic combinations. Transplantation, 33:530-533, 1982. PMID: 6953687

196. Pellegrino MA, Russo C, Ng AK, Pellegrino AG, Ferrone S. An antiglobulin microcytotoxicity assay to analyze non-complement fixing monoclonal antibodies to human histocompatibility antigens. J Immunol Methods, 8:119-128, 1982. PMID: 6978360

197. Quagliata F, Beckerdite-Quagliata S, Alsobrook RA, Russo C, Indiveri F, Pellegrino MA, Ferrone S. Functional and immunological characterization of the stimulation of human lymphocytes with a mitogen from group A streptococci (SM). Cell Immunol, 68:146-154, 1982. PMID: 6211249

198. Wilson BS, Kay NE, Imai K, Ferrone S. Heterogeneity of human melanoma-associated antigens defined by monoclonal antibodies and conventional xenoantisera. Cancer Immunol Immunother, 13:69-74, 1982. PMID: 7159874

199. Giacomini P, Ng AK, Kantor RRS, Natali PG, Ferrone S. Double determinant immunoassay to measure a human high-molecular-weight melanoma-associated antigen. Cancer Res, 43:3586-3590, 1983. PMID: 6344987

200. Imai K, Nakanishi T, Noguchi T, Yachi S, Ferrone S. Selective in vitro toxicity of purothionin conjugated to the monoclonal antibody 225.28S to a human-high-molecular-weight melanoma-associated antigen. Cancer Immunol Immunother, 15:206-209, 1983. PMID: 6555062

201. Indiveri F, Pierri I, Viglione D, Pende D, Russo C, Pellegrino MA, Ferrone S. Human T lymphocytes in aging and malignancy: abnormalities in PHA-induced Ia antigen expression and in functional activity in autologous and allogeneic MLR. Cell Immunol, 76:224-231, 1983. PMID: 6220809

202. Indiveri F, Scudeletti M, Pende D, Barabino A, Russo C, Pellegrino MA, Ferrone S. Inhibitory effect of a low dose of prednisone on PHA-induced Ia antigen expression by human T cells and on proliferation of T cells stimulated with autologous PHA-T cells. Cell Immunol, 80:320-328, 1983. PMID: 6411356

203. Natali PG, Cavaliere R, Bigotti A, Nicotra MR, Russo C, Ng AK, Giacomini P, Ferrone S. Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol, 130:1462-1466, 1983. PMID: 6600484

204. Natali PG, Giacomini P, Bigotti A, Imai K, Nicotra MR, Ng AK, Ferrone S. Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res, 43:660-668, 1983. PMID: 6336658

205. Natali PG, Segatto O, Zupi G, Cavaliere R, Giacomini P, Ferrone S. Isolation of viable melanoma cells from surgically removed lesions using dishes coated with monoclonal antibody to a high molecular weight melanoma associated antigen. J Immunol Methods, 62:337-346, 1983. PMID: 6886437

206. Natali PG, Viora M, Nicotra MR, Giacomini P, Bigotti A, Ferrone S. Antigenic heterogeneity of skin tumors of nonmelanocyte origin: analysis with monoclonal antibodies to tumor-associated antigens and to histocompatibility antigens. J Natl Cancer Inst, 71:439-447, 1983. PMID: 6577218

207. Russo C, Callegaro L, Lanza E, Ferrone S. Re: Purification of IgG monoclonal antibody by caprylic acid precipitation. J Immunol Methods, 65:269-271, 1983. PMID: 6655243

208. Russo C, Ng AK, Pellegrino MA, Ferrone S. The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells. Immunogenetics, 18:23-35, 1983. PMID: 6190744

209. Thorsby E, Ferrone S, Nousiainen H, Hirschberg H. HLA-D restriction of antigen-specific proliferative T cell responses. Inhibitory activity of antisera against HLA determinants or stimulatory antigen. Tissue Antigens, 21:148-158, 1983. PMID: 6189261

210. Wilson BS, Ruberto G, Ferrone S. Immunochemical characterization of a human high molecular weight-melanoma associated antigen identified with monoclonal antibodies. Cancer Immunol Immunother, 14:196-201, 1983. PMID: 6188530

211. Buraggi GL, Callegaro L, Turrin A, Cascinelli N, Attili A, Emanuelli H, Gasparini M, Deleide G, Plassio G, Dovis M, Mariani G, Natali PG, Scassellati GA, Rosa U, Ferrone S. Immunoscintigraphy with 123I, 99mTc and 111In-labelled F (ab') 2 fragments of monoclonal antibodies to a human high molecular weight-melanoma associated antigen. J Nucl Med Allied Sci, 28:283-295, 1984.

212. Fawwaz R, Wang TST, Srivastava SC, Rosen JM, Ferrone S, Hardy MA, Alderson PO. Potential of Palladium-109-labeled antimelanoma monoclonal antibody for tumor therapy. J Nucl Med, 25:796-799, 1984. PMID: 6737078

213. Fitchen JH, Russo C, Ferrone S. Complement-dependent killing of human hematopoietic progenitor cells with noncomplement-fixing monoclonal antibodies in an antiglobulin assay. Blood, 63:873-877, 1984. PMID: 6584186

214. Flomenberg N, Russo C, Ferrone S, Dupont B. HLA Class I specific T lymphocyte clones with dual alloreactive functions. Immunogenetics, 19:39-51, 1984. PMID: 6229477

215. Giacomini P, Aguzzi A, Pestka S, Fisher PB, Ferrone S. Modulation by recombinant DNA leukocyte (α) and fibroblast (β) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. J Immunol, 133:1649-1655, 1984. PMID: 6747299

216. Giacomini P, Veglia F, Cordiali Fei P, Rehle T, Natali PG, Ferrone S. Level of a membrane-bound high-molecular-weight melanoma-associated antigen and a cytoplasmic melanoma-associated antigen in surgically removed tissues and in sera from patients with melanoma. Cancer Res, 44:1281-1287, 1984. PMID: 6692408

217. Glassy MC, Ferrone S. Ia antigen expression is increased on tunicamycin-resistant human B-lymphoid cells. Clin Immunol Immunopathol, 32:90-100, 1984. PMID: 6610518

218. Igarashi M, Obata F, Yoshii M, Kashiwagi N, Ferrone S. Structural polymorphism of human Ia antigens recognized by the monoclonal antibody I2 and by cross-reacting I-Ek-specific alloantibodies. Immunogenetics, 19:249-255, 1984. PMID: 6584396

219. Lordon RE, Stelzer GT, Ferrone S. The early posttransplant prognosis of acute renal allograft rejection as determined by detection of cytotoxic antibodies to lymphoid B cell lines. Transplantation, 38:493-497, 1984. PMID: 6388071

220. Marder P, Hinson A, Russo C, Ferrone S, Ades E. Heterogeneity of human peripheral blood mononuclear cells detected by monoclonal antibodies to monomorphic determinants of human Ia antigens. Immunobiol, 167:483-494, 1984. PMID: 6084642

221. Natali PG, Bigotti A, Cavaliere R, Nicotra MR, Ferrone S. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Nat Cancer Inst, 73:13-24, 1984. PMID: 6376904

222. Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S. Distribution of human Class I (HLA-A, B, C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res, 44:4679-4687, 1984. PMID: 6590117

223. Natali PG, Segatto O, Ferrone S, Tosi R, Corte G. Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens. Immunogenetics, 19:109-116, 1984. PMID: 6421723

224. Ruiter DJ, Bergman W, Welvaart K, Scheffer E, van Vloten WA, Russo C, Ferrone S. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res, 44:3930-3935, 1984. PMID: 6204749

225. Russo C, Flomenberg N, Dupont B, Ferrone S. Reactivity patterns with HLA-A2 variants indicate lack of identity between determinants defined by monoclonal antibodies and cytotoxic-T-cell clones. Cell Immunol, 88:228-232, 1984. PMID: 6206957

226. Russo C, Pellegrino MA, Ferrone S. Analysis of the repertoire of anti-HLA antibodies with anti-idiotypes to a murine anti-HLA-A2, A28 monoclonal antibody. Hum Immunol, 10:57-67, 1984. PMID: 6609912

227. Scudeletti M, Torrielli F, Pende D, Piccardo C, Indiveri F, Ferrone S. Human T cells in cord blood: abnormalities in Ia antigens induction by phytohemagglutinin and in autologous mixed lymphocyte reactions. Cell Immunol, 88:521-530, 1984. PMID: 6237733

228. Spooner RL, Ferrone S. Cross reaction of monoclonal antibodies to human MHC class I and class II products with bovine lymphocyte subpopulations. Tissue Antigens, 24:270-277, 1984. PMID: 6334909

229. Wang TST, Srivastava SC, Fawwaz RA, Giacomini P, Ferrone S, Richards P, Hardy M, Alderson PO. A comparison of the cyclic anhydride and mixed anhydride methods for In-DTPA chelation to monoclonal antibodies. Nucl Med, 23:193-195, 1984. PMID: 6483630

230. Zweig SE, Ferrone S, Shevach EM. Monoclonal antibodies directed against human Ia antigens detect an evolutionary conserved epitope on guinea pig Ia antigens with unique functional properties. J Leukoc Biol, 35:101-113, 1984. PMID: 6200553

231. Akiyama Y, Zicht R, Ferrone S, Bonnard GD, Herberman RB. Effect of monoclonal antibodies (MoAb) to Class I and Class II HLA antigens on lectin-and MoAb OKT3-induced lymphocyte proliferation. Cell Immunol, 91:477-491, 1985. PMID: 2581701

232. Buraggi GL, Callegaro L, Mariani G, Turrin A, Cascinelli N, Attili A, Bombardieri E, Terno G, Plassio G, Dovis M, Mazzuca N, Natali PG, Scassellati GA, Rosa U, Ferrone S. Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F (ab') 2 fragments. Cancer Res, 45:3378-3387, 1985.

233. Crepaldi T, Richiardi P, Malavasi F, Carbonara AO, Igarashi M, Ferrone S. The monoclonal antibody AC1.59 defines a new polymorphic determinant on HLA-DR molecules. Tissue Antigens, 26:25-34, 1985. PMID: 2412306

234. Fawwaz RA, Wang TST, Estabrook A, Rosen JM, Hardy MA, Alderson PO, Srivastava SC, Richards P, Ferrone S. Immunoreactivity and biodistribution of indium-111-labeled monoclonal antibody to a human high molecular weight-melanoma associated antigen. J Nucl Med, 26:488-492, 1985. PMID: 3989605

235. Giacomini P, Aguzzi A, Tecce R, Fisher PB, Ferrone S. A third polypeptide associated with heavy and light chain subunits of class I HLA antigens in immune interferon-treated human melanoma cells. Eur J Immunol, 15:946-951, 1985. PMID: 3930263

236. Giacomini P, Natali PG, Ferrone S. Analysis of the interaction between a human high molecular weight-melanoma associated antigen and the monoclonal antibodies to three distinct antigenic determinants. J Immunol, 135:696-702, 1985. PMID: 2582052

237. Giacomini P, Imberti L, Aguzzi A, Fisher PB, Trinchieri G, Ferrone S. Immunochemical analysis of the modulation of human melanoma-associated antigens by DNA recombinant immune interferon. J Immunol, 135:2887-2894, 1985. PMID: 3928760

238. Greiner JW, Schlom J, Pestka S, Langer JA, Giacomini P, Kusama M, Ferrone S, Fisher PB. Modulation of tumor associated antigen expression and shedding by recombinant human leukocyte and fibroblast interferons. Pharmacol Ther, 31:209-236, 1985. PMID: 3843352

239. Indiveri F, Pierri I, Rogna S, Poggi A, Montaldo P, Romano R, Pende A, Morgano A, Barabino A, Ferrone S. Circadian variations of autologous mixed lymphocyte reactions and endogenous cortisol. J Immunol Methods, 82:17-24, 1985. PMID: 3161951

240. Indiveri F, Scudeletti M, Pende D, Piccardo C, Pierri I, Ferrone S. Analysis of the role of xenogeneic antigens in the proliferation of human T cells stimulated with autologous non-T cells and phytohemagglutinin-activated T cells. Cell Immunol, 92:210-217, 1985. PMID: 3158398

241. Mottolese M, Natali PG, Atlante G, Cavallari A, DiFilippo F, Ferrone S. Antigenic profile and functional characterization of human peritoneal macrophages. J Immunol, 135:200-206, 1985. PMID: 3158701

242. Natali PG, Bigotti A, Cavaliere R, Liao SK, Taniguchi M, Matsui M, Ferrone S. Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. Cancer Res, 45:2883-2889, 1985. PMID: 3157450

243. Natali PG, Bigotti A, Cavalieri R, Wakabayaski S, Taniguchi M, Ferrone S. Distribution of a cross-species melanoma associated antigen in normal and neoplastic human tissues. J Invest Dermatol, 85:340-346, 1985. PMID: 3900230

244. Romagnani S, Almerigogna F, Biagiotti R, Giudizi MG, Alessi A, Damiani G, Ricci M, Ferrone S. Role of Class II histocompatibility antigens in Staphylococcus aureus protein A-induced activation of human T lymphocytes. Cell Immunol, 90:52-64, 1985. PMID: 3871365

245. Turco MC, De Felice M, Corbo L, Morrone G, Mertelsmann R, Ferrone S, Venuta S. Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation. J Immunol, 135:2268-2273, 1985. PMID: 2411790

246. Uadia P, Blair AH, Ghose T, Ferrone S. Uptake of methotrexate linked to polyclonal and monoclonal antimelanoma antibodies by a human melanoma cell line. J Natl Cancer Inst, 74:29-35, 1985. PMID: 3855485

247. Ziai RM, Imberti L, Ferrone S. An enzyme-linked double antibody immunoassay to measure murine immunoglobulins--its application to determine the specific activity of radiolabeled monoclonal antibodies. J Immunol Methods, 82:233-241, 1985. PMID: 3876390

248. Ziai RM, Imberti L, Tongson A, Ferrone S. Differential modulation by recombinant immune interferon of the expression and shedding of HLA antigens and melanoma associated antigens by a melanoma cell line resistant to the antiproliferative activity of immune interferon. Cancer Res, 45:5877-5882, 1985. PMID: 3931909

249. Allen JI, Ferrone S, Boue D, Kay NE. The monoclonal antibody CJA3 down-regulates the susceptibility of human tumor cell lines to natural cell-mediated cytotoxicity. J Immunol, 136:2318-2322, 1986. PMID: 3950415

250. Crepaldi T, Crump A, Newman M, Ferrone S, Antczak DF. Equine T lymphocytes express MHC Class II antigens. J Immunogenet, 13:349-360, 1986. PMID: 3494086

251. Fukusato T, Gerber MA, Thung SN, Ferrone S, Schaffner F. Expression of HLA Class I antigens on hepatocytes in liver disease. Am J Pathol, 123:264-270, 1986. PMID: 2422944

252. Giacomini P, Aguzzi A, Ferrone S. Differential susceptibility to modulation by recombinant immune interferon of HLA-DR and -DQ antigens synthesized by melanoma Colo 38 cells. Hybridoma, 5:277-288, 1986. PMID: 3100420

253. Igarashi M, Gebhard DH, Chen YX, Safai B, Evans RL, Ferrone S. Identification with the monoclonal antibody 26.163 of a determinant shared by the β chains of the gene products of the HLA-DR, DQ and DP loci. Hum Immunol, 16:347-355, 1986. PMID: 2428781

254. Indiveri F, Pierri I, Rogna S, Poggi A, Romano R, Tavano A, Ratto G, Motta G, Ferrone S. Abnormalities of T cells isolated from mediastinal lymph nodes and peripheral blood of patients with lung carcinoma: deficit in PHA-induced expression of HLA Class II antigens and in autologous mixed lymphocyte reactions. Cancer Immunol Immunother, 22:232-235, 1986. PMID: 2942252

255. Indiveri F, Scudeletti M, Pierri I, Traverso A, Cerri C, Ferrone S. PHA-T cells in systemic lupus erythematosus and in rheumatoid arthritis: abnormalities in HLA Class II antigen induction and in autologous mixed lymphocyte reactions. Cell Immunol, 97:197-203, 1986. PMID: 2943425

256. Kantor RRS, Albino AP, Ng AK, Ferrone S. Biosynthesis and intracellular processing of four human melanoma associated antigens. Cancer Res, 46:5223-5228, 1986. PMID: 2428476

257. Natali PG, Bigotti A, Cavalieri R, Nicotra MR, Tecce R, Manfredi D, Chen YX, Nadler LM, Ferrone S. Gene products of the HLA-D region in normal and malignant tissues of nonlymphoid origin. Hum Immunol, 15:220-233, 1986. PMID: 3081470

258. Pende D, Indiveri F, Pierri I, Criscuolo D, Ferrone S. In vitro enhancement of the proliferative response of human T cells to autologous non-T cells by hydralazine. Immunopharmacology, 11:183-187, 1986. PMID: 3488304

259. Ruiter DJ, Brocker EB, Ferrone S. Expression and susceptibility to modulation by interferons of HLA Class I and II antigens on melanoma cells. Immunohistochemical analysis and clinical relevance. J Immunogenet, 13:229-234, 1986. PMID: 2434574

260. Santoli D, Radka SF, Igarashi M, Kreider BL, Ferrone S. Autologous B lymphoblastoid cell lines and long-term cultured T cells as stimulators in the mixed lymphocyte reaction: analysis of the role of HLA Class II antigens as stimulatory molecules. J Immunol, 137:400-407, 1986. PMID: 2941479

261. Scudeletti M, Indiveri F, Pierri I, Picciotto A, Ferrone S. T cells from patients with chronic liver diseases: Abnormalities in PHA-induced expression of HLA Class II antigens and in autologous mixed-lymphocyte reactions. Cell Immunol, 102:227-233, 1986. PMID: 2948660

262. Siccardi AG, Buraggi GL, Callegaro L, Mariani G, Natali PG, Abbati A, Bestagno M, Caputo V, Mansi L, Masi R, Paganelli G, Riva P, Salvatore M, Sanguineti M, Troncone L, Turco GL, Scassellati G, Ferrone S. Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res, 46:4817-4822, 1986.

263. Slovin SF, Lackman RD, Ferrone S, Kiely PE, Mastrangelo MJ. Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol, 137:3042-3048, 1986. PMID: 3093588

264. Taramelli D, Fossati G, Mazzocchi A, Delia D, Ferrone S, Parmiani G. Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions. Cancer Res, 46:433-439, 1986. PMID: 3079589

265. Tsujisaki M, Kusama M, Sakaguchi K, Perosa F, Ferrone S. A sandwich assay to detect and characterize syngeneic anti-idiotypic antibodies to murine anti-HLA and tumor associated antigen monoclonal antibodies. J Immunol Methods, 95:47-55, 1986. PMID: 3782825

266. van Duinen SG, Ruiter DJ, Ferrone S. Associated expression of HLA Class I and Class II antigens on melanoma cells in surgically removed metastases. J Pathol, 149:339-348, 1986. PMID: 3531448

267. Ziai MR, Imberti L, Kobayashi M, Perussia B, Trinchieri G, Ferrone S. Distinct functional domains on the recombinant human immune interferon molecule. Cancer Res, 46:6187-6190, 1986. PMID: 3096556

268. De Felice M, Turco MC, Carandente Giarrusso P, Corbo L, Pizzano R, Martinelli V, Ferrone S, Venuta S. Differential regulatory role of monomorphic and polymorphic determinants of histocompatibility leukocyte antigen Class I antigens in monoclonal antibody OKT3-induced T cell proliferation. J Immunol, 139:2683-2689, 1987. PMID: 2443568

269. Giacomini P, Viora M, Tecce R, Knowles DM, Natali PG, Ferrone S. A cytoplasmic human melanoma associated antigen as a marker of activation in lymphoid cells. Cancer Res, 47:5175-5180, 1987. PMID: 3497718

270. Giudizi MG, Biagiotti R, Almerigogna F, Alessi A, Tiri A, Del Prete GF, Ferrone S, Romagnani S. Role of HLA Class I and Class II antigens in activation and differentiation of B cells. Cell Immunol, 108:97-108, 1987. PMID: 3111726

271. Gulwani B, Maio M, Imberti L, Melamede RJ, Ferrone S. Immunosuppressive activity of T cell clones generated from human T cells stimulated with autologous TPHA cells. J Immunol, 139:2130-2136, 1987. PMID: 2958539

272. Hamby CV, Liao SK, Kanamaru T, Ferrone S. Immunogenicity of human melanoma-associated antigens defined by murine monoclonal antibodies in allogeneic and xenogeneic hosts. Cancer Res, 47:5284-5289, 1987. PMID: 3115563

273. Igarashi M, Suciu-Foca N, Ferrone S. Differential expression of HLA-DR allospecificities on antigen specific T cell clones. Tissue Antigens, 29:160-167, 1987. PMID: 2440145

274. Kusama M, Kageshita T, Tsujisaki M, Perosa F, Ferrone S. Syngeneic antiidiotypic antisera to murine antihuman high-molecular-weight melanoma-associated antigen monoclonal antibodies. Cancer Res, 47:4312-4317, 1987. PMID: 3607764

275. Liao SK, Smith JW, Kwong PC, Natali PG, Kusama M, Hamby CV, Ferrone S. Cross-reactivity of murine anti-human high molecular weight-melanoma associated antigen monoclonal antibodies with guinea pig melanoma cells. Cancer Res, 47:4835-4841, 1987.

276. Matsui M, Temponi M, Ferrone S. Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. J Immunol, 139:2088-2095, 1987. PMID: 3114385

277. Milo GE, Casto B, Ferrone S. Comparison of features of carcinogen-transformed human cells in vitro with sarcoma-derived cells. Mutat Res, 199:387-398, 1987. PMID: not available

278. Natali PG, Roberts JT, DiFilippo F, Bigotti A, Dent PB, Ferrone S, Liao SK. Immunohistochemical detection of antigen in human primary and metastatic melanomas by the monoclonal antibody 140.240 and its possible prognostic significance. Cancer, 59:55-63, 1987. PMID: 3539308

279. Perosa F, Ferrone S. Syngeneic anti-idiotypic antisera to murine anti-HLA Class II monoclonal antibodies. J Immunol, 139:1232-1239, 1987. PMID: 3611788

280. Perosa F, Tsujisaki M, Ferrone S. Syngeneic anti-idiotypic antisera to murine monoclonal antibodies to monomorphic and polymorphic determinants of HLA Class I antigens. J Immunol, 138:2202-2207, 1987. PMID: 2435792

281. Ruggiero G, Manzo C, Fontana S, Scala G, Pirozzi G, Ferrone S, Zappacosta S. Inhibition by anti-HLA class II monoclonal antibodies of monocyte-dependent T cell proliferation induced by monoclonal antibody OKT3. Eur J Immunol, 17:1585-1592, 1987. PMID: 2824212

282. Russo C, Fotino M, Carbonara A, Ferrone S. A double determinant immunoassay for HLA Class I typing using serum as an antigen source. Hum Immunol, 19:69-77, 1987. PMID: 3495524

283. Russo C, Nepo A, Lanza E, Igarashi M, Ferrone S. Antibody-induced association between discrete regions of HLA Class I and II antigens. J Immunol, 138:3152-3158, 1987. PMID: 2437183

284. Sieratzki J, Thung SN, Gerber MA, Ferrone S, Schaffner F. Major histocompatibility antigen expression in the liver in acquired immunodeficiency syndrome. Arch Pathol Lab Med, 111:1045-1049, 1987. PMID: 3310957

285. Tsujisaki M, Igarashi M, Sakaguchi K, Eisinger M, Herlyn M, Ferrone S. Immunochemical and functional analysis of HLA Class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. J Immunol, 138:1310-1316, 1987. PMID: 3100635

286. van den Ingh HF, Ruiter DJ, Griffioen G, van Muijen GNP, Ferrone S. HLA antigens in colorectal tumours--low expression of HLA class I antigens in mucinous colorectal carcinomas. Br J Cancer, 5:125-130, 1987. PMID: 3028461

287. Ziai MR, Imberti L, Nicotra MR, Badaracco G, Segatto O, Natali PG, Ferrone S. Analysis with monoclonal antibodies of the molecular and cellular heterogeneity of human high molecular weight melanoma associated antigen. Cancer Res, 47:2474-2480, 1987. PMID: 3552215

288. Cordiali-Fei P, Mottolese M, Tecce R, Natali PG, Ferrone S. Accessory cell function of human melanoma cells in mitogen-induced T cell proliferation. Cell Immunol, 116:149-162, 1988. PMID: 3262428

289. Graf LH Jr, Rosenberg CD, Mancino V, Ferrone S. Transfer and co-amplification of a gene encoding a 96-kDa immune IFN-inducible human melanoma-associated antigen. Preferential expression by mouse melanoma host cells. J Immunol, 141:1054-1060, 1988. PMID: 3135310

290. Maio M, Gulwani B, Tombesi S, Langer JA, Duigou GJ, Kerbel RS, Fisher PB, Ferrone S. Differential induction by immune interferon of the gene products of the HLA-D region on the melanoma cell line MeWo and its metastatic variant MeM 50-10. J Immunol, 141:913-920, 1988. PMID: 3135316

291. Matsui M, Nakanishi T, Noguchi T, Ferrone S. Synergistic in vitro and in vivo anti-tumor effect of daunomycin-anti-96-kDa melanoma-associated antigen monoclonal antibody CL 207 conjugate and recombinant IFN-γ. J Immunol, 141:1410-1417, 1988. PMID: 3135332

292. Okada H, Ono R, Addonizio JC, Nagamatsu GR, Ferrone S. A solid-phase immunoassay to screen anti-HLA monoclonal antibodies. J Immunol Methods, 107:179-187, 1988. PMID: 3257997

293. Perosa F, Ferrone S. Syngeneic anti-idiotypic monoclonal antibodies to the murine anti-HLA-DR, DP monoclonal antibody CR11-462. Hum Immunol, 23:255-269, 1988. PMID: 3266207

294. Sakaguchi K, Ono R, Tsujisaki M, Richiardi P, Carbonara A, Park MS, Tonai R, Terasaki PI, Ferrone S. Anti-HLA-B7, B27, Bw42, Bw54, Bw55, Bw56, Bw67, Bw73 monoclonal antibodies: specificity, idiotypes, and application for a double determinant immunoassay. Hum Immunol, 21:193-207, 1988. PMID: 3259570

295. Santoli D, Radka SF, Kreider BL, Ferrone, S. Regulatory role of monomorphic and polymorphic determinants of HLA Class I antigens in the proliferation of T cells stimulated by autologous and allogeneic B and T lymphoid cells. Cell Immunol, 116:263-273, 1988. PMID: 2460247

296. Temponi M, Kekish U, Ferrone S. Immunoreactivity and affinity of murine IgG monoclonal antibodies purified by caprylic acid precipitation. J Immunol Methods, 115:151-152, 1988. PMID: 3192945

297. Tsujisaki M, Sakaguchi K, Igarashi M, Richiardi P, Perosa F, Ferrone S. Fine specificity and idiotype diversity of the murine anti-HLA-A2, A28 monoclonal antibodies CR11-351 and KS1. Transplantation, 45:632-639, 1988. PMID: 3162340

298. Turco MC, De Felice M, Corbo L, Carandente Giarrusso P, Yang SY, Ferrone S, Venuta S. Enhancing effect of anti-HLA Class I monoclonal antibodies on T cell proliferation induced via CD2 molecule. J Immunol, 141:2275-2281, 1988. PMID: 3262654

299. van Duinen SG, Ruiter DJ, Broecker EB, van der Velde EA, Sorg C, Welvaart K, Ferrone S. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res, 48:1019-1025, 1988. PMID: 3338074

300. van Vreeswijk H, Ruiter DJ, Brocker EB, Welvaart K, Ferrone S. Differential expression of HLA-DR, DQ and DP antigens in primary and metastatic melanoma. J Invest Dermatol, 90:755-760, 1988. PMID: 3283252

301. Ziai MR, Giordano A, Armandola E, Ferrone S. Purification by ammonium sulfate precipitation of bacteriophage λgt11 DNA for restriction analysis of cloned cDNA inserts. Anal Biochem, 171:192-196, 1988. PMID: 2841887

302. De Felice M, Turco MC, Corbo L, Carandente Giarrusso P, Lamberti A, Valerio G, Temponi M, Costanzo F, Ferrone S, Venuta S. Lack of a role of monocytes in the inhibition by monoclonal antibodies to monomorphic and polymorphic determinants of HLA Class I antigens of PHA-P-induced peripheral blood mononuclear cell proliferation. Cell Immunol, 122:164-177, 1989. PMID: 2473845

303. Gilliland LK, Norris NA, Grosmaire LS, Ferrone S, Gladstone P, Ledbetter JA. Signal transduction in lymphocyte activation through crosslinking of HLA Class I molecules. Hum Immunol, 25:269-289, 1989. PMID: 2475477

304. Guarini L, Temponi M, Edwalds GM, Vita JR, Fisher PB, Ferrone S. In vitro differentiation and antigenic changes in human melanoma cell lines. Cancer Immunol Immunother, 30:262-268, 1989. PMID: 2624919

305. Kumari HL, Shuler CF, Lehman T, Ferrone S, Milo GE. Development of neoplastic phenotype following transfection of HNF cells with sarcoma DNA. Carcinogenesis, 10:401-404, 1989. PMID: 2912591

306. Kusama M, Kageshita T, Chen ZJ, Ferrone S. Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight-melanoma associated antigen monoclonal antibodies. J Immunol, 143:3844-3852, 1989. PMID: 2584721

307. Maio M, Gulwani B, Langer JA, Kerbel RS, Duigou GJ, Fisher PB, Ferrone S. Modulation by interferons of HLA antigen, high-molecular-weight melanoma associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. Cancer Res, 49:2980-2987, 1989. PMID: 2497970

308. Maio M, Gulwani B, Morgano A, Ferrone S. Differential modulation by tumor necrosis factor and immune interferon of HLA Class II antigens expressed by melanoma cells. Int J Cancer, 44:554-559, 1989. PMID: 2506138

309. Maio M, Gulwani B, Tombesi S, Ferrone S. Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10. Cancer Immunol Immunother, 30:34-42, 1989. PMID: 2513111

310. Maio M, Tessitori G, Pinto A, Temponi M, Colombatti A, Ferrone S. Differential role of distinct determinants of intercellular adhesion molecule-1 in immunologic phenomena. J Immunol, 143:181-188, 1989. PMID: 2471735

311. Matzku S, Kirchgessner H, Schmid U, Temponi M, Ferrone S. Melanoma targeting with a cocktail of monoclonal antibodies to distinct determinants of the human HMW-MAA. J Nucl Med, 30:390-397, 1989. PMID: 2472474

312. Natali PG, Bigotti A, Nicotra MR, Nardi RM, Delovu A, Segatto O, Ferrone S. Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. Cancer Res, 49:1269-1274, 1989. PMID: 2917356

313. Ono R, Sakaguchi K, Ferrone S. Modulation by antiidiotypic monoclonal antibodies of immune lysis mediated by anti-HLA monoclonal antibodies. J Immunol, 143:1921-1929, 1989. PMID: 2528584

314. Perosa F, Ferrone S. Murine antiidiotypic monoclonal antibodies that bear the internal image of HLA-DR allospecificities. J Clin Invest, 84:907-914, 1989. PMID: 2474577

315. Scambia G, Benedetti Panici P, Baiocchi G, Coli A, Ferrone S, Natali PG, Mancuso S. A primary amelanotic melanoma of the vagina diagnosed by immunocytochemistry. Int J Gynaecol Obstet, 29:159-164, 1989. PMID: 2568292

316. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S. Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma, 8:85-95, 1989. PMID: 2784406

317. Turco MC, De Felice M, Alfinito F, Lamberti A, Costanzo F, Giordano M, Martinelli V, Rotoli B, Ferrone S, Venuta S. Proliferative pathways in CD1- CD3+ CD4+ CD8+ T-prolymphocytic leukemic cells: analysis with monoclonal antibodies and cytokines. Blood, 74:1651-1657, 1989. PMID: 2790191

318. Ziai MR, Ferrone S. Specific phosphorylation by calcium-EGTA complex of a 75kDa human tumor plasma membrane protein (pp75). Int J Biochem, 21:731-738, 1989. PMID: 2503405

319. Ziai MR, Hamby CV, Reddy R, Hayashibe K, Ferrone S. Rapid purification of plasmid DNA following acid precipitation of bacterial proteins. Biotechniques, 7:147, 1989. PMID: 2698194

320. De Felice M, Giarrusso PC, Lamberti A, Turco MC, Valerio G, van Lier AW, Yang SY, Ferrone S, Venuta S. Mitogenic activity of anti-CD28 MoAb CLB-CD28/1 on peripheral blood mononuclear cells and its cooperation with other anti-T cells MoAb in the activation of purified T lymphocytes. Tissue Antigens, 36:12-18, 1990. PMID: 1701062

321. De Felice M, Turco MC, Costanzo F, Corbo L, Ferrone S, Venuta S. Inhibition by anti-HLA Class I mAb of IL-2 and IL-2 receptor synthesis in lymphocytes stimulated with PHA-P. Cell Immunol, 126:420-427, 1990. PMID: 2311126

322. Flajnik MF, Ferrone S, Cohen N, Du Pasquier L. Evolution of the MHC: antigenicity and unusual tissue distribution of Xenopus (Frog) Class II molecules. Mol Immunol, 27:451-462, 1990. PMID: 2366760

323. Guarini L, Temponi M, Bruce JN, Bollon AP, Duigou GJ, Moulton TA, Ferrone S, Fisher PB. Expression and modulation by cytokines of the intercellular adhesion molecule-1 (ICAM-1) in human central nervous system tumor cell cultures. Int J Cancer, 46:1041-1047, 1990. PMID: 1979069

324. Kaufman J, Ferrone S, Flajnik M, Kilb M, Volk H, Parisot R. MHC-like molecules in some nonmammalian vertebrates can be detected by some cross-reactive monoclonal antibodies. J Immunol, 144:2273-2280, 1990. PMID: 1690241

325. Maio M, Pinto A, Carbone A, Zagonel V, Gloghini A, Marotta G, Cirillo D, Colombatti A, Ferrara F, Del Vecchio L, Ferrone S. Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders. Blood, 76:783-790, 1990.

326. Manzo C, Ruggiero G, del Vecchio L, Racioppi L, Pirozzi G, Temponi M, Ferrone S, Fontana S, Zappacosta S. Monoclonal antibody OKT3-induced T cell proliferation: differential role of HLA Class II determinants expressed by T cells and monocytes. Cell Immunol, 125:79-91, 1990. PMID: 1688405

327. Mittelman A, Chen ZJ, Kageshita T, Yang H, Yamada M, Baskind P, Goldberg N, Puccio C, Ahmed T, Arlin Z, Ferrone S. Active specific immunotherapy in patients with melanoma: a clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high molecular weight-melanoma associated antigen monoclonal antibodies. J Clin Invest, 86:2136-2144, 1990. PMID: not available

328. Natali PG, Nicotra MR, Cavaliere R, Bigotti A, Romano G, Temponi M, Ferrone S. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res, 50:1271-1278, 1990. PMID: 1967552

329. Perosa F, Carbone R, Ferrone S, Dammacco F. Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate. J Immunol Methods, 128:9-16, 1990. PMID: 2324507

330. Racioppi L, Moscarella A, Ruggiero G, Manzo C, Ferrone S, Fontana S, Zappacosta S. Inhibition by anti-HLA class II monoclonal antibodies of monoclonal antibody OKT3-induced T cell proliferation. Studies at the mRNA level. J Immunol, 145:3635-3640, 1990. PMID: 1978847

331. Rosenberg CD, Ferrone S, Hamby CV, Mancino V, Graf LH Jr. Interspecific DNA-mediated transfer and amplification of a gene specifying Mr 100,000 human melanoma-associated cell surface glycoprotein. Cancer Res, 50:1559-1565, 1990. PMID: 2302716

332. Schlingemann RO, Rietveld FJ, de Waal RM, Ferrone S, Ruiter DJ. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol, 136:1393-1405, 1990. PMID: 1694058

333. Shinji T, Ono R, Ferrone S. Fine specificity and idiotype diversity of a murine anti-HLA-DQw3 monoclonal antibody elicited with a syngeneic antiidiotypic monoclonal antibody. J Immunol, 144:4291-4297, 1990. PMID: 2341722

334. Siccardi AG, Buraggi GL, Natali PG, Scassellati GA, Viale G, Ferrone S, The European Multicentre Study Group. European multicentre study on melanoma immunoscintigraphy by means of 99mTc-labelled monoclonal antibody fragments. Eur J Nucl Med, 16:317-323, 1990. PMID: 2161772

335. Temponi M, Pupa S, Ferrone S. Purification of immunoreactive radiolabeled monoclonal antibodies with anti-idiotypic monoclonal antibodies. J Immunol Methods, 126:223-229, 1990. PMID: 2406347

336. Arkin S, Naprstek B, Guarini L, Ferrone S, Lipton JM. Expression of intercellular adhesion molecule-1 (CD54) on hematopoietic progenitors. Blood, 77:948-953, 1991. PMID: 1671649

337. Chattopadhyay P, Kaveri SV, Byars N, Starkey J, Ferrone S, Raychaudhuri S. Human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1. Cancer Res, 51:6045-6051, 1991. PMID: 1933867

338. Chen ZJ, Yang H, Ferrone S. Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2-23. Characterization of the immunogenicity in syngeneic hosts. J Immunol, 147:1082-1090, 1991. PMID: 1861071

339. Chen ZJ, Yang H, Kageshita T, Ferrone S. Human high-molecular-weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371. Cancer Res, 51:4790-4797, 1991. PMID: 1716513

340. D'Errico A, Facchini A, Meliconi R, Grigioni FW, Ferrone S. Reactivity of monoclonal antibody (mAb) GD9 with a cytoplasmic antigen preserved in formalin-fixed, paraffin-embedded gastrointestinal tumors. Hybridoma, 10:113-119, 1991. PMID: 2032731

341. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest, 87:284-292, 1991. PMID: 1898655

342. Ghose T, Ferrone S, Blair AH, Kralovec Y, Temponi M, Singh M, Mammen M. Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen. Cancer Immunol Immunother, 34:90-96, 1991. PMID: 1760821

343. Graham GM, Guarini L, Moulton TA, Datta S, Ferrone S, Giacomini P, Kerbel RS, Fisher PB. Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons. Cancer Immunol Immunother, 32:382-390, 1991. PMID: 1672507

344. Hayashibe K, Mishima Y, Ferrone S. Cloning and in vitro expression of a melanoma-associated antigen immunogenic in patients with melanoma. J Immunol, 147:1098-1104, 1991. PMID: 1861072

345. Kageshita T, Nakamura T, Yamada M, Kuriya N, Arao T, Ferrone S. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. Cancer Res, 51:1726-1732, 1991. PMID: 1671829

346. Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA Class I antigen expression by transfection with B2m gene. J Clin Invest, 88:282-289, 1991. PMID: 1905328

347. Mariani SM, Armandola EA, Ferrone S. Diversity in the fine specificity and idiotypic profile of mouse anti-HLA-DR monoclonal antibody elicited with the syngeneic anti-idiotypic monoclonal antibody F5-830. J Immunol, 147:1322-1330, 1991. PMID: 1714480

348. Perosa F, Dannecker G, Ferrone S, Dammacco F. Immunochemical and functional characterization of anti-idiotypic antibodies to a mouse anti-CD4 monoclonal antibody. Int J Clin Lab Res, 21:179-185, 1991. PMID: 1815763

349. Perosa F, Ferrone S, Dammacco F. Anti-idiotypic monoclonal antibodies reacting with idiotope on isolated-denatured chains of an anti-CD4 monoclonal antibody. Immunology, 74:748-750, 1991. PMID: 1783432

350. Reddy PG, Graham GM, Datta S, Guarini L, Moulton TA, Jiang H, Gottesman MM, Ferrone S, Fisher PB. Effect of recombinant fibroblast interferon and recombinant immune interferon on growth and the antigenic phenotype of multidrug-resistant human glioblastoma multiforme cells. J Natl Cancer Inst, 83:1307-1315, 1991. PMID: 1653364

351. Ruggiero G, Racioppi L, Manzo C, Pirozzi G, D'Oro U, Ferrone S, Zappacosta S, Fontana S. HLA Class II molecules on monocytes regulate T cell proliferation through physical interaction in the CD3 activation pathway. Eur J Immunol, 21:29-33, 1991. PMID: 1825060

352. Temponi M, Fawwaz RA, Kekish U, Wang TST, Ferrone S. Improvement by affinity chromatography on antiidiotypic monoclonal antibodies (MAbs) of immunoreactivity and in vivo targeting of radiolabelled anti-HMW-MAA MAb TP61.5 in nude mice bearing human melanoma lesions. Int J Cancer, 49:624-630, 1991. PMID: 1917164

353. Turco MC, Alfinito F, De Felice M, Lamberti A, Ferrone S, Venuta S. T-cell malignancies with mature phenotypes: altered cell cycle regulation by HLA Class I molecules. Blood, 78:2045-2052, 1991. PMID: 1680497

354. Armandola EA, Mariani SM, Zwickl M, Hardman N, Ferrone S. Molecular analysis of anti-idiotypic monoclonal antibodies in the HLA-DR antigenic system. Eur J Immunol, 22:2893-2899, 1992. PMID: 1425914

355. Dal Canton A, Fuiano G, Sepe V, Caglioti A, Ferrone S. Mesangial expression of intercellular adhesion molecule-1 in primary glomerulosclerosis. Kidney Int, 41:951-955, 1992. PMID: 1381006

356. Guarini L, Graham GM, Jiang H, Ferrone S, Zucker S, Fisher PB. Modulation of the antigenic phenotype of human melanoma cells by differentiation-inducing and growth-suppressing agents. Pigment Cell Res, 2:123-131, 1992. PMID: 1357650

357. Kageshita T, Ono T, Hirai S, Yoshii A, Kimura T, Arao T, Ferrone S. Ganglioside, adhesion molecule, and HLA antigen expression in basal cell carcinoma lesions. Cancer Res, 52:3201-3207, 1992. PMID: 1350511

358. Mariani SM, Armandola EA, Ferrone S. Diversity of anti-HLA-DR antibodies elicited by distinct anti-idiotypic monoclonal antibodies recognizing idiotopes co-expressed by the immunizing monoclonal antibody. Immunology, 77:597-603, 1992. PMID: 1283602

359. Mariani SM, Armandola EA, Ferrone S. Heterogeneity in the anti-HLA-DR immune response elicited by the antiidiotypic monoclonal antibody F5-444. Analysis at the clonal level. Transplantation, 54:1078-1084, 1992. PMID: 1281563

360. Matsui M, Yoshimura S, Nakanishi T, Ferrone S. Effect of tumor size on the enhancement by gamma interferon of the localization of radiolabeled F (ab') 2 fragments of anti-intercellular adhesion molecule-1 monoclonal antibodies in human colon carcinoma cells grafted in nude mice. Cancer Res, 52:1309-1313, 1992. PMID: 1346588

361. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA, 89:466-470, 1992. PMID: 1731316

362. Tanabe M, Sekimata M, Ferrone S, Takiguchi M. Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA Class I alpha 3 domain. J Immunol, 148:3202-3209, 1992. PMID: 1374450

363. Tatake RJ, Ferrone S, Zeff RA. The role of beta-2 microglobulin in temperature-sensitive and interferon-gamma-induced exocytosis of HLA Class I molecules. Transplantation, 54:395-403, 1992. PMID: 1412716

364. Temponi M, Gold AM, Ferrone S. Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen. Cancer Res, 52:2497-2503, 1992. PMID: 1373670

365. Wang Z, Cao Y, D'Urso CM, Ferrone S. Differential susceptibility of cultured human melanoma cell lines to enhancement by retinoic acid of intercellular adhesion molecule 1 expression. Cancer Res, 52:4766-4772, 1992. PMID: 1355009

366. Altomonte M, Gloghini A, Bertola G, Gasparollo A, Carbone A, Ferrone S, Maio M. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res, 53:3343-3348, 1993. PMID: 7686816

367. Armandola EA, Mariani SM, Ferrone S. Serological and molecular characterization of mouse anti-idiotypic monoclonal antibodies elicited with the syngeneic anti-HLA-A2, 28 monoclonal antibody CR11-351. Mol Immunol, 30:287-300, 1993. PMID: 8433707

368. Chen ZJ, Yang H, Liu CC, Hirai S, Ferrone S. Modulation by adjuvants and carriers of the immunogenicity in xenogeneic hosts of mouse anti-idiotypic monoclonal antibody MK2-23, an internal image of human high molecular weight-melanoma associated antigen. Cancer Res, 53:112-119, 1993. PMID: 8416734

369. Di Rosa F, D'Oro U, Ruggiero G, Racioppi L, Acquaviva A, Ferrone S, Fontana S, Zappacosta S. HLA Class II molecules transduce accessory signals affecting the CD3 but not the interleukin-2 activation pathway in T blasts. Hum Immunol, 38:251-260, 1993. PMID: 8138420

370. Ferrone S. Human tumor-associated antigen mimicry by anti-idiotypic antibodies. Immunogenicity and clinical trials in patients with solid tumors. Ann NY Acad Sci, 690:214-224, 1993. PMID: 8368740

371. Ferrone S. Anti-idiotypes in melanoma. Hybridoma, 12:509-514, 1993. PMID: 8300123 372. Fishman P, Azizi E, Shoenfeld Y, Sredni B, Yecheskel G, Ferrone S, Zigelman R, Chaitchik S, Floro S, Djaldetti M.

Vitiligo autoantibodies are effective against melanoma. Cancer, 72:2365-2369, 1993. PMID: 8402450 373. Kageshita T, Kuriya N, Ono T, Horikoshi T, Takahashi M, Wong GY, Ferrone S. Association of high molecular

weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. Cancer Res, 53:2830-2833, 1993. PMID: 8504426

374. Kageshita T, Wang Z, Calorini L, Yoshii A, Kimura T, Ono T, Gattoni-Celli S, Ferrone S. Selective loss of human leukocyte Class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of Class I human leukocyte antigens. Cancer Res, 53:3349-3354, 1993. PMID: 7686817

375. Kageshita T, Yoshii A, Kimura T, Kuriya N, Ono T, Tsujisaki M, Imai K, Ferrone S. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res, 53:4927-4932, 1993. PMID: 8104688

376. Mariani SM, Armandola EA, Ferrone S. Preferential selection of a subset of anti-HLA-DR monoclonal antibodies by a syngeneic anti-idiotypic monoclonal antibody. Transplantation, 55:1176-1181, 1993. PMID: 7684538

377. Pouletty P, Chang C, Kalil J, Atwood E, Ferrone S, Shimizu B, Howson W, Mazaheri R, Del Villano B, Grumet C. Typing of serum-soluble HLA-B27 antigen by ELISA. Tissue Antigens, 42:14-19, 1993. PMID: 8248889

378. Pouletty P, Ferrone S, Amesland F, Cohen N, Westhoff U, Charron D, Shimizu RM, Gross-Wilde H. Summary report from the first international workshop on soluble HLA antigens. Paris, August 1992. Tissue Antigens, 42:45-54, 1993. PMID: 7504328

379. Tedesco F, Narchi G, Radillo O, Meri S, Ferrone S, Betterle C. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol, 151:1562-1570, 1993. PMID: 7687635

380. Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, Ferrone S. Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods, 161:239-256, 1993. PMID: 8505553

381. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA Class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in β2-microglobulin messenger RNA. J Clin Invest, 91:684-692, 1993. PMID: 8432869

382. Wang Z, Hu XZ, Tatake RJ, Yang SY, Zeff RA, Ferrone S. Differential effect of human and mouse β2-microglobulin on the induction and the antigenic profile of endogenous HLA-A and -B antigens synthesized by β2-microglobulin gene-null FO-1 melanoma cells. Cancer Res, 53:4303-4309, 1993. PMID: 7689931

383. Yang H, Chen ZJ, Kageshita T, Yamada M, Ferrone S. Idiotypic cascade in the human high molecular weight melanoma-associated antigen system: fine specificity and idiotypic profile of anti-anti-idiotypic monoclonal antibodies. Eur J Immunol, 23:1671-1677, 1993. PMID: 7686858

384. Yang YM, Rutberg SE, Luo FC, Spratt TE, Halaban R, Ferrone S, Ronai Z. A transcriptional inhibitor induced in human melanoma cells upon ultraviolet irradiation. Cell Growth Differ, 4:595-602, 1993. PMID: 8398900

385. Castagnoli C, Stella M, Magliacani G, Ferrone S, Momigliano-Richiardi P. Similar ectopic expression of ICAM-1 and HLA Class II molecules in hypertrophic scars following thermal injury. Burns, 20:430-433, 1994. PMID: 7999272

386. Iwasaki Y, Takabatake H, Shinji T, Monestier M, Ferrone S. Structural profile of idiotype, anti-idiotype and anti-anti-idiotype monoclonal antibodies in the HLA-DQ3 antigenic system. Eur J Immunol, 24:2874-2881, 1994. PMID: 7957578

387. Kageshita T, Kimura T, Yoshii A, Hirai S, Ono T, Ferrone S. Antigenic profile of mucosal melanoma lesions. Int J Cancer, 56:370-374, 1994. PMID: 8314324

388. May LT, Patel K, Garcìa D, Ndbuisi MI, Ferrone S, Mittelman A, Mackiewicz A, Sehgal PB. Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy. Blood, 84:1887-1895, 1994. PMID: 8080995

389. Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res, 54:415-421, 1994. PMID: 8275478

390. Puppo F, Brenci S, Lanza L, Bosco O, Imro MA, Scudeletti M, Indiveri F, Ferrone S. Increased level of serum HLA Class I antigens in HIV infection. Correlation with disease progression. Hum Immunol, 40:259-266, 1994. PMID: 8002375

391. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res, 54:4848-4850, 1994. PMID: 8069850

392. Takamiya Y, Schönbach C, Nokihara K, Yamaguchi M, Ferrone S, Kano K, Egawa K, Takiguchi M. HLA-B*3501 - peptide interactions: role of anchor residues of peptides in their binding to HLA-B*3501 molecules. Int Immunol, 6:255-261, 1994. PMID: 8155602

393. Arkin S, Ferrone S, Lipton JM. Modulation of adhesion molecule CD54 expression on CD34+ hematopoietic progenitors. Exp Hematol, 23:588-596, 1995. PMID: 7541368

394. Baharav E, Merimsky O, Altomonte M, Shoenfeld Y, Pavlovic M, Maio M, Ferrone S, Fishman P. Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen. Melanoma Res, 5:337-343, 1995. PMID: 8541724

395. Iwasaki Y, Takabatake H, Monestier M, Ferrone S. Idiotypic diversity and variable region gene usage by mouse anti-HLA-DQ3 mAb. Immunogenetics, 42:90-100, 1995. PMID: 7607710

396. Kageshita T, Hirai S, Ono T, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic MAb MK2-23. Immunohistochemical analysis of the reactivity of anti-anti-idiotypic MAb with surgically removed melanoma lesions. Int J Cancer, 60:334-340, 1995. PMID: 7829240

397. Mittelman A, Chen GZJ, Wong GY, Liu C, Hirai S, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res, 1:705-713, 1995. PMID: 9816036

398. Ban N, Day J, Wang X, Ferrone S, McPherson A. Crystal structure of an anti-anti-idiotype shows it to be self-complementary. J Mol Biol, 255:617-627, 1996. PMID: 8568901

399. Boccaletti V, Temponi M, Wang Z, Manganoni AM, Marcelli M, Maio M, Ferrone S, De Panfilis G. The vitronectin receptor alpha-v beta 3, contrary to ICAM-1, is not modulated by interferon-gamma and tumour necrosis factor-alpha on melanoma cell lines. Acta Derm Venereol, 76:269-273, 1996. PMID: 8869681

400. Hicklin DJ, Kageshita T, Ferrone S. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Tissue Antigens, 48:38-46, 1996. PMID: 8864173

401. Merimsky O, Shoenfeld Y, Baharav E, Altomonte M, Chaitchik S, Maio M, Ferrone S, Fishman P. Melanoma-associated hypopigmentation: where are the antibodies? Am J Clin Oncol, 19:613-618, 1996. PMID: 8931683

402. Puppo F, Brenci S, Ghio M, Bignardi D, Contini P, Bacigalupo A, Van Lint MT, Scudeletti M, Ferrone S, Indiveri F. Serum HLA class I antigen levels in allogeneic bone marrow transplantation: a possible marker of acute GVHD. Bone Marrow Transplant, 17:753-758, 1996. PMID: 8733693

403. Wang Z, Margulies L, Hicklin DJ, Ferrone S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA Class I antigen expression. Tissue Antigens, 47:382-390, 1996. PMID: 8795138

404. Dellaratta D, Hicklin DJ, Kishore R, Kageshita T, Ferrone S. Characterization of rabbit antisera elicited with human LMP2- and LMP7-specific peptides and recombinant proteins. Tissue Antigens, 50:567-575, 1997. PMID: 9458109

405. Fisch P, Meuer E, Pende D, Rothenfußer S, Viale O, Kock S, Ferrone S, Fradelizi D, Klein G, Moretta L, Rammensee HG, Boon T, Coulie P, van der Bruggen P. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vγ9/Vδ2 T cells in tumor immunity. Eur J Immunol, 27:3368-3379, 1997. PMID: 9464825

406. Hamby CV, Chinol M, Manzo C, Ferrone S. Purification by affinity chromatography with anti-idiotypic monoclonal antibodies of immunoreactive monoclonal antibodies following labeling with 188Re. Hybridoma, 16:27-31, 1997. PMID: 9085125

407. Hicklin DJ, Dellaratta DV, Kishore R, Liang B, Kageshita T, Ferrone S. β2-microglobulin gene mutations in human melanoma cells: molecular characterization an implications for immune surveillance. Melanoma Res, 7:S67-S74, 1997. PMID: 9578419

408. Mutz M, Hawthorne T, Ferrone S, Pluschke, G. Titration calorimetry study of anti-idiotypic antibody cascade in a human melanoma-associated antigen system. Mol Immunol, 34: 695-707, 1997. PMID: 9430197

409. Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, DiFilippo F, Giannarelli D, Temponi M, Ferrone S. Clinical significance of αvβ3 integrin and intercellar adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res, 57:1554-1560, 1997. PMID: 9108459

410. Turco MC, Romano MF, Lamberti A, Petrella A, Bisogni R, Sun SC, Ferrone S, Bonelli P, Cerra M, Venuta S. Induction of nuclear factor κB/Rel nuclear activity in human peripheral blood T lymphocytes by anti-HLA class I monoclonal antibodies. Tissue Antigens, 50:1-7, 1997. PMID: 9243748

411. Zhu X, Bavari S, Ulrich R, Sadegh-Nasseri S, Ferrone S, McHugh L, Mage M. A recombinant single-chain human Class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of α chain, β chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens. Eur J Immunol, 27:1933-1941, 1997. PMID: 9295029

412. Bresciani A, Pirozzi G, Spera M, Lombardi ML, Ambrosone L, Migliaresi S, Ferrone S, Manzo C. Increased level of serum HLA class I antigens in patients with systemic lupus erythematosus. Correlation with disease activity. Tissue Antigens, 52:44-50, 1998. PMID: 9714473

413. Burlingham W, Jankowska-Gan E, DeVito-Haynes L, Fechner JH Jr, Hogan KT, Claas FHJ, Mulder A, Wang X, Ferrone S. HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies. J Immunol, 161:6705-6714, 1998. PMID: 9862700

414. Chatterjee-Kishore M, Kishore R, Hicklin DJ, Marincola FM, Ferrone S. Different requirements for signal transducer and activator of transcriptmass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J Biol Chem, 273:16177-16183, 1998. PMID: 9632673

415. Desai SA, Wang X, Noronha EJ, Kageshita T, Ferrone S. Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. Cancer Res, 58:2417-2425, 1998. PMID: 9622083

416. Fayen J, Huang JH, Ferrone S, Tykocinski ML. Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events. Int Immunol, 10:1347-1358, 1998. PMID: 9786434

417. Hamby CV, Chinol M, Palestro CJ, Manzo C, Ferrone S. Improved tumor targeting of Rhenium-186-labeled anti-human high-m.w. melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2-23. Int J Cancer, 78:486-490, 1998. PMID: 9797138

418. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. β2-microglobulin mutations, HLA Class I antigen loss and tumor progression in melanoma. J Clin Invest, 101: 2720-2729, 1998. PMID: 9637706

419. Kishore R, Hicklin DJ, Dellaratta DV, Golde U, Kageshita T, Seliger B, Ferrone, S. Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. Tissue Antigens, 51:129-140, 1998. PMID: 9510369

420. Noronha EJ, Wang X, Desai SA, Kageshita T, Ferrone S. Limited diversity of human scFv fragments isolated by panning a synthetic phage-display scFv library with cultured human melanoma cells. J Immunol, 161:2968-2976, 1998. PMID: 9743360

421. Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, Cadei M, Hicklin JD, Ferrone S. HLA Class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res, 58:737-742, 1998. PMID: 9485029

422. Völk H, Charlemagne J, Tournefier A, Ferrone S, Jost R, Parisot R, Kaufman J. Wide tissue distribution of axolotl class II molecules occurs independently of thyroxin. Immunogenetics, 47:339-349, 1998. PMID: 9510551

423. Wang Z, Arienti F, Parmiani G, Ferrone S. Induction and functional characterization of 2-microglobulin (2-)-

free HLA class I heavy chains expressed by 2--deficient human FO-1 melanoma cells. Eur J Immunol, 28:2817-2826, 1998. PMID: 9754569

424. Wang Z, Seliger B, Mike N, Momburg F, Knuth A, Ferrone S. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. Cancer Res, 58:2149-2157, 1998. PMID: 9605759

425. Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer, 80:781-790, 1999. PMID: 10048982

426. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma association with disease progression. Am J Pathol, 154:745-754, 1999. PMID: 10079252

427. Perosa F, Luccarelli G, Prete M, Ferrone S, Dammacco F. Increased serum levels of β2m-free HLA class I heavy chain in multiple myeloma. Br J Haematol, 106:987-994, 1999. PMID: 10520002

428. Perosa F, Prete M, Luccarelli G, Favoino B, Ferrone S, Dammacco F. Serum levels of beta-2-microglobulin-free heavy chain of HLA class I antigen in healthy individuals: relationship to their class I allotype. Hum Immunol, 60: 1058-1066, 1999. PMID: 10600003

429. Puppo F, Bignardi D, Contini P, Hamby CV, Brenci S, Lanza L, Ghio M, Scudeletti M, Indiveri F, Ferrone S. β2-µ free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with β2-µ associated HLA class I heavy chain levels and HLA phenotype. Tissue Antigens, 53: 253-262, 1999. PMID: 10203018

430. Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G, Ferrone S, Indiveri F. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8+ Fas (CD95) + T lymphocytes. Intl Immunol, 12:195-203, 1999. PMID: not available

431. Rebmann V, Pfeiffer K, Päßler M, Ferrone S, Maier S, Weiss E, Grosse-Wilde H. Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens, 53:14-22, 1999. PMID: 10082427

432. Reinhold U, Liu L, Lüdtke-Handjery HC, Heuser C, Hombach A, Wang X, Tilgen W, Ferrone S, Abken H. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. J Invest Dermat, 112: 744-750, 1999. PMID: 10233766

433. Wang Z, Marincola FM, Rivoltini L, Parmiani G, Ferrone S. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med, 190:205-215, 1999. PMID: 10432284

434. Willers J, Lucchese A, Kanduc D, Ferrone S. Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides, 20:1021-1026, 1999. PMID: 10499418

435. Zhou Q, Desai SA, Wang X, Noronha EJ, Neri M, Ferrone S. Identification of monoclonal antibody defined epitopes on human leukocyte antigens utilizing phage display peptide libraries. Lett Peptide Sci, 6:77-86, 1999.

436. Desai SA, Wang X, Noronha EJ, Zhou Q, Rebmann V, Grosse-Wilde H, Moy FJ, Powers R, Ferrone S. Structural

relatedness of distinct determinants recognized by mAb TP25.99 on 2-microglobulin-associated and 2-microglobulin-free HLA class I heavy chains. J Immunol, 165:3275-3283, 2000. PMID: 10975844

437. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S. v3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis. Cancer Immunol Immunother, 49:314-318, 2000. PMID: 10946813

438. Moy FJ, Desai SA, Wang X, Noronha EJ, Zhou Q, Ferrone S, Powers R. Analysis by NMR spectroscopy of the structural homology between the linear and the cyclic peptide recognized by anti-HLA class I mAb TP25.99. J Biol Chem, 275:24679-24685, 2000. PMID: 10825172

439. Puppo F, Brenci S, Contini P, Bignardi D, Hamby CV, Filaci G, Ghio M, Scudeletti M, Picciotto A, Indiveri F, Ferrone S. Increased β2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. Tissue Antigens, 55:333-341, 2000. PMID: 10852385

440. Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G, Ferrone S, Indiveri F. Soluble human MHC class I molecules induce soluble Fas Ligand secretion and trigger apoptosis in activated CD8 (+) Fas (CD95) (+) T lymphocytes. Int Immunol, 12:195-203, 2000. PMID: 10653855

441. All-Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, Larsson O. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci, 42:2153-2156, 2001. PMID: 11527924

442. Kamarashev J, Ferrone S, Seifert B, Boni R, Nestle FO, Burg G, Dummer R. TAP 1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer, 95:23-28, 2001. PMID: 11241306

443. Seliger B, Ritz U, Abele R, Bock M, Tampé R. Sutter G, Drexler I, Huber C, Ferrone S. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res, 61:8647-8650, 2001. PMID: 11751378

444. Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer, 92:369-376, 2001. PMID: 11466692

445. Wetzler M, Baer MR, Stewart SJ, Donohue K, Ford L, Stewart CC, Repasky EA, Ferrone S. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia, 15:128-133, 2001. PMID: 11243380

446. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res, 62:6178-6186, 2002. PMID: 12414645

447. Rothenfusser S, Buchwald A, Kock S, Ferrone S, Fisch P. Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. Cell Immunol, 215:32-44, 2002. PMID: 12142034

448. Wang ZC, Smith AG, Yunis EJ, Selvakumar A, Ferrone S, McKinney S, Lee JH, Fernandez-Vina M, Hansen JA. Molecular characterization of the HLA-Cw*0409N allele. Hum Immunol, 63:295-300, 2002. PMID: 12039411

449. Chang CC, Murphy SP, Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Hum Immunol, 64:1057-1063, 2003. PMID: 14602236

450. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A, -B, -C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol, 33:125-134, 2003. PMID: 12594841

451. Dissemond J, Götte P, Mörs J, Lindeke A, Goos M, Ferrone S, Wagner SN. Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Res, 13:253-258, 2003. PMID: 12777979

452. Dissemond J, Goette P, Moers J, Lindeke A, Goos M, Ferrone S, Wagner SN. Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression. Melanoma Res, 13:371-377, 2003. PMID: 12883363

453. Ogino T, Bandoh N, Hayashi T, Miyokawa N, Harabuchi Y, Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res, 9:4043-4051, 2003. PMID: 14519625

454. Ogino T, Wang X, Ferrone S. Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods, 278:33-44, 2003. PMID: 12957394

455. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens, 62:385-393, 2003. PMID: 14617045

456. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol, 171:1918-1926, 2003. PMID: 12902494

457. Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, Storkel S. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res, 9:1721-1727, 2003. PMID: 12738726

458. Wang X, Liang B, Rebmann V, Lu J, Celis E, Kageshita T, Grosse-Wilde H, Ferrone S. Specificity and functional characteristics of anti-HLA-A mAbs LGIII-147.4.1 and LGIII-220.6.2. Tissue Antigens, 62:139-148, 2003. PMID: 12889994

459. Weinman EC, Roche PC, Kasperbauer JL, Cha SS, Sargent DJ, Cheville J, Murphy LM, Chen L, Wettstein PJ, Gostout B, Ferrone S, Strome SE. Characterization of antigen processing machinery and survivin expression in tonsillar squamous cell carcinoma. Cancer, 97:2203-2211, 2003. PMID: 12712472

460. Wetzler M, McElwain BK, Stewart CC, Blumenson L, Mortazavi A, Ford LA, Slack JL, Barcos M, Ferrone S, Baer MR. HLA-DR antigen-negative acute myeloid leukemia. Leukemia, 17:707-715, 2003. PMID: 12682628

461. Yang T, McNally BA, Ferrone S, Liu Y, Zheng P. A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line. J Biol Chem, 278:15291-15296, 2003. PMID: 12582163

462. Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Storkel S, Seliger B. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer, 109:265-273, 2004. PMID: 14750179

463. Atkins D, Ferrone S, Schmahl GE, Störkel S, Seliger B. Down-regulation of HLA Class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol, 171:885-889, 2004. PMID: 14713847

464. Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, Ferrone S. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood, 103:3122-3130, 2004. PMID: 15070694

465. Murray JL, Gillogly M, Kawano K, Efferson CL, Lee JE, Ross M, Wang X, Ferrone S, Ioannides CG. Fine specificity of high molecular weight-melanoma-associated antigen specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res, 64:5481-5488, 2004. PMID: 15289358

466. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia, 6:558-568, 2004. PMID: 15548365

467. Wang X, Campoli M, Ko E, Luo W, Ferrone S. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods, 294:23-35, 2004. PMID: 15604013

468. Whiteside TL, Stanson J, Shurin MR, Ferrone S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol, 173:1526-1534, 2004. PMID: 15265880

469. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida J, Simpson MA, McCarthy JB. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol, 165:881-891, 2004. PMID: 15210734

470. Albers A, Abe K, Hu Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hot-spot β2-microglobulin gene mutations, HLA-A2 allospecificity loss and antigen process machinery component downregulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol, 174:1462-1471, 2005. PMID: 15661905

471. Chang CC, Hernandez-Guzman FG, Luo W, Wang X, Ferrone S, Ghosh D. Structural basis of antigen mimicry in a clinically relevant melanoma antigen system. J Biol Chem, 280:41546-41552, 2005. PMID: 16227204

472. Claus JA, Brady MT, Lee J, Donohue KA, Sait SN, Ferrone S, Wetzler M. T cell activation by t(9:22) acute lymphoblastic leukemia-derived dendritic-like cells is associated with increased tapasin expression. Cancer Immunol Immunother, 12:1-6, 2005. PMID: 16024597

473. Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M, Campoli M, Ferrone S. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res, 11: 8304-8311, 2005. PMID: 16322289

474. Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, Schmidt WM, Jasinska J, Kundi M, Wolff K, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer, 114:426-432, 2005. PMID: 15578703

475. Kageshita T, Ishihara T, Campoli M, Ferrone S. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens, 65:419-428, 2005. PMID: 15853896

476. nt J, Wang J, Lopez-Albaitero A, Schaefer C, Gooding W, Whiteside TL, Ferrone S, DeLeo A, Ferris RL. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res, 65:11146-11155, 2005. PMID: 16322265

477. Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens, 66:185-194, 2005. PMID: 16101829

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Albers+A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Abe+K%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Hunt+J%22%5BAuthor%5D



















http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Wang+J%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Lopez%2DAlbaitero+A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Schaefer+C%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Gooding+W%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Whiteside+TL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Ferrone+S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22DeLeo+A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Search&term=%22Ferris+RL%22%5BAuthor%5D

478. Bolesta E, Kowalczyk A, Wierzbicki A, Rotkiewicz P, Bambach B, Tsao CY, Horwacik I, Kolinski A, Rokita H, Brecher M, Wang X, Ferrone S, Kozbor D. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res, 65:3410-3418, 2005. PMID: 15833876

479. Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, von Knebel Doeberitz M. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res, 65:6418-6424, 2005. PMID: 16024646

480. Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S. Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J Immunol, 174:7104-7110, 2005. PMID: 15905554

481. Meissner M, Reichert TE, Kunke M, Gooding W, Whiteside TL, Ferrone S, Seliger B. Defects in the HLA class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res, 11:2552-2560, 2005. PMID: 15814633

482. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Morandi F, Bocca P, Gambini C, Ferrone S, Pistoia V. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett, 228:155-161, 2005. PMID: 15923080

483. Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C, Wang X, Ferrone S, Pistoia V. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene, 24:4634-4644, 2005. PMID: 15897905

484. Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, Hensel N, Melenhorst J, Li J, Ferrone S, Barrett JA. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukema involves NKG2D-target cell interactions. Blood, 106: 3666-3672, 2005. PMID: 16046526

485. Tourkova IL, Shurin GV, Chatta GS, Perez L, Finke J, Whiteside TL, Ferrone S, Shurin MR. Restoration by IL-15 of MHC class I antigen processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J Immunol, 175:3045-3052, 2005. PMID: 16116192

486. Vergilis IJ, Szarek M, Ferrone S, Reynolds SR. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol, 125: 526-531, 2005. PMID: 16117794

487. Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S. HLA Class I antigen downregulation in primary ovary carcinoma lesions: Association with disease stage. Clin Cancer Res, 11: 67-72, 2005. PMID: 15671529

488. Wagner S, Hafner C, Allwardt D, Jasinska J, Ferrone S, Zielinski C, Scheiner O, Wiedermann U, Pehamberger H, Breiteneder H. Vaccination with a human high molecular weight-melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol, 174:976-982, 2005. PMID: 15634921

489. Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods, 299:139-151, 2005. PMID: 15896802

490. Wang X, Ko EC, Peng L, Gillies SD, Ferrone S. Human high molecular weight melanoma associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic (anti-id) mAb MK2-23: enhancement of immunogenicity of anti-id mAb MK2-23 by fusion with interleukin-2. Cancer Res, 65:6976-6983, 2005. PMID: 16061683

491. Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S, Slingluff CL Jr. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol, 174:6863-6871, 2005. PMID: 15905528

492. Almeciga I, Wang ZC, Zúñiga J, Fernandez-Viña M, Clavijo O, Araujo H, Romero V, Henry J, Ferrone S, Yunis EJ. Allorecognition of an HLA-A*01 aberrant allele by an HLA identical family member carrying the HLA-A*0101 allele. J Immunol, 177:8643-8649, 2006. PMID: 17142764

493. Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S. Association of antigen processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res, 66:6405-6411, 2006. PMID: 16778219

494. Chang CC, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, Slingluff CL Jr, Ferrone S. Defective HLA class I-associated antigen presentation caused by a novel β2-microglobulin loss-of-function in melanoma cells. J Biol Chem, 281:18763-18773, 2006. PMID: 16648140

495. Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, Deleo AB, Ferrone S, Ferris RL. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol, 176:3402-3409, 2006. PMID: 16517708

496. Luo W, Ko E, Hsu JC, Wang X, Ferrone S. Targeting melanoma cells with HMW-MAA-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol, 176:6046-6054, 2006. PMID: 16670313

497. Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S. Regulation of human high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene, 25:2873-2884, 2006. PMID: 16407841

498. Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res, 66:9281-9289, 2006. PMID: 16982773

499. Peng L, Ko E, Luo W, Wang X, Shrikant PA, Ferrone S. CD4-dependent potentiation of a high molecular weight-melanoma-associated antigen-specific CTL response elicited in HLA-A2/Kb transgenic mice. J Immunol, 176:2307-2315, 2006. PMID: 16455987

500. Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M. Co-expression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxcity. Cancer Res, 66:6503-6511, 2006. PMID: 16818621

501. Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, Ferrone S. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother, 55:891-899, 2006. PMID: 16187081

502. Reynolds S, Vergilis IJ, Szarek M, Ferrone S, Bystryn JC. Cytoplasmic melanoma associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy? Int J Cancer, 119:157-161, 2006. PMID: 16450373

503. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res, 12:5503-5510, 2006. PMID: 17000686

504. Connolly N, Riddler S, Stanson J, Gooding W, Rinaldo CR, Ferrone S, Whiteside TL. Levels of antigen processing machinery components in dendritic cells generated for vaccination of HIV-1+ subjects. AIDS, 21:1683-1692, 2007. PMID: 17690565

505. Dierssen JWF, de Miranda NFCC, Ferrone S, van Puijenbroek M, Cornelisse CJ, Fleuren GJ, van Wezel T, Morreau H. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer, 7:33-44, 2007. PMID: 17316446

506. Ko E, Luo W, Peng L, Wang X, Ferrone S. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res, 67:7875-7884, 2007. PMID: 17699794

507. Leys CM, Nomura S, Lafleur BJ, Ferrone S, Kaminishi M, Montgomery E, Goldering JR. Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery 141:41-50, 2007. PMID: 17188166

508. Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol, 114:111-119, 2007. PMID: 17541610

509. Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, Prigione I, Pistoia V. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res, 67:6433-6441, 2007. PMID: 17616704

510. Oflazoglu E, Elliott M, Takita H, Ferrone S, Henderson RA, Repasky EA. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model. J Transl Med, 5:29, 2007. PMID: 17592641

511. Ogino T, Moriai S, Ishida Y, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer, 120:2401-2410, 2007. PMID: 17315195

512. Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garre ML, Cama A, Basso G, Ferrone S, Gambini C, Pistoia V. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res, 67:5471-5478, 2007. PMID: 17545629

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Morandi%20F%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Levreri%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Bocca%20P%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Galleni%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Raffaghello%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ferrone%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Prigione%20I%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pistoia%20V%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Oflazoglu%20E%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Elliott%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Takita%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus


http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Henderson%20RA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Repasky%20EA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

513. Signorino E, Brusa D, Granata R, Malavasi F, Ferrone S, Matera L. Contribution of dendritic cells FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies. Cancer Biol Ther, 6:1932-1937, 2007. PMID: 18087220

514. Theurillat JP, Zürrer-Härdi U, Varga Z, Storz M, Probst-Hensch NM, Seifert B, Fehr MK, Fink D, Ferrone S, Pestalozzi B, Jungbluth AA, Chen YT, Jäger D, Knuth A, Moch H. NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol Immunother, 56:1723-1731, 2007. PMID: 17410359

515. Tsuda N, Chang DZ, Mine T, Efferson C, García-Sastre A, Wang X, Ferrone S, Ioannides CG. Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. Cancer Res, 67:8378-8387, 2007. PMID: 17804754

516. Vermeulen CF, Jordanova ES, ter Haar NT, Kolkman-Uljee SM, de Miranda NF, Ferrone S, Peters AA, Fleuren GJ. Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma. Gynecol Oncol, 105:593-599, 2007. PMID: 17382375

517. Wang W, Edington H, Rao UNM, Jukic D, Land S, Becker D, Ferrone S, Kirkwood JM. Modulation of signal

transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFN2b. Clin Cancer Res, 13:1523-1531, 2007. PMID: 17332298

518. Belicha-Villanueva A, McEvoy S, Cycon K, Ferrone S, Gollnick SO, Bangia N. Differential contribution of TAP and tapasin to HLA class I antigen expression. Immunology, 124:112-120, 2008. PMCID: PMC2434385

519. Goto Y, Ferrone S, Arigami T, Kitago M, Tanemura A, Sunami E, Nguyen SL, Turner RR, Morton DL, Hoon DS. Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res, 11:3401-3407, 2008. PMCID: PMC2686177

520. Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther, 7:3642-3653 2008. PMID: 19001446. PMCID: in process (NIHMS395033)

521. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, DeGeest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK. HLA class I antigen processing machinery component expression and ntratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res, 14:3372-3379, 2008. PMID: 18519766. PMCID: in process (NIHMS395034)

522. Maciag PC, Seavy MM, Pan ZK, Ferrone S, Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res, 68:8066-8075, 2008. PMCID: PMC3004011

523. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother, 57:197-206, 2008. PMCID: PMC2082063

524. Morandi F, Raffaghello L, Bianchi G, Meloni F, Salis A, Millo E, Ferrone S, Barnaba V, Pistoia V. Immunogenicity of human mesenchymal stem cells in HLA-class I restricted T cell responses against viral or tumor-associated antigens. Stem Cellsm, 26:1275-1287, 2008. PMCID: PMC2726787

525. Schwenkert M, Birkholz K, Schwemmien M, Kellner C, Kügler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dörrie J, Ferrone S, Kämpgen E, Fey GH. A single chain immunotoxin, targeting the melanoma-associated chondrotin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. Melanoma Res, 18:73-84, 2008. PMCID: PMC2741307

526. Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, Somasundaram R, Ferrone S, Tsao CY, Herlyn D. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother, 57:1079-1089, 2008. PMID: 18157673. PMCID: in process (NIHMS395364)

527. Wongsena W, Sconocchia G, Cho HS, Chang CC, Wang X, Klumkrathok K, Ferrone S, Leelayuwat C. Production and characterization of monoclonal antibodies against major histocompatibility complex class I chain-related gene A. Tissue Antigens, 72:431-440, 2008. PMID: 18937790. PMCID: in process (NIHMS395362)

528. Drake AS, Brady MT, Wang X, Sait SJ, Earp JC, Ghoshal-Gupta S, Ferrone S, Wang E, Wetzler MA. Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer Immunol Immunother, 58:415-427, 2009. PMCID: PMC2741306

529. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol, 182:5240-5249, 2009. PMID: 19380770. PMCID: in process (NIHMS395361)

http://www.ncbi.nlm.nih.gov/pubmed/18087220?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Theurillat%20JP%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Z%C3%BCrrer-H%C3%A4rdi%20U%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Varga%20Z%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Storz%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Probst-Hensch%20NM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Seifert%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Fehr%20MK%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Fink%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus


http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pestalozzi%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Jungbluth%20AA%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Chen%20YT%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22J%C3%A4ger%20D%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Knuth%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Moch%20H%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17382375&ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum


http://www.ncbi.nlm.nih.gov/pubmed/19001446?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum


http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mehta%20AM%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Jordanova%20ES%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Kenter%20GG%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus


http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Fleuren%20GJ%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVAbstractPlus





530. Hsieh CH, Hsu YJ, Chang CC, Liu HC, Chuang KL, Chuang CK, Pang ST, Hasumi K, Ferrone S, Liao SK. Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta(2)-microglobulin genes. Cancer Immunol Immunother, 58:395-408, 2009. PMCID: PMC2793116

531. Kitago M, Koyanagi K, Nakamura T, Goto Y, Faries M. O'Day SJ, Morton DL, Ferrone S, Hoon DS. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem, 55:757-764, 2009. PMCID: PMC2760934

532. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Höglund P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A, Kärre K, Shibuya A, Carbone E, Colucci F. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest, 119:1251-1263, 2009. PMCID: PMC2673866

533. La Rocca R, Fulciniti M, Lakshmikanth T, Mesuraca M, Ali TH, Mazzei V, Amodio N, Catalano L, Rotoli B, Ouerfelli O, Grieco M, Gulletta E, Bond HM, Morrone G, Ferrone S, Carbone E. Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells. J Immunol, 182:4529-4537, 2009. PMCID: PMC2747523

534. Lin J, Takata M, Murata H, Goto Y, Kido K, Ferrone S, Saida T. Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst, 101:1423-1427, 2009. PMCID: PMC2765260

535. López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother, 58:1855-1864, 2009. PMID: 19319529. PMCID: in process (NIHMS395350)

536. López-Albaitero A, Maillard R, Hackman T, Andrade-Filho P, Wang X, Gooding W, Ferrone S, Kalinski P, Ferris RL. Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. J Immunother, 32:465-473, 2009. PMCID: PMC2913548

537. Mine T, Matsueda S, Li Y, Tokumitsu H, Gao H, Danes C, Wong KK, Wang X, Ferrone S, Ioannides CG. Breast cancer cells expressing stem cell markers CD44(+) CD24 (lo) are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother, 58:1185-1194, 2009. PMCID: PMC2726795

538. Paul AK, Ciesielski MJ, Sajjad M, Wang X, Ferrone S, Abdel-Nabi H, Fenstermaker RA. Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting. J Neurooncol, 94:21-30, 2009. PMCID: PMC2741310

539. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res, 69:2887-2895, 2009. PMCID: PMC2664865

540. Schwab J, Boland P, Agaram N, Socci N, Guo T, O'Toole G, Wang X, Ostroumov E, Hunter C, Block J, Doty S, Ferrone S, Healey J, Antonescu CR. Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother, 58:339-349, 2009. PMID: 18641983. PMCID: in process (NIHMS395036)

541. Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, Moch H, Terracciano L, Tornillo L. Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. Neoplasia, 11:662-671, 2009. PMCID: PMC2697352

542. Shen Y, Xia M, Zhang J, Xu L, Yang J, Chen A, Miao F, Ferrone S, Xie W. IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells. Mol Immunol, 46:2045-2053, 2009. PMID: 19428110. PMCID: in process (NIHMS395039)

543. Tourkova IL, Shurin GV, Ferrone S, Shurin MR. Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells. Cancer Immunol Immunother, 58:567-574, 2009. PMCID: PMC2726804

544. Tosello V, Zamarchi R, Merlo A, Gorza M, Piovan E, Mandruzzato S, Bronte V, Wang X, Ferrone S, Amadori A, Zanovello P. Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. Eur J Immunol, 39:56-66, 2009. PMCID: PMC2747509

545. Verheyden S, Ferrone S, Mulder A, Claas FH, Schots R, De Moerloose B, Benoit Y, Demanet C. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunol Immunother, 58:855-865, 2009. PMID: 18841361. PMCID: in process (NIHMS395042)





























http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Verheyden%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Ferrone%20S%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Mulder%20A%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Claas%20FH%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Schots%20R%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22De%20Moerloose%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Benoit%20Y%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Demanet%20C%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus

546. Vujanovic L, Whiteside TL, Potter DM, Chu J, Ferrone S, Butterfield LH. Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol Immunother, 58:121-133, 2009. PMID: 18488218. PMCID: in process (NIHMS395035)

547. Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA, McCarthy JB. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res, 69:7538-7547, 2009. PMID: 19738072. PMCID: in process (NIHMS395045)

548. Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res, 70:3027-3033, 2010. PMID: 20395199. PMCID: in process (NIHMS395046)

549. Cathro HP, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, Frierson HF Jr. Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother, 59:465-472, 2010. PMID: 19756593. PMCID: in process (NIHMS395051)

550. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, Mortini P, Ferrone S, Doglioni C, Marincola FM, Galli R, Parmiani G, Maccalli C. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res, 16:800-813, 2010. PMCID: PMC2842003

551. Goto Y, Arigami T, Murali R, Scolyer RA, Tanemura A, Takata M, Turner RR, Nguyen L, Nguyen, T, Morton DL, Ferrone S, Hoon DS. High molecular weight-melanoma-associated antigen as a biomarker of desmoplastic melanoma. Pigment Cell Melanoma Res, 23:137-140, 2010. PMCID: PMC2879036

552. Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin Cancer Res, 16:825-834, 2010. PMCID: PMC2818599

553. Michel S, Linnebacher M, Alcaniz J, Voss M, Wagner R, Dippold W, Becker C, von Knebel Doeberitz M, Ferrone S, Kloor M. Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer, 127:889-898, 2010. PMCID: PMC2892639

554. Mine T, Matsueda S, Gao H, Li Y, Wong KK, Peoples GE, Ferrone S, Ioannides CG. Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells. Oncol Rep, 23:1537-1543, 2010. PMID: 20428807. PMCID: in process (NIHMS395054)

555. Racanelli V, Leone P, Frassanito MA, Brunetti C, Perosa F, Ferrone S, Dammacco F. Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood, 115:1185-93, 2010. PMCID: PMC2826230

556. Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, Hartmann A. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother, 59:529-540, 2010. PMID: 19820934. PMCID: in process (NIHMS395055)

557. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy J, Brufsky A, Chivukula M, Khoury T, Hsu D, Lyerly H, Clay T, Ferrone S. CSPG4 as a new target for antibody-based immunotherapy of triple negative breast cancer. J Natl Cancer Inst, 102:1496-1512, 2010. PMCID: PMC2950168

558. zu Horste GM, Heidenreich H, Lehmann HC, Ferrone S, Hartung HP, Wiendl H, Kieseier BC. Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies. Glia, 58:80-92, 2010. PMID: 19544394. PMCID: PMC3480724

559. Brady MT, Lee J, Ferrone S, Wang ES, Wetzler M. Interferon-γ secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. Leuk Res, 35:275-277, 2011. PMCID: PMC3021772

560. Chikamatsu K, Takahashi G, Sakakura K, Ferrone S, Masuyama K. Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck, 33:208-215, 2011. PMID: 20848440. PMCID: in process (NIHMS395061)

561. Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, Kieber-Emmons AM, Siegel ER, Suva LJ, Ferrone S, Kieber-Emmons T, Monzavi-Karbassi B. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selection ligands in aggressive breast cancer cells. Breast Cancer Res, 13:R58, 2011. PMID: 21658254. PMCID: PMC3218947

562. Latzka J, Gaier S, Hofstetter G, Balazs N, Smole U, Ferrone S, Scheiner O, Breiteneder H, Pehamberger H, Wagner



http://www.ncbi.nlm.nih.gov/pubmed?term=%22Burns%20WR%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Zhao%20Y%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Frankel%20TL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hinrichs%20CS%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Zheng%20Z%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Xu%20H%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Feldman%20SA%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ferrone%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rosenberg%20SA%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Morgan%20RA%22%5BAuthor%5D




http://www.ncbi.nlm.nih.gov/pubmed/20103663?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1


http://www.ncbi.nlm.nih.gov/pubmed?term=%22Scolyer%20RA%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tanemura%20A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Takata%20M%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Turner%20RR%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nguyen%20L%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nguyen%20T%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Morton%20DL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ferone%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hoon%20DS%22%5BAuthor%5D





http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mine%20T%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Matsueda%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gao%20H%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Li%20Y%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Wong%20KK%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Peoples%20GE%22%5BAuthor%5D


http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ioannides%20CG%22%5BAuthor%5D








http://www.ncbi.nlm.nih.gov/pubmed/20943267




S. Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity. PLoS One, 6:e19383, 2011. PMID: 21573118. PMCID: PMC3089623

563. Lee SC, Srivastava RM, López-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res, 50:248-254, 2011. PMID: 21717064. PMCID: in process (NIHMS395027)

564. Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother, 6:525-535, 2011. PMCID: PMC3426276

565. Mayayo SL, Prestigio S, Maniscalco L, Rosa GL, Aricò A, Maria RD, Cavallo F, Ferrone S, Buracco P, Iussich S. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. Vet J, 190:e26-e30, 2011. PMID: 21482159. PMCID: Not available

566. Morandi F, Corrias MV, Levreri I, Scaruffi P, Raffaghello L, Carlini B, Bocca P, Prigione I, Stigliani S, Amoroso L, Ferrone S, Pistoia V. Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunol Immunother, 60:1485-1495, 20011. PMCID: PMC3186874

567. Price MA, Wanshura LE, Yang J, Carlson J, Xiang B, Li G, Ferrone S, Dudek AZ, Turley EA, McCarthy JB. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res, 24:1148-1157, 2011. PMID: 22004131. PMCID: in process (NIHMS394813)

568. Respa A, Bukur J, Ferrone S, Pawelec G, Zhao Y, Wang E, Marincola FM, Seliger B. Association of IFN-{gamma} signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res, 17:2668-2678, 2011. PMID: 21248298. PMCID: in process (NIHMS394800)

569. Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopouloum E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Droeser R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli GC. Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer, 128:2663-2672, 2011. PMID: 20715106. PMCID: in process (NIHMS394811)

570. Visus C, Wang YY, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, Brand RE, Ferrone CR, Whiteside S, Ferrone S, Deleo A, and Wang X. Targeting ALDHbright human carcinoma initiating cells with ALDH1A1-specific CD8+ T cells. Clin Cancer Res, 17:6174-6184, 2011.

571. Wang X, Katayama A, Wang Y, Yu L, Favoino E, Sakakura K, Favole A, Tsuchikawa T, Silver S, Watkins SC, Kageshita T, Ferrone S. Functional characterization of an scFV antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res, 71:7410-7422, 2011. PMID: 22021902. PMCID: in process (NIHMS394798)

572. Zarour H, Ferrone S. Cancer immunotherapy: progress and challenges in the clinical setting. Eur J Immunol, 41:1510-1515, 2011. PMID: 21618503. PMCID: in process (NIHMS394802)

573. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother, 2012. PMID: 22258792. PMCID: not available

574. Campoli M, Fitzpatrick JE, High W, Ferrone S. HLA antigen expression in melanocytic lesions: is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes? J Am Acad Dermatol, 66:911-916, 2012. PMCID: NIHMS28439

575. Favole A, Cascio P, Cerruti F, Sereno A, Tursi M, Tomatis A, Beffa CD, Ferrone S, Bollo E. MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma. Transl Oncol, 5:48-55, 2012. PMCID: PMC3281407

576. Khoury T, Foluso A, Chandraseekhar R, DeLeo A, Ferrone S, Wang Y, Wang X. Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Modern Pathol, 25:388-397, 2012. PMID: 22080062. PMCID: in process (NIHMS395026)

577. Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S, Okada H. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother, 61:789-801, 2012. PMCID: PMC3365630

578. Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res, 18:5352-5363, 2012. PMID: 22893632. PMCID: not available.

579. Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, Saida T, Ferrone S, Takata M, Uhara H,





http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mayayo%20SL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Prestigio%20S%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Maniscalco%20L%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rosa%20GL%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Aric%C3%B2%20A%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Maria%20RD%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Cavallo%20F%22%5BAuthor%5D


http://www.ncbi.nlm.nih.gov/pubmed?term=%22Buracco%20P%22%5BAuthor%5D

http://www.ncbi.nlm.nih.gov/pubmed?term=%22Iussich%20S%22%5BAuthor%5D

Okuyama R. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer, 106:939-946, 2012. PMCID: PMC3305957

580. Tanaka K, Tsuchikawa T, Miyamoto M, Maki T, Ichinokawa M, Kubota KC, Shichinohe T, Hirano S, Ferrone S, Dosaka-Akita H, Matsuno Y, Kondo S. Down-regulation of human leukocyte antigen class I heavy chain in tumors is associated with poor prognosis in advanced esophageal cancer patients. Int J Oncol, 40:965-974, 2012. PMID: 22134332. PMCID: not available

581. Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A. Role of Apollon in human melanoma resistance to anti-tumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res, 18:3316-3327, 2012; PMID: 22553342. PMCID: in process (NIHMS395277)

582. Concha-Benavente F, Srivastava RM, Ferrone S, Ferris RL. EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3. Oncoimmunology. 2:e27215. 2013. PMID: 24501692.

583. Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, Ferrone S, Peretz T, Machlenkin A, Lotem M. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. J Immunol. 190:5856-5865, 2013. PMID: 23626012.

584. Hamilton R, Krauze M, Romkes M, Omolo B, Konstantinopoulos P, Reinhart T, Harasymczuk M, Wang Y, Lin Y, Ferrone S, Whiteside T, Bortoluzzi S, Werley J, Nukui T, Fallert-Junecko B, Kondziolka D, Ibrahim J, Becker D, Kirkwood J, Moschos S. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer, 119:2737-46. 2013 PMID: 23695963.

585. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 133:624-636, 2013. PMID: 23364915. PMCID: 3663913.

586. Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, Ferrone S, Ferris RL. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res. 19:798-808, 2013 PMID: 23363816. PMCID: 3578140.

587. Morandi B, Bonaccorsi I, Mesiti M, Conte R, Carrega P, Costa G, Iemmo R, Martini S, Ferrone S, Cantoni C, Mingari MC, Moretta L, Ferlazzo G. Characterization of human afferent lymph dendritic cells from seroma fluids. J Immunol. 191:4858-66, 2013. PMID: 24078697.

588. Sabbatino F, Ferrone S. Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy? Clin Cancer Res.19:958-960, 2013. PMID: 23340298.

589. Schilling B, Harasymczuk M, Schuler P, Egan J, Ferrone S, Whiteside TL. IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells. PloS one. 8:e47234, 2013. PMID: 23408925. PMCID: 3567103.

590. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, Lopez-Albaitero A, Gibson SP, Gooding WE, Ferrone S, Ferris RL. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 19:1858-1872, 2013. PMID: 23444227. PMCID: 3640274.

591. Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H. LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res. 19:1816-26, 2013. PMID: 23401227. PMCID: 3618546.

592. Wastowski IJ, Simoes RT, Yaghi L, Donadi EA, Pancoto JT, Poras I, Lechapt-Zalcman E, Bernaudin M, Valable S, Carlotti CG, Jr., Flajollet S, Jensen SS, Ferrone S, Carosella ED, Kristensen BW, Moreau P. Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-gamma treatments: results from a multicentric study. Am J Pathol. 182:540-552, 2013. PMID: 23219427. PMCID: 3562737.

593. Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto C, Galgani M6, Matarese G, Bifulco M, Ferrone S, Colucci F, Moretta A, Kärre K, Carbone E. Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun. 5:5639,2014. PMID: 25472612.

594. Fauci JM, Sabbatino F, Wang Y, Londono-Joshi AI, Straughn JM, Jr. Landen CN, Ferrone S, Buchsbaum DJ. Monoclonal antibody-based immunotherapy of ovarian cancer: Targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecol Oncol. 132:203-10, 2014. PMID: 24216048.

595. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 5:403-16, 2014. PMID: 24480782.

596. Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, Del Vecchio M, Creighton CJ, Ittmann MM, Ferrone S, Dotti G. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res. 20:962-71, 2014. PMID: 24334762.

597. Leone P, Di Tacchio M, Berardi S, Santantonio T, Fasano M, Ferrone S, Vacca A, Dammacco F, Racanelli V. Dendritic cell maturation in HCV infection: altered regulation of MHC class I antigen processing-presenting machinery. J Hepatol. pii: S0168-8278(14)00256-6, 2014. PMID: 24732300.

598. Morandi F, Di Carlo E, Ferrone S, Petretto A, Pistoia V, Airoldi I. IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation. J Immunol. 192:2634-42, 2014. PMID: 24554774.

599. Riccardo F, Iussich S, Maniscalco L, Mayayo SL, Rosa GL, Arigoni M, Maria RD, Gattino F, Lanzardo S, Lardone E, Martano M, Morello E, Prestigio S, Fiore A, Quaglino E, Zabarino S, Ferrone S, Buracco P, Cavallo F. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res. 20:3753-62, 2014. PMID: 24874834.

600. Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014. PMID: 24732172.

601. Sabbatino F, Fusciello C, Somma D, Pacelli R, Poudel R, Pepin D, Leonardi A, Carlomagno C, Della Vittoria Scarpati G, Ferrone S, Pepe S. Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation. Cytometry A. 85:953-61, 2014. PMID: 25182801.

602. Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, Lauro D, Lugli A, Han J, Iezzi G, Ferrone C, Ferlosio A, Tornillo L, Droeser R, Rossi P, Attanasio A, Ferrone S, Terracciano L. HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia. 16:31-42, 2014. PMID: 24563618.

603. Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, Ferrelli F, Coppola A, Arriga R, Lauro D, Lezzi G, Terracciano L, Ferrone S. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology. 3:e952197, 2014. PMID: 25610741.

604. Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2:690-8, 2014. PMID: 24866169.

605. Sucker A, Zhao F, Real B, Heeke C, Bielefeld N, Maβen S, Horn S, Moll I, Maltaner R, Horn PA, Schilling B, Sabbatino F, Lennerz V, Kloor M, Ferrone S, Schadendorf D, Falk CS, Griewank K, Paschen A. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin Cancer Res. 20:6593-604, 2014. PMID: 25294904.

606. Volonte A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, Bissolati M, Ghirardelli L, Orsenigo E, Ferrone S, Doglioni C, Stassi G, Dellabona P, Staudacher C, Parmiani G, Maccalli C. Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell-Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4. J Immunol. 192:523-32, 2014. PMID: 24277698.

607. Wang Y, Li W, Patel SS, Cong J, Zhang N, Sabbatino F, Liu X, Qi Y, Huang P, Lee H, Taghian A, Li J, DeLeo AB, Ferrone S, Epperly MW, Ferrone CR, Ly A, Brachtel EF, Wang X. Blocking the formation of radiation–induced breast cancer stem cells Oncotarget. 5:3743-55, 2014. PMID: 25003837.

608. Fenton M, Whiteside TL, Ferrone S, Boyiadzis M. Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts. Oncol Res. 22:117-21, 2015. PMID: 25706398.

609. Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, Whiteside TL, Ferris RL. CTLA-4+ Regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 75:2200-10, 2015. PMID: 25832655

610. Ruiz C, Li J, Luttgen MS, Kolatkar A, Kendall JT, Flores E, Topp Z, Samlowski WE, McClay E, Bethel K, Ferrone S, Hicks J, Kuhn P. Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol. 12:016008, 2015. PMID: 25574741.

611. Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, Branstetter BF, Ferrone S, Ferris

RL. STAT1-Induced HLA Class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC Patients. Cancer Immunol Res. 3:936-45. 2015 PMID: 25972070

612. Surmann EM, Voigt AY, Michel S, Bauer K, Reuschenbach M, Ferrone S, von Knebel Doeberitz M, Kloor M. Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer. Cancer Immunol Immunother. 64:357-66, 2015. PMID: 25445815.

613. Wang Y, Wang X, Ferrone CR, Schwab JH, Ferrone S. Intracellular antigens as targets for antibody based immunotherapy of malignant diseases. Mol Oncol. 9:1982-93, 2015. PMID: 26597109.

614. Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, Lauro D, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, Sconocchia G. Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage. Oncotarget. 7:2070-9, 2016. PMID: 26655503

615. Chang CC, Pirozzi G, Wen SH, Chung IH, Chiu BL, Errico S, Luongo M, Lombardi ML, Ferrone S. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. J Biol Chem. 290:26562-75, 2015. PMID: 26381407

616. Conteduca G, Fenoglio D, Parodi A, Battaglia F, Kalli F, Negrini S, Tardito S, Ferrera F, Salis A, Millo E, Pasquale G, Barra G, Damonte G, Indiveri F, Ferrone S, Filaci G. AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma. Oncotarget.7:60872-60884, 2016. PMID:27563821

617. Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget. 7:7390-402, 2016. PMID: 26862729.

618. Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A, Zhu AX, Goyal L, Ting DT, Bardeesy N, Hong TS, Fernandez-del Castillo C, Tanabe KK, Lillemoe KD, Ferrone S, Ferrone CR. PD-L1 and HLA Class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin Cancer Res. 22:470-8, 2016. PMID: 26373575

619. Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, Anniciello AM, Palmieri G, Pepe S, Botti G, Ascierto PA, Ferrone CR, Ferrone S. Antitumor activity of BRAF inhibitor and IFNa combination in BRAF-mutant melanoma. J Natl Cancer Inst. 108, pii: djv435. doi: 10.1093 2016. PMID: 26851802.

620. Schoenfeld AJ, Wang X, Wang Y, Hornicek FJ, Nielsen GP, Duan Z, Ferrone S, Schwab JH. CSPG4 as a prognostic biomarker in chordoma. Spine J 16:722-7, 2016. PMID: 26689475.

621. Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, Favoino E, Orgiano L, Roberts J, Ferrone S, Kärre K, Colucci F, Carbone E. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol. 46:409-19, 2016. PMID: 26564811.

622. Trivedi S, Srivastava RM, Concha-Benavente F, Ferrone S, Garcia-Bates TM, Li J, Ferris RL. Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients. Clin Cancer Res. 22:5229-5237, 2016. PMID: 27217441.

623. Villani V, Mahadevan KK, Ligorio M, Fernandez-Del Castillo C, Ting DT, Sabbatino F, Zhang I, Vangel M, Ferrone S, Warshaw AL, Lillemoe KD, Wargo J, Deshpande V, Ferrone CR. Phosphorylated histone H3 (PHH3) is a superior proliferation marker for prognosis of pancreatic neuroendocrine tumors. Ann Surg Oncol. 23(suppl 5):609-617, 2016. PMID: 27020585

624. Cai L, Michelakos T, Ferrone CR, Zhang L, Deshpande V, Shen Q, DeLeo A, Yamada T, Zhang G, Ferrone S, Wang X. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Oncotarget 8:37646-37656, 2017. PMID: 28430580

625. Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ. B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol. 47:23-30. 2017 PMID: 28104527.

626. Piras LA, Riccardo F, Issuch S, Maniscalco L, Gattino F, Martano M, Morello E, Lorda Mayayo S, Rolih V, Garavaglia F, De Maria R, Lardone E, Collivignarelli F, Mignacca D, Giacobino D, Ferrone S, Cavallo F, Buracco P. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination. Vet Comp Oncol. In press 2017 PMID: 27146852

627. Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, Ugurel S, Schrama D, Becker JC. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci Rep 7:2290, 2017. PMID: 28536458

628. Srivastava RM, Trivedi S, Concha-Benavente F, Gibson SP, Reeder C, Ferrone S, Ferris RL. CD137 stimulation enhances cetuximab-induced natural killer: dendritic cell priming of antitumor T-cell immunity in patients with head and neck cancer. Clin Cancer Res. 23:707-716, 2017. PMID: 27496866.

629. Yang KS, Im H, Hong S, Pergolini I, Del Castillo AF, Wang R, Clardy S, Huang CH, Pille C, Ferrone S, Yang R, Castro CM, Lee H, Del Castillo CF, Weissleder R. Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci Transl Med. 9:391, 2017. PMID: 28539469

NON PEER REVIEWED PUBLICATIONS 1. Sirchia G, Ferrone S, Mercuriali F. Alcune osservazioni sulla differente capacita' emolitica di sieri diversi verso le

emazie dell: emoglobinuria parossistica notturna. Nota preliminare. Min Med, 55:3709-3710, 1964. PMID: 14241234

2. Sirchia G, Montella S, Ferrone S, Mercuriali F. Emoglobinuria parossistica notturna. Studio di due casi. Haematol Lat, 7:203-217, 1964. PMID: 14302647

3. Sirchia G, Mercuriali F, Ferrone S. The erythrocytic reduced glutathione in paroxysmal nocturnal hemoglobinuria. Haematol Lat, 7:273-276, 1964. PMID: 5825803

4. Jean G, Sirchia G, Lambertenghi G, Ferrone S. L'ultrastruttura degli eritrociti nellèmoglobinuria parossistica nottura. Boll Soc Ital Emat, 13:183-190, 1965.

5. Sirchia G, Pisani E, Della Grazia M, Ferrone S, Ponticelli C. La trasfusione di sangue nell'insufficienza renale acuta. Atti Accad Med Lomb, 20:1-4, 1965.

6. Sirchia G, Marangoni L, Ferrone S, Zanella A, Mercuriali F. Scopo di un centro di immunoematologia ospedaliero e sua organizzazione. Atti Accad Med Lomb, 20:1-5, 1965.

7. Sirchia G, Ferrone S, Zanella A. Emazie umane normali trattate con composti sulfidrilici. Studio della cinetica dell'emolisi e del sistema emolitico in relazione alle emazie dellèmoglobinuria parossistica notturna. Haematol Lat, 8:53-63, 1965. PMID: 5867150

8. Sirchia G, Ferrone S, Mercuriali F. A case of paroxysmal cold haemoglobinuria with unusual serological findings. Haematol Lat, 8:103-112, 1965. PMID: 5861585

9. Sirchia G, Sironi A, Ferrone S, Masera G. Làcetilcolinesterasi eritrocitaria nella malattia emolitica del neonato. Boll Soc Ital Emat, 13:197, 1965.

10. Sirchia G, Spinelli-Ressi F, Ferrone S. Sul comportamento in vivo di emazie umane normali trattate con composti sulfidrilici. Boll Soc Ital Emat, 13:225, 1965.

11. Crosti PF, Sirchia G, Ferrone S, Sironi AM. II glutatione ridotto eritrocitario nella cirrosi epatica. Riforma Med, 40:3-23, 1966.

12. Crosti PF, Sirchia G, Belli L, Ferrone S. Confronto statistico fra il quadro clinico-funzionale di soggetti epatopatici cronici operati di anastomosi porto-sistemica e non operati. Atti Accad Med Lomb, 21:373-376, 1966.

13. Sirchia G, Ferrone S, D’ambrosio F. Isoanticorpi citotossici leucocitari nelle gravide. Nota preliminare. La Trasfusione del Sangue, 11:96-99, 1966.

14. Sirchia G, Mercuriali F, Ferrone S. La specificita' degli autoanticorpi nelle malattie emolitiche autoimmuni. Gazz. Sanit, 37:113, 1966.

15. Sirchia G, Ferrone S, Milani R, Masera G. Studio dell'attivita’-acetilcolinesterasica eritrocitaria nella malattia emolitica del neonato. Haematol Lat, 9:215-220, 1966. PMID: 4966138

16. Sirchia G, Ferrone S, Marangoni L. Il centro di immunoematologia dell'ospedale policlinico di Milano: Esperienze acquisite in un anno di attivita. La Trasfusione del Sangue, 11:127-132, 1966.

17. Sirchia G, Ferrone S, Crosti PF. Glutathione in liver cirrhosis. Lancet, 2:1363-1364, 1966. 18. Ferrone S, Tosi RM, Centis D. Anti-complementary factors affecting the lymphocytotoxicity test. In:

"Histocompatibility Testing, 1967" (Curtoni ES, Mattiuz PL, and Tosi RM, eds.), Munksgaard, pp. 357-363, 1967. 19. Morelli A, Rossi U, Ferrone S. La resistenza osmotica eritrocitaria e l'autoemolisi nell'emoglobinuria parossistica

notturna. Haematologica (Archivio), 52:1335, 1967. 20. Sirchia G, Dambrosio F, Mercuriali F, Ferrone S. La malattia emolitica del neonato: moderni orientamenti

immunoematologici. Gazz Sanit, 38:170-177, 1967.

https://www.ncbi.nlm.nih.gov/pubmed/28539469

https://www.ncbi.nlm.nih.gov/pubmed/28539469

21. Sirchia G, Ferrone S, Zanella A, Tagliabue M. Metabolismo cerebrale. Attivita enzimatiche degli eritrociti. In: Polli E. - I comi metabolici. Relazione al 68 Congr Soc Ital Med Int, Pozzi, Roma, pp. 494, 1967.

22. Ferrone S, Mercuriali F, Farina C. Emoglobinuria parosistica notturna ed emoglobinuria parossistica "a frigore": studio comparativo della cinetica dell`emolisi. Haematol Lat, 11:61-69, 1968. PMID: 5722010

23. Ferrone S, Sirchia G, Farina C, Dambrosio F. Isoimmunizzazione leucocitaria in gravidanza. Ric Clin Lab, 7:3-51, 1968.

24. Ferrone S, Mercuriali F, and Sirchia G. La capacita emolitica dei sieri cirrotici verso le emazie di emoglobinuria parossistica notturna: relazione con alcuni indici ematochimici. Boll Soc Ital Emat, 16:16-24, 1968.

25. Ferrone S, Mercuriali F, Zanella A. Azione della cefalotina sul sangue in vitro: influenza di alcuni componenti plasmatici sulla sensibilita delle emazie al farmaco. Giorn Clin Med, 49:870-884, 1968. PMID: 5716825

26. Sirchia G, Ferrone S, Mercuriali F. La determinazione dell'acetilcolinesterasi eritrocitaria con il metodo dell'acido ditiobisnitroben zioco, eseguito con reagent pronti. Haematol Lat, 11:383-386, 1968. PMID: 5736508

27. Sirchia G, Ferrone S. La tipizzazione loucocitaria come prova di istocompatibilita. Boll Soc Ital Emat, 16:3, 1968. 28. Sirchia G, Ferrone S, Mercuriali F, Pizzi C. Il candidato al trapianto: aspetti immunologici. Editrice Ancora,

Milano, 1969. 29. Ferrone S, Zanella A, Bianchi Porro G, Flores A, and Ranzi T. Studio di alcune attivita enzimatiche e metaboliche

eritrocitarie nelle nefropatie croniche. Acta Vitaminol Enzymol, 24:70-80, 1970. PMID: 5469045 30. Ferrone S, Mercuriali F, Giovannelli CA, Sirchia G. Serum complements titre and C3 concentration in liver

cirrhosis: relationship to some biochemical indices. Ital J Immunol Immunopathol, 1:65, 1970. 31. Ferrone S, Morosini PL, Zanella A, Pizzi C, Flores A, Marubini E. Studio statistico dei metodi di determinazione di

alcune attivita' enzimatiche e metaboliche eritrocitarie. Collana di Monografie Zambon, 5:119-135, 1970. 32. Ferrone S, Zanella A, Sirchia G, Flores A. Attivita' enzimatiche e metaboliche eritrocitarie nell' emoglobinuria

parossistica notturna. Acta Vitaminol Enzymol, 24:237-263, 1970. PMID: 5537938 33. Ferrone S, Zanella A, Sirchia G, Flores A. Study of the acetylcholinesterase activity of AET-treated normal red

cells (PNH-like cells). Acta Vitaminol Enzymol, 24:222-225, 1970. PMID: 5537936 34. Polli E, Sirchia G, Ferrone S, Mercuriali F. Il problema dell'isoimmunizzazione transfusionale del candidato al

trapianto. Riv Emoter Immunoematol, 17:1-22, 1970. PMID: 4945870 35. Sirchia G, Ferrone S, Marubini E, Mercuriali F, Morosini P, Zanella A. Attivita enzimatiche e metaboliche

eritrocitarie nelle malattie emolitiche autoimmuni. Haematologica (Archivo), 55:81-152, 1970. PMID: 4100750 36. Sirchia G, Mercuriali FM, Ferrone S. The routine detection of erythrocyte and leucocyte iso-antibodies. Proc.

"International Symposium on Standardization of Hematological Methods", Milano 1968, Angeli, Milano, pp. 341-347, 1970.

37. Sirchia G, Ferrone S, Mercuriali F. Prevention of leucocyte-antibody formation. Lancet, 1:898, 1970. PMID: 4191544

38. Sirchia G, Ferrone S, Zanella A. Determination of red cell acetylcholinesterase activity by diagnostic kit: modification of the method. Acta Vitaminol Enzymol (Milano), 24:219-221, 1970. PMID: 5537935

39. Ferrone S. Leucocyte cytotoxic isoantibodies after massive transfusion for open heart surgery. Boll Ist Sieroter Milan, 50:1-5, 1971. PMID: 4812964

40. Lambertenghi-Deliliers G, Ferrone S, Ranzi T, Pizzi C. L'eritrocita umano in condizioni normali e patologiche al microscopio elettronico a scansione. Gazz Sanit, 42:15-20, 1971.

41. Sirchia G, Ferrone S, Mercuriali F. Antigeni leucocitari e istocompatibilita'. Il Policlinico (Sez Prat), 78:315-331, 1971. PMID: 5570191

42. Zanella A, Ferrone S, Sirchia G. La costante de Michaelis dell'acetilcolinesterasi eritrocitaria nell`emoglobinuria parossistica notturna. Haematologica (Archivo), 46:169, 1971.

43. Papermaster BW, Papermaster VM, Reisfeld RA, Pellegrino MA, Ferrone S, Kahan BD, Terasaki PI, Takasugi M, Albert EA. Characterization and isolation of HL-A antigens from continuous cultured human lymphocyte cell lines: a report of current progress. In: "Cellular Antigens" (Nowotny, A., ed.), Springer-Verlag, New York, pp. 186-199, 1972.

44. Pellegrino MA, Ferrone S, Pellegrino A. Serologic detection of soluble HL-A antigens. In: "Transplantation Antigens: Markers of Biological Individuality" (Kahan, B.D. and Reisfeld, R.A., eds.), Academic Press, New York, pp. 433-452, 1972.

45. Ferrone S, Pellegrino MA, Gotze D, Mittal KK, Terasaki PI, Reisfeld RA. Cytotoxic heteroantisera against soluble HL-A antigens. In: "International Symposium on Standardization of HL-A Reagents" Copenhagen, 1972: Symp. Series Immunobiol, Vol. 18, Karger/Basel, pp. 218-223, 1973.

46. Ferrone S, Pellegrino MA. HL-A antigens, antibody and complement in the lymphocytotoxic reaction. In: "Contemporary Topics in Molecular Immunology" Vol. 2 (Reisfeld, R.A. and Mandy, W.J., eds.), Plenum Press, New York, pp. 185-235, 1973. PMID: 4589160

47. Gotze BD, Lee S, Ferrone S, Pellegrino MA, Reisfeld RA. Cross-reactivity between HL-A and H-2 antigens. II. Allogeneic sensitization by xenogeneic soluble lymphocyte antigens (HL-A). Transplant Proc, 5:467-470, 1973. PMID: 4572106

48. Pellegrino MA, Ferrone S, Pellegrino A, Reisfeld RA. A critical evaluation of the serologic assay for soluble HL-A alloantigens. In: "International Symposium on Standardization of HL-A Reagents" Copenhagen 1972; Symposium Series Immunobiology, Vol.18, Karger/Basal, pp. 209-217, 1973.

49. Pellegrino MA, Ferrone S, Del Villano B, and Reisfeld RA. Effects of inhibitors of macromolecular synthesis on cell surface expression of HL-A antigens. Transplant Proc, 5:91-94, 1973. PMID: 4695959

50. Polli E, Sirchia G, Ferrone S, Mercuriali F, Zanella A. Emoglobinuria parossistica notturna. Revisione critica. Edizioni Cilag-Chemie Italiana. Milano, 1973. PMID: 4199940

51. Reisfeld RA, Pellegrino MA, Ferrone S, Kahan BD. Chemical and molecular nature of HL-A antigens. Transplant Proc, 5:447-450, 1973. PMID: 4121176

52. Ting A, Hasegawa T, Ferrone S, Reisfeld RA. Presensitization detected by sensitive crossmatch tests. Transplant Proc, 5:813-817, 1973. PMID: 4572143

53. Ferrone S. Leucocyte cytotoxic isoantibodies after massive transfusion for open heart surgery. Boll Ist Sieroter Milan, 50:3-5, 1974. PMID: 4812964

54. Ferrone S, Polli EE. Cell growth cycle and expression of histocompatibility antigens on cultured human lymphoid cells. Haematologica, 59:25-37, 1974. PMID: 4212983

55. Ferrone S, Cooper NR, Pellegrino MA, Reisfeld RA. The role of complement in the HL-A antibody-mediated lysis of lymphocytes. Transplant Proc, 6:13-19, 1974. PMID: 4856285

56. Ferrone S, Pellegrino MA, Dierich MP, Reisfeld RA. Expression of histocompatibility antigens during the growth cycle of cultured lymphoid cells. Curr Top Microbiol Immunol, 66:1-27, 1974. PMID: 4140052

57. Poulik MD, Ferrone S, Pellegrino MA, Sevier DE, Oh SK, Reisfeld RA. Association of HL-A antigens and beta 2-microglobulin: concepts and questions. Transplant Rev, 21:106-125, 1974. PMID: 4139784

58. Reisfeld RA, Ferrone S, Pellegrino MA. Isolation and serological evaluation of HL-A antigens solubilized from cultured human lymphoid cells. In: "Methods in Membrane Biology" Vol. 1 (Korn, E.D., ed.), Plenum Press, New York, pp. 143-199, 1974.

59. Ferrone S, Pellegrino MA, Reisfeld RA. A biological and chemical profile of histocompatibility antigens. In: "The Antigens", Vol. 3 (Sela, M., ed.) Academic Press, New York, pp. 361-441, 1975.

60. Ferrone S, Pellegrino MA, Reisfeld RA, Polli EE. AET-treated sheep red blood cells: a sensitive tool for the rosette formation test with human lymphoid T cells. In: "Excerpta Medica International Congress Series No. 348, Current Studies on Standardization Problems in Clinical Pathology, Haematology and Radiotherapy in Hodgkin's Disease" (Astaldi, G., ed.), pp. 113-117, 1975.

61. Ferrone S, Pellegrino MA, Dierich MP, Reisfeld RA. Characterization and isolation of cell surface antigens. Expression of major histocompatibility system antigens on cultured human lymphoid cells. Transplant Proc, 7:205-207, 1975.

62. Reisfeld RA, Pellegrino MA, Ferrone S, Oh SK. Expression of HL-A antigens on lymphoblastoid cells. In: "Fundamental Aspects of Neoplasia", (Gottlieb, A.A., Plescia, O.J. and Bishop, D.H.L., eds.), Springer-Verlag, New York, pp. 109-121, 1975.

63. Reisfeld RA, Oh SK, Pellegrino MA, Ferrone S, Sevier ED, Poulik MD. Chemical and molecular nature of HL-A antigens in serum. Transplant Proc, 7:185-187, 1975.

64. Ferrone S, Pellegrino MA, Reisfeld RA. HLA antigens. In: "Textbook of Immunopathology", (Miescher PA and Muller-Eberhard HJ, eds.), Grune and Stratton, New York, pp. 279-302, 1976.

65. Ferrone S, Pellegrino MA, Reisfeld RA. The major histocompatibility complex in man: biological and molecular approaches. In: "Progress in Allergy" (Waksman BH, ed.) 21:61, 1976.

66. Ferrone S, Reisfeld RA, Terasaki PI, Pellegrino MA. The use of cultured human lymphoid cells to detect cytotoxic antibodies to B lymphoid cell antigens. In: "1st HLA Workshop of the Americas” (Duquesnoy RJ and Fuller TC, eds.), US NIH DHEW Publication #76-1064, pp. 199, 1976.

67. Ferrone S, Pellegrino MA, Allison JP, Reisfeld RA. Biological and chemical aspects of histocompatibility antigens in serum. Haematologica, 61:397-417, 1976. PMID: 828605

68. Ferrone S, Mittal KK. Identification of human cultured cell lines using histocompatibility (HLA) markers. In: "Proc. Workshop on Cell Substrates for Vaccine Production" FDA publication, pp. 69, 1976.

69. Golub SH, Hanson DC, Sulit HL, Morton DL, Pellegrino MA, Ferrone S. Comparison of histocompatibility antigens on cultured human tumor cells and fibroblasts by quantitative antibody absorption and sensitivity to cell-mediated cytotoxicity. J Natl Cancer Inst, 56:167-170, 1976. PMID: 56444

70. Pellegrino MA and Ferrone S. Isolation of human B and T lymphocytes by rosetting and peripheral lymphocytes with 2-aminoethylisothiquronium bromide (AET)-treated sheep red blood cells. In: 1st HLA Workshop of the Americas (Duquesnoy, R.J. and Fuller, T.C., eds.) US NIH DHEW Publication #76-1064, pp. 176, 1976.

71. Pellegrino MA, Ferrone S, Reisfeld RA. Receptor for complement components and xenogeneic erythrocytes on human T-and B-lymphoid cells. Ric Clin Lab, 6:99-110, 1976. PMID: 798257

72. Reisfeld RA, Pellegrino MA, Ferrone S, Oh SK, Gotze D. An approach to the characterization of lymphoid cell surface antigens. Atti dei Convegni Lincei, 20:81-93, 1976.

73. Reisfeld RA, Allison JP, Ferrone S, Pellegrino MA, Poulik MD. HL-A antigens in serum and urine: isolation, characterization, and immunogenic properties. Transplant Proc, 8:173-178, 1976. PMID: 59439

74. Thompson JS, Blascke JW, Severson CD, Ferrone S, Walford RL. Identification of antisera detecting unique specificities on lymphocytes of the B-type. In: 1st HLA Workshop of the Americas (Duquesnoy, R.J. and Fuller, T.C., eds.) UUS NIH DHEW Publication#76-1064, pp. 215, 1976.

75. Allison JP, Ferrone S, Pellegrino MA, Reisfeld RA. Procedure for the selection of HLA xenoantisera for immunochemical characterization of HLA antigens. Transplant Proc, 9:601-604, 1977. PMID: 194373

76. Allison JP, Pellegrino MA, Ferrone S, Callahan GN, Reisfeld RA. Biologic and chemical characterization of HLA antigens in human serum. J Immunol, 118:1004-1009, 1977. PMID: 191523

77. Allison JP, Pellegrino MA, Reisfeld RA, Ferrone S. An immune adsorption technique for analysis of antigenic determinants reacting with HLA xenoantisera. Transplant Proc, 9:1691-1693, 1977. PMID: 74875

78. Ferrone S. Rabbit complement in the lymphocytotoxicity test. Tissue Antigens, 9:223-226, 1977. PMID: 877952 79. Ferrone S, Pellegrino MA, van Rood JJ, van Leeuwen A. Functional properties of anti-B-cell antigen alloantisera.

Transplant Proc, 9:675-678, 1977. PMID: 141136 80. Thompson JS, Braun WE, Carpenter CB, Dossetor JB, Dupont B, Falk JA, Ferrone S, Johnson AH, Shaw JF, Sinal DP,

Terasaki PI, Troup GM, Walford RL. Report on the second New World B-cell workshop. Transplant Proc 9 (Suppl 1):9-12, 1977. PMID: 300930

81. Thompson JS, Severson CD, Greazel NA, Ferrone S. Detection of HLA (Ia) and non-HLA specificities by "B-cell"antisera. Transplant Proc, 9:597-600, 1977. PMID: 68591

82. Callahan GN, Pellegrino MA, McCabe RP, Frugis L, Allison JP, Ferrone S. Histocompatibility antigens on tumor cells: spatial and structural relationship with tumor associated antigens. Behring Inst Mitt, 62:115-128, 1978.

83. Ferrone S, Pellegrino MA. Antigens and antibodies in malignant melanoma. In: "Handbook of Cancer/Immunology" (Waters H, ed.) Vol. 3, pp. 291-327, Garland Publishing, New York, 1978.

84. Ferrone S, Allison JP, Pellegrino MA. Human DR (Ia-like) antigens: biological and molecular profile. In: "Contemporary Topics in Molecular Immunology" Vol. 7, pp. 239-281, 1978. PMID: 103685

85. Ferrone S, Pellegrino MA, Allison JP. Expression of WIA antigens on B lymphoid cells in long term culture. In: "Histocompatibility Testing 1977" (Bodmer W, ed.), Munksgaard, Copenhagen, pp. 583-585, 1978.

86. Ferrone S, Pellegrino MA, Belvedere M, Reisfeld RA, Curry R, Allison JP. Human B cell antigens: biological and immunogenic properties. In: "Protides of the Biological Fluids: 25th Colloquim 1977. Proteins and Related Subjects: Volume 25”, (Peters H, ed.) Pergamon Press, New York, pp. 645-655, 1978.

87. Kovithavongs T, Ferrone S, Thorsby E, Schlaut J, Pazderka F, Dossetor JB. ADCC detects a public B-cell specificity broader than DRw3 and DRw6. Transplant Proc, 10:829-832, 1978. PMID: 83717

88. Wilson BS, Pellegrino MA, Reisfeld RA, Ferrone S. A simple method for production of specific xenoantisera to human histocompatibility (HLA-A, -B, -C) antigens. Transplant Proc, 10:741-743, 1978. PMID: 366831

89. Belvedere M, Allison JP, Reisfeld RA, Pellegrino MA, Ferrone S. Serum HLA antigens: serological and immunogenic properties. In: "HLA Antigens in Clinical Medicine and Biology", (Ferrone S, Curtoni E, and Gorini S, eds.), Garland STPM Press, New York, pp. 19-36, 1979.

90. Belvedere M, Olivetti E, Pellegrino MA, Ferrone S. Reactivity of DR xenoantisera in a cytotoxic test with human complement. Transplant Proc, 11:1327-1328, 1979. PMID: 314179

91. Callahan GN, Ng A, Pellegrino MA, Ferrone S. Cross-reacting xenoantibodies to human and murine β2-microglobulin. Transplant Proc, 11:1739-1742, 1979. PMID: 93798

92. Cochrum K, Hanes D, Van Speybroeck J, Perkins H, Ferrone S, Indiveri F, Amend W, Vincenti F, Feduska N, Salvatierra O. HLA-D antigen disparity and HLA-DRw antibodies in intrafamilial renal allograft survival. Transplant Proc, 11:404-410, 1979. PMID: 156426

93. Curry RA, Quaranta V, Wilson BS, McCabe RP, Natali PG, Pellegrino MA, Ferrone S. Expression of HLA antigens on cultured human melanoma cells: lack of association with melanoma-associated antigens. In: "Current Trends in Tumor Immunology", (Ferrone S, Gorini S, Herberman RB, and Reisfeld RA, eds.), Garland STPM Press, New York, pp. 347-366, 1979.

94. Ferrone S, Pellegrino MA, Allison JP. Rabbit complement in the cytotoxic test with antibody-coated nucleated cells: properties and role of human antigens reactive with rabbit natural antibodies. In: "HLA Antigens in Clinical Medicine and Biology" (Ferrone S, Curtoni ES, Gorini L, eds.), Garland STPM Press, New York, pp. 58-73, 1979.

95. Ferrone S, Pellegrino MA. Serological detection of human melanoma-associated antigens. In: "Cancer Immunodiagnosis", (Herberman RB and McIntire R, eds.), Marcel-Dekker, New York, pp. 588-632, 1979.

96. Ferrone S. Assay: complement dependent microcytotoxic test to detect antibodies in melanoma-associated antigens. In: "Compendium of Assays for Immunodiagnosis of Human Cancer", (Herberman RB, ed.), Elsevier North-Holland, Inc., New York, pp. 577-579, 1979.

97. Glassy MC, Pellegrino MA, Quaranta V, Molinaro GA, Ferrone S. Lack of DR antigens on human B-lymphocyte-mouse fibroblast hybrids that express HLA-A, B antigens. Transplant Proc, 11:1719-1721, 1979. PMID: 93795

98. Indiveri F, Fagiolo U, Pellegrino MA, Ferrone S. Uremic patients immunized with planned blood transfusions: detection of HLA antibodies with cytotoxic test and an indirect rosette microassay. Transplant Proc, 11:167-170, 1979. PMID: 377624

99. McCabe RP, Galloway DR, Ferrone S, Reisfeld RA. Human melanoma-associated antigens (MAA): serological and structural characterization. In: "Current Trends in Tumor Immunology", (Ferrone S, Gornini S, Herberman RB, and Reisfeld RA, eds.), Garland STPM Press, New York, pp. 269-286, 1979.

100. Pellegrino MA, Wilson BS, Ferrone S. Immunogenicity of HLA-A, B antigens expressed by human melanoma-murine fibroblast cell hybrids. Transplant Proc, 11:1706-1709, 1979. PMID: 531923

101. Silver J, Ferrone S. Structural organization of human DR antigens and their murine analog, I-E antigens: serologic, genetic, and functional implications. Transplant Proc, 11:1743-1744, 1979. PMID: 531927

102. Walker LE, Allison JP, Silver J, Pellegrino MA, Reisfeld RA, Ferrone S. Is serological polymorphism of human DR antigens determined by structural differences in the smaller (β) chain? In: "Cell Biology and Immunology of Leukocyte Function", (Quastel MR, ed.), Academic Press, New York, pp. 271-275, 1979.

103. Wilson BS, Indiveri F, Pellegrino MA, Ferrone S. Absence of DR antigens on human T lymphoid cells: serologic and immunochemical studies with xenoantisera. Transplant Proc, 11:712-714, 1979. PMID: 377706

104. Ferrone S, Imai K, McCabe RP, Molinaro GA, Galloway DR, Reisfeld RA. Production, characterization and use of xenoantisera to human melanoma-associated antigens. In: "Serologic Analysis of Human Cancer Antigens", (Rosenberg SA, ed.), Academic Press, New York, pp. 445-459, 1980.

105. Ferrone S, Indiveri F, Pellegrino MA. The lymphomicrocytotoxicity test for HLA-A, B, C and HLA-DR typing. In: "Immunoassays: Clinical Laboratory Techniques for the 1980s", (Nakamura RM, Dito WR, and Tucker ES, eds.), Allan R. Liss, Inc., New York, pp. 255-285, 1980.

106. Imai K, Molinaro GA, Ferrone S. Monoclonal antibodies to human melanoma-associated antigens. Transplant Proc, 12:380-383, 1980. PMID: 7222216

107. Imai K, Molinaro GA, Ferrone S. A rosetting microassay for detecting antibodies to human melanoma-associated antigens in alloantisera and xenoantisera. In: "Serologic Analysis of Human Cancer Antigens", (Rosenberg SA, ed.), Academic Press, Inc., New York, pp. 697-700, 1980.

108. Indiveri F, Wilson BS, Natali PG, Pellegrino MA, Ferrone S. Immunogenicity of DR antigens isolated from body fluids. Transplant Proc, 12:121-124, 1980. PMID: 7368284

109. Indiveri F, Pellegrino MA, Quaranta V, Molinaro GA, Ferrone S. Monoclonal and polyclonal xenoantibodies to the HLA-A, B, C antigenic molecular complex do not affect the functional activity of C3 receptors. Immunobiol, 158:17-21, 1980. PMID: 6782009

110. Iwaki Y, Terasaki PI, Cardman L, Hermes M, Morris P, Ting A, Fuller T, Burroughs JC, Drakopoulos C, Betuel H, Dossetor J, Kovithavongs T, Ferrone S, Indiveri F, Fagiolo U, Guttmann R. International pretransplant serum analysis. In: "Histocompatibility Testing 1980", (Teraskai PI, ed.), UCLA Tissue Typing Laboratory, Los Angeles, pp. 625-633, 1980.

111. McCabe RP, Ferrone S. Quantitation of xenoantibody binding to human melanoma cells using 125I-labeled protein A. In: "Serologic Analysis of Human Cancer Antigens", (Rosenberg SA, ed.), Academic Press, Inc., New York, pp. 655-659, 1980.

112. Pellegrino MA, Ferrone S. HLA and tumor associated antigens in urine. In: "The Handbook of Cancer Immunology", (Waters H, ed.), Vol. 8, Garland STPM Press, New York & London, pp. 105-134, 1980.

113. Quaranta V, Imai K, Molinaro GA, Ferrone S. Manufacture of monoclonal antibodies to human melanoma associated and histocompatibility antigens. In: "Immunoassays. Clinical Laboratory Techniques for the 1980s", (Nakamura RM, Dito WR, and Tucker ES, III, eds.), Alan R. Liss, Inc., New York, pp. 301-324, 1980.

114. Russo C, Indiveri F, Quaranta V, Molinaro GA, Pellegrino MA, Ferrone S. Use of monoclonal antibodies to investigate immunologic cross-reactivity of histocompatibility antigens from various animal species. Transplant Proc, 12:376-379, 1980. PMID: 6784298

115. Wilson BS, Indiveri F, Molinaro GA, Quaranta V, Ferrone S. Characterization of DR antigens on cultured melanoma cells by using monoclonal antibodies. Transplant Proc, 12:125-129, 1980. PMID: 6966094

116. Belvedere M, Pellegrino MA, Ferrone S. Polyclonal and monoclonal xenoantibodies to polymorphic determinants of human histocompatibility antigens. In: "The Immune System-A Festschrift in Honor of Niels Kaj Jerne on the Occasion of his Seventieth Birthday" (Steinberg, C.M. and Lefkovits, I., eds.) S. Karger (Basel), Vol. I, pp. 226-233, 1981.

117. Callahan GN, Ferrone S, Allison JP, Reisfeld RA. Histocompatibility and tumor associated antigens in serum. In: "Handbook of Cancer Immunol." (Waters, H., ed.), Vol. 8, Garland STPM Press, New York, pp. 79-104, 1981.

118. Galloway DR, Imai K, Ferrone S, Reisfeld RA. Molecular profiles of human melanoma-associated antigens. Fed Proc, 40:231-236, 1981. PMID: 7461145

119. Imai K, Wilson BS, Kay NE, Ferrone S. Monoclonal antibodies to human melanoma cells: comparison of serological results of several laboratories and molecular profile of melanoma-associated antigens. In: "Monoclonal Antibodies and T Cell Hybrids" (Hammerling GJ, Hammerling U, Kearney JF, eds.), Elsevier Co., pp. 183-190, 1981.

120. Indiveri F, Scudeletti M, Viglione D, Grifoni P, Russo C, Pellegrino MA, Ferrone S. Modulation of Ia-like antigens on PHA activated T lymphocytes. In: "Mechanisms of Lymphocyte Activation. Proc. 14th International Leucocyte Conference, 1981" (Resch K, Kirchner H, eds.). Elsevier/ North Holland Biomedical Press, Amsterdam.

121. Natali PG, Quaranta V, Nicotra MR, Apollonj C, Pellegrino MA, Ferrone S. Tissue distribution of Ia-like antigens in different species: analysis with monoclonal antibodies. Transplant Proc, 13:1026-1029, 1981. PMID: 7022914

122. Natali PG, Russo C, Apollonj C, Pellegrino MA, Ferrone S. Human Ia-like antigens (analysis of the tissue distribution and immunochemical profile with monoclonal antibodies). Ric Clin Lab, 11:287-300, 1981. PMID: 7034133

123. Nathanson SD, Pellegrino MA, Ferrone S. Serum HLA-A and B alloantigens in patients with malignant melanoma. Transplant Proc, 13:1939-1941, 1981. PMID: 7330977

124. Pellegrino MA, Weaver JF, Nelson-Rees WA, Ferrone S. Ia-like and HLA-A, B antigens on tumor cells in long-term culture. Transplant Proc, 13:1935-1938, 1981. PMID: 6949386

125. Quagliata F, Beckerdite-Quagliata S, Russo C, Bisno A, Indiveri F, Pellegrino M, Ferrone S. Induction of Ia-like antigens by a group A Streptococcal product with mitogenic activity. Transplant Proc, 13:1049-1050, 1981. PMID: 7022915

126. Quaranta V, Glassy MC, Indiveri F, Natali PG, Ng AK, Pellegrino MA, Russo C, Wilson BS, Ferrone S. Analysis of human Ia-like antigens with monoclonal antibodies. In: "mmunobiology of the Major Histocompatibility Complex", 7th Intl Convoc Immunol, Niagara Falls, New York, (Zaleski MB, Abeyounis CJ, Kano K, eds.) S. Karger, A. G. Basel Publisher, pp. 155-164, 1981.

127. Quaranta V, Russo C, Pellegrino MA, Ferrone S. Fine specificity of monoclonal xenoantibodies to distinct immunological domains of human Ia-like antigens. In: "Monoclonal Antibodies and T Cell Hybrids" (Hammerling GJ, Hammerling U, Kearney JF, eds.) Elsevier Co., pp. 84-92, 1981.

128. Walker LE, Ferrone S, Pellegrino MA, Reisfeld RA. Structural analysis of HLA-DR antigens. In: "Current Trends in Histocompatibility" (Reisfeld RA, Ferrone S, eds.), Plenum Press, New York, Vol. 1, pp. 511-529, 1981.

129. Walker LE, Quaranta V, Ferrone S, Pellegrino MA, Reisfeld RA. Structural characterization of human Ia-like antigens by peptide mapping. In: "Immunology of the Major Histocompatibility Complex" (Zaleski MB, Abeyounis CJ, Kano K, eds.) S. Karger, A.G. Basel Publisher, pp.147-154, 1981.

130. Wilson BS, Indiveri F, Quaranta V, Pellegrino MA, Ferrone S. Level of Ia-like antigens on human B and T lymphocytes. Transplant Proc, 13:1033-1034, 1981. PMID: 6973853

131. Wilson BS, Ng AK, Quaranta V, Ferrone S. HLA polyclonal and monoclonal xenoantibodies. Production, characterization and application to the study of HLA antigens. In: "Current Trends in Histocompatibility" (Reisfeld RA, Ferrone S, eds.) Plenum Press, New York, Vol. 1, pp. 307-345, 1981.

132. Burchiel SW, Imai K, Ferrone S, Warner NL. Heterogeneity of cell surface antigen expression on human melanoma cells: analysis with monoclonal antibodies and flow cytometry. In: "Hybridomas in Cancer Diagnosis and Treatment" (Mitchell MS, Oettgen HF, eds.), Raven Press, New York, pp. 195-197, 1982.

133. Ghose T, Blair AH, Martin RH, Norvell ST, Ramakrishman S, Belitsky P, Imai K, Ferrone S. Tumor imaging by antitumor antibody-linked radionuclides: experimental models and clinical applications. In: "Tumor Imaging. The Radioimmunochemical Detection of Cancer" (Burchiel SW, Rhodes BA, eds.) Masson Publishing USA, Inc., New York, pp. 167-178, 1982.

134. Imai K, Wilson BS, Ruberto G, Nakanishi T, Yachi A, Ferrone S. Molecular heterogeneity of a high molecular weight human-melanoma associated antigen detected by monoclonal antibodies. In: "Protides of the Biological Fluids: 29th Colloquium 1981" (Peeters H, ed.) Pergamon Press, New York, pp. 893-897, 1982.

135. Imai K, Yachi A, Ng AK, Ferrone S. Antigen expression and immune lysis of human melanoma cells: analysis with monoclonal antibodies. In: "Protides of the Biological Fluids: 29th Colloquium 1981" (Peeters H, ed.) Pergamon Press, New York, pp. 883-888, 1982.

136. Imai K, Yachi A, Ferrone S. Preparation and characterization of monoclonal antibodies to human melanoma associated antigens (MAA). In: "Tumor Imaging: The radioimmunochemical detection of cancer" (Burchiel SW, Rhodes BA, eds.) Masson Publishing, New York, pp. 141-150, 1982.

137. Kantor RRS, Ng AK, Giacomini P, Ferrone S. Analysis of the NIH Workshop monoclonal antibodies to human melanoma antigens. Hybridoma, 1:473-482, 1982. PMID: 6208142

138. Natali PG, Russo C, Ng AK, Giacomini P, Indiveri F, Pellegrino MA, Ferrone S. Tissue distribution of human Ia-like antigens. In: "Ia Antigens" (Ferrone S, David CS, eds.), Vol. II, CRC Press, Inc., Boca Raton, Florida, pp. 81-110, 1982.

139. Natali PG, Segatto O, Giacomini P, Cavallari A, Cavaliere R, Estabrook A, Ferrone S. A human high molecular weight-melanoma associated antigen (HMW-MAA) identified with monoclonal antibodies (MoAb). Heterogeneity, shedding and marker to purify melanoma cells. In: "Membranes in Tumor Growth" (Galeotti T, Cittadini A, Neri G, Papa S, eds.), Elsevier Biomedical Press, Amsterdam, pp. 115-120, 1982.

140. Pellegrino MA, Natali PG, Ng AK, Imai K, Russo C, Bigotti A, Wolf P, Ferrone S. Unorthodox expression of Ia-like antigens on human tumor cells of nonlymphoid origin: immunological properties, structural profile, and clinical relevance. In: "Immunologic analysis. Recent Progress in Diagnostic Laboratory Immunology", (Nakamura RM, Dito WR, Tucker ES, eds.) Mason, New York, pp. 159-173, 1982.

141. Pellegrino MA, Ferrone S. HLA typing of cells in long-term culture. In: "HLA Typing: Methodology and Clinical Aspects", (Ferrone S, Solheim BG, eds.), Vol. 2, CRC Press, Inc., Boca Raton, Florida, pp. 25-34, 1982.

142. Russo C, Pellegrino MA, Ng AK, Wilson BS, Ferrone S. Antigenic constitution of HLA-A, B, C molecules: immunochemical analysis with monoclonal antibodies. In: "HLA Typing: Methodology and Clinical Aspects" (Ferrone S, Solheim BG, eds.), Vol. 2, CRC Press, Boca Raton, pp. 77-100, 1982.

143. Sobol RE, Dillman RO, Smith JD, Imai K, Ferrone S, Shawler D, Glassy MC, Royston I. Phase I evaluation of murine monoclonal anti-melanoma antibody in man: preliminary observations. In: "Hybridoma in Cancer Diagnosis and Treatment" (Mitchell M, Oettgen H, eds.), Raven Press, New York, pp. 199-206, 1982.

144. Solheim BG, Ferrone S. Operationally specific xenoantisera to allospecificities of the HLA antigenic system. In: "HLA Typing: Methodology and Clinical Aspects" (Ferrone S, Solheim BG, eds.) CRC Press, Vol. I, pp. 72-75, 1982.

145. Wilson BS, Imai K, Natali PG, Kay NE, Cavaliere R, Pellegrino MA, Ferrone S. Immunochemical analysis of the antigenic profile of human melanoma cells with monoclonal antibodies. In: "Melanoma Antigens and Antibodies" (Reisfeld RA, Ferrone S, eds.) Plenum Press, New York, pp. 401-433, 1982.

146. Wilson BS, Giacomini P, Imai K, Natali PG, Nakanishi T, Ruberto G, Ferrone S. Human melanoma-associated antigens identified with monoclonal antibodies. Structural profile and potential usefulness in immunodiagnosis and immunotherapy. Ric Clin Lab, 12:517-538, 1982. PMID: 6760354

147. Bodmer WF, Ferrone S. Monoclonal antibodies and their use in the analysis of MHC systems. Transplant Proc, 15:1511-1512, 1983.

148. Ferrone S, Pellegrino MA. HLA antigens and susceptibility to disease. In: "Pathology Update Series", Vol. 1, Lesson 15, pp. 1-8, 1983.

149. Ferrone S, Giacomini P, Natali PG, Ruiter D, Buraggi G, Callegaro L, Rosa U. A human high molecular weight-melanoma associated antigen (HMW-MAA) defined by monoclonal antibodies: a useful marker to radioimage tumor lesions in patients with melanoma. In: Proc. 1st Int. Symp. on Neutron Capture Therapy, Brookhaven National Laboratory, Associated Universities, Inc., pp. 174-183, 1983.

150. Ghose T, Kulkarni N, Ferrone S, Norvell ST, Kulkarni R, Blair AH. Imaging human tumors in nude mice. In: "Radioimmunoimaging and Radioimmunotherapy" (Burchiel SW, Rhodes BA, eds.), Elsevier Science Publishing Co., Inc., pp. 255-263, 1983.

151. Giacomini P, Imai K, Natali PG, Ferrone S. A double determinant immunoassay (DDIA) with monoclonal antibodies to a human high molecular weight-melanoma associated antigen (HMW-MAA). In: "Protides of the Biological Fluids: 30th Colloquium 1982" (Peters H, ed). Pergamon Press, New York, pp. 329-332, 1983.

152. Gold AM, Kantor RRS, Giacomini P, Ng AK, Steinbach G, Ferrone S. Heterogeneity and topography of determinants recognized by monoclonal antibodies on a human high molecular weight-melanoma associated antigen. In: Recent Advances in Analytical Methodology in the Life Sciences. Proceedings of the Eighth in the Series of U.S. Food and Drug Administration Science Symposia, (Beaver, L.A., ed.), U.S. Department of Health and Human Services, Public Health Services, Food and Drug Administration, pp. 316-332, 1983.

153. Imai K, Murakami H, Moriya Y, Ferrone S, Yachi A. Hybridomas grown in serum-free medium. In: "Protides of the Biological Fluids: 30th Colloquium 1982" (Peeters H, ed.). Pergamon Press, New York, 273-278, 1983.

154. Imai K, Nakanishi T, Matsui M, Noguchi T, Yachi A, Ferrone S. In vivo effect of the conjugate of monoclonal antibody with cytotoxic agent on the tumor growth of human melanoma. In: "Protides of the Biological Fluids: 30th Colloquium 1982" (Peeters H, ed.). Pergamon Press, New York, pp. 365-368, 1983.

155. Imai K, Wada T, Ferrone S. Potential usefulness of the monoclonal antibodies to human melanoma-associated antigens. Clin Immunol Newsletter, 4:74-78, 1983.

156. Imai K, Sasanami T, Fujita H, Moriya Y, Tsujisaki M, Kawaharada M, Ferrone S, Yachi A. Antibody-dependent cell-mediated cytotoxicity using monoclonal antibodies reacting with CEA. Ann NY Acad Sci, 417:443-451, 1983. PMID: 6200045

157. Indiveri F, Scudeletti M, Pende D, Barabino A, Russo C, Pellegrino MA, Ferrone S. Role of distinct domains of Ia antigens in autologous and allogeneic mixed lymphocyte reactions. Behring Inst Mitt, 72:95-100, 1983. PMID: 6242347

158. Natali PG, Aguzzi A, Veglia F, Imai K, Burlage RS, Giacomini P, Ferrone S. The impact of monoclonal antibodies on the study of human malignant melanoma. J Cutan Pathol, 10:514-528, 1983. PMID: 6198345

159. Natali PG, Giacomini P, Russo C, Steinbach G, Fenoglio C, Ferrone S. Antigenic profile of human melanoma cells. Analysis with monoclonal antibodies to histocompatibility antigens and to melanoma-associated antigens. J Cutan Pathol, 10:225-237, 1983. PMID: 6350388

160. Ng AK, Giacomini P, Ferrone S. Monoclonal antibodies and immunologic approaches to malignant tumors. Adv Intern Med, 28:253-276, 1983. PMID: 6340428

161. Ng AK, Imai K, Pellegrino MA, Vitiello A, Indiveri F, Wilson BS, Ferrone S. Modulation of immune lysis of tumor cells by interferon. Biomembranes, 11:313-339, l983. PMID: 6187384

162. Russo C, Pellegrino MA, Ferrone S. A double-determinant immunoassay to quantitate human Ia antigens. Transplant Proc, 15:57-59, 1983. PMID: not available

163. Russo C, Pellegrino MA, Ferrone S. A double-determinant immunoassay with monoclonal antibodies to the HLA-A, B, C complex. Transplant Proc, 15:66-68, 1983. PMID: not available

164. Russo C, Pellegrino MA, Natali PG, Indiveri F, Corte G, Ades E, Karr RW, Schwartz BD, Ferrone S. Perfil estructural, heterogeneidad antigenica y analisis funcional de los productos geneticos de la region I humana. In:

"Transplante Renal" (Caralps A, Gil-Vernet JM, Vives J, Andreu J, Brulles A, Tornos D, eds.). Ediciones Toray, S.A., Barcelona, 1983.

165. Sobol RE, Dillman RO, Halpern S, Shawler DL, Hagan P, Ferrone S, Glassy MC, Royston I. Serotherapy and radioimmunodetection of tumors with monoclonal antibodies. In: "Cellular Oncology. New Approaches in Biology, Diagnosis and Treatment" (Moloy PJ, Nicolson GL, eds.), Praeger Press, New York, pp. 256-281, 1983.

166. Buraggi GL, Callegaro L, Ferrone S, Turrin A, Cascinelli N, Attili A, Bombardieri E, Mariani G, Deleide G. In vivo immunodiagnosis with radiolabeled anti-melanoma antibodies and F (ab') 2 fragments (Schmidt HAE, Adam WE, eds.) In: Nuklearmedizin" 21st International Annual Meeting of the Society of Nuclear Medicine". F.K. Schattauer Verlage Stuttgart, New York, pp. 713-717, 1984.

167. Lordon RE, Stelzer GT, Garrison RN, Ferrone S. Early determination of renal allograft survival: a correlation between cytotoxic antibodies in recipient sera, renal pathology, and response to antirejection therapy. Transplant Proc, 16:1588-1590, 1984. PMID: 6390867

168. Mariani G, Callegaro L, Mazzuca N, Macchia D, Mencacci S, Ferrone S, Rosa U, Bianchi R. In vivo distribution of anti-human melanoma monoclonal antibodies. In: "Protides of the Biological Fluids: Volume 31" (Peeters H, ed.) Pergamon Press, Oxford and New York, pp. 971-976, 1984.

169. Natali PG, Bigotti A, Ferrone S. Human histocompatibility antigens in malignant tumors of nonlymphoid origin. In: "Histocompatibility Testing 1984" (Albert ED, Baur MP, Mayr WR, eds.). Springer-Verlag, Berlin Heidelberg, pp. 417-418, 1984.

170. Natali PG, Cavaliere R, Matsui M, Buraggi G, Callegaro L, Ferrone S. Human melanoma associated antigens identified with monoclonal antibodies: characterization and potential clinical application. In: "Cutaneous Melanoma and Precursor Lesions" (Ruiter DJ, Welvaart K, Ferrone S, eds.), Martinus Nijhoff Publishers, pp. 19-37, 1984.

171. Sakaguchi K, Ferrone S. A double determinant immunoassay with anti class I HLA monoclonal antibodies: sensitivity, reproducibility and application. In: "Cost/Benefit and Predictive Value of Radioimmunoassay" (Albertini A, Ekins RP, Galen RS, eds.) Elsevier Science Publishers B.V., pp. 103-110, 1984.

172. Andreassi L, Mancianti ML, Natali PG, Ferrone S, Fimiani M, Castelli A, Raffaelli M. Human melanocyte cultures from normal skin and pigmented lesions. In: "Biological, Molecular and Clinical Aspects of Pigmentation. Proceedings of the XIIth International Pigment Cell Conference, Giessen, Federation of Germany, (Bagnara J, Klaus SN, Paul E, Schartl M, eds.) University Tokyo Press, Tokyo, pp. 563-568, 1985.

173. Facchini A, Grigioni WF, D'Errico A, Mariani E, Astaldi-Ricotti GCB, Matsui M, Ferrone S. Immunocytochemical characterization of gastrointestinal neoplasia by monoclonal antibodies. In: "Protides of the Biological Fluids. Proceedings of the Thirty-Second Colloquium”, 1984. (Peeters H, ed.), Pergamon Press, Oxford, New York, Toronto, Sydney, Paris, Frankfurt, pp. 507-511, 1985.

174. Ferrone S, Buraggi G, Temponi M, Hamby CV, Matsui M, Natali PG. Monoclonal antibodies to human melanoma associated antigens with special emphasis on their clinical relevance. In: "Biotechnology in Diagnostics" (Koprowski H, Ferrone S, Albertini A, eds.), Elsevier Science Publishers, Amsterdam, The Netherlands, pp. 135-146, 1985.

175. Ghose T, Blair AH, Uadia P, Kulkarni PN, Goundalkar A, Mezei M, Ferrone S. Antibodies as carriers of cancer chemotherapeutic agents. Ann NY Acad Sci, 446:213-227, 1985. PMID: 3860152

176. Matsui M, Nakanishi T, Noguchi T, Imai K, Yachi A, Ferrone S. Suppression of human melanoma growth in nude mice injected with anti high-molecular-weight melanoma-associated antigen monoclonal antibody 225.28S conjugated to purothionin. Jpn J Cancer Res (Gann), 76:119-123, 1985. PMID: 3920101

177. Natali PG, Bigotti A, Russo C, Sakaguchi K, Igarashi M, Ferrone S. Monoclonal antibodies and human histocompatibility antigens. In: "Handbook of monoclonal antibodies: applications in biology and medicine” (Ferrone S, Dierich MP, eds.), Noyes Publications, Park Ridge, New Jersey, pp. 382-403, 1985”.

178. Natali PG, Giacomini P, Buraggi G, Cavaliere R, Bigotti A, Callegaro L, Ferrone S. Serological and binding characteristics of a monoclonal antibody (MoAb) to a human high molecular weight-melanoma associated antigen (HMW-MAA) for tumor imaging. In: "From Oncogenes to Tumor Antigens", (Giraldo G, Beth E, Castello G, Giordano GG, Zarrilli D, eds.) Elsevier Science Publishers B.V., pp. 127-134, 1985.

179. Natali PG, Liao SK, Taniguchi M, Matsui M, Noguchi T, Ferrone S. Phenotype of surgically removed lesions of melanocyte origin with monoclonal antibodies to human melanoma-associated antigens (MAA) and to histocompatibility. In: "Pigment Cell, 1985. Biological, Molecular and Clinical Aspects of Pigmentation.

Proceedings of the XIIth International Pigment Cell Conference", Giessen, Federal Republic of Germany, (Bagnara J, Klaus SN, Paul E, Schartl M, eds.), University Tokyo Press, pp. 403-414, 1985.

180. Natali PG, Nicotra MR, Viora M, DiFilippo F, Sakaguchi K, Ferrone S. Changes in the expression of MHC antigens associated with malignant transformation of human cells-clinical relevance. In: "From Oncogenes to Tumor Antigens" (Giraldo G, Beth E, Castello G, Giordano GG, Zarrilli D, eds.) Elsevier Science Publishers B.V., pp.103-114, 1985.

181. Venuta S, Turco MC, Ferrone S, Corbo L, Morrone G, Welte K, Mertelsmann R. Il-2 and leukemia. In: "From Oncogenes to Tumor Antigens" (Giraldo G, Beth E, Castello G, Giordano GG, Zarrilli D, eds.) Elsevier Science Publishers B.V., pp. 59-68, 1985.

182. Ferrone S, Fukusato T, Gerber MA, Pullano TG, Ruiter DJ, Thung SH, van den Ingh HF. Class I and Class II HLA antigens in colorectal and liver carcinomas. Gann, 31:75-83, 1986. PMID: not available

183. Ferrone S, Imberti L, Natali PG, Schrier PI, Ruiter D. HLA antigens on tumor cells. In: "Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment" (Roth JA, ed.) Futura Publishing Company, Inc., New York, pp. 111-139, 1986.

184. Fisher PB, Hermo H Jr, Solowey WE, Dietrich MC, Edwalds GM, Weinstein IB, Langer JA, Pestka S, Giacomini P, Kusama M, Ferrone S. Effect of recombinant human fibroblast interferon and mezerein on growth, differentiation, immune interferon binding and tumor associated antigen expression in human melanoma cells. Anticancer Res, 6:765-774, 1986. PMID: not available

185. Igarashi M, Imberti L, Maio M, Tsujisaki M, Perosa F, Sakaguchi K, Natali PG, Ferrone S. Preparation, characterization, and utilization of monoclonal antibodies to the gene products of the HLA-D region, with special emphasis on those to polymorphic determinants. In: "HLA Class II Antigens: A Comprehensive Review of Structure and Function” (Solheim BG, Moller E, Ferrone S, eds.) Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, pp. 224-248, 1986.

186. Pullano TG, Tsujisaki M, Temponi M, Puppo F, Matsui M, Natali PG, Ferrone S. Human melanoma associated antigens recognized by monoclonal antibodies. In: "Immunoscintigraphy", Proceedings of the European Symposium on Immunoscintigraphy, Saariselka, Finland, August 1984, (Donato L, Britton K, eds.), Gordon and Breach Science Publishers, New York, London, Paris, Montreux, Tokyo, pp. 183-202, 1986.

187. Ruiter DJ, van Duinen SG, Tsujisaki M, Ferrone S. Class II HLA antigens in benign and malignant lesions of melanocytic origin. In: "HLA Class II Antigens: A Comprehensive Review of Structure and Function", (Solheim BG, Moller E, Ferrone S, eds.), Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, pp. 429-441, 1986.

188. Tsujisaki M, Sakaguchi K, Richiardi P, Perosa F, Ferrone S. Syngeneic polyclonal and monoclonal antiidiotypic antibodies to murine anti HLA-B7, B27 monoclonal antibodies. In: "Biologically Based Immunomodulators in the Therapy of Rheumatic Diseases", (Pincus SH, Pisetsky DS, Rosenwasser LJ, eds.), Elsevier Science Publishers, New York, Amsterdam, London, pp. 205-217, 1986.

189. Ferrone S, Buraggi G, Hamby CV, Temponi M, Natali PG. Human high molecular weight-melanoma associated antigen: immunochemical profile and clinical applications. In: "Cellular, Molecular and Genetic Approaches to Immunodiagnosis and Immunotherapy" (Kano K, Mori S, Sugisaki T, Torisu M, eds.), University of Tokyo Press, pp. 395-406, 1987.

190. Ferrone S, Sakaguchi K, Bhalla RB, Schwartz MK, Thung SN, Gerber MA. Abnormal tissue distribution of HLA antigens in patients with acquired immunodeficiency syndrome. In: "Second International Congress on A.I.D.S." Proceedings (Del Giacco GS, Manconi PE, eds.). OIC Medical Press, Firenze, Italy, pp. 52-56, 1987.

191. Igarashi M, Kashiwagi N, Ferrone S. Serological and structural heterogeneity of HLA-DR and DQ antigens in HLA-DR4 homozygous B lymphoid cells. Kitasato Med, 17:194-207, 1987.

192. Kusama M, Tsujisaki M, Temponi M, Perosa F, Ferrone S. Syngeneic monoclonal antiidiotypic antibodies to murine anti human high molecular weight-melanoma associated antigen monoclonal antibodies. In: "Monoclonals and DNA Probes in Diagnostic and Preventive Medicine", (Gallo RC, Della Porta G, Albertini A, eds.), Raven Press, New York, pp. 101-110, 1987.

193. Natali PG, Bigotti A, Cavaliere R, Ruiter DJ, Ferrone S. HLA Class II antigens synthesized by melanoma cells. Cancer Rev, 9:1-33, 1987. PMID: not available

194. Ruiter DJ, Broecker EB, Vennegoor C, Ferrone S. Monoclonal antibodies recognizing melanoma-associated antigens. In: "Application Monoclonal Antibodies in Tumor Pathology", (Ruiter DJ, Fleuren GJ, Warnaar SO, eds.), Martinus Nijhoff Publishers, Dordrecht, Boston, Lancaster, pp. 131-165, 1987.

195. Temponi M, Matsui M, Kusama M, Tsujisaki M, Natali PG, Ferrone S. Monoclonal antibody defined markers of human melanoma cells. In: "Human Tumor Markers", (Cimino F, Birkmayer GD, Klavins JV, Pimentel E, Salvatore F, eds.), Walter de Gruyter & Co., Berlin, New York, Germany, pp. 403-414, 1987.

196. Tsujisaki M, Kusama M, Perosa F, Imberti L, Sakaguchi K, Ferrone S. Syngeneic polyclonal and monoclonal anti-idiotypic antibodies to murine anti-human high molecular weight- melanoma associated antigen and anti-HLA monoclonal antibodies. In: "Cellular, Molecular and Genetic Approaches to Immunodiagnosis and Immunotherapy", (Kano K, Mori S, Sugisaki T, Torisu M, eds.), University of Tokyo Press, pp. 251-258, 1987.

197. Ferrone S, De Felice M, Turco MC, Corbo L, Venuta S. Effect of anti-HLA Class I monoclonal antibodies on the proliferation of T cells induced by PHA-P. Comparison with the effect on T cell activation via the CD2 and CD3 pathways. In: "MHC + X. Complex Formation and Antibody Induction", (Ivanyi P, ed.), Springer-Verlag, Berlin, Heidelberg, New York, London, Paris, Tokyo, pp. 100-106, 1988.

198. Ferrone S, Temponi M, Gargiulo D, Scassellati GA, Cavaliere R, Natali PG. Selection and utilization of monoclonal antibody defined melanoma associated antigens for immunoscintigraphy in patients with melanoma. In: "Radiolabeled Monoclonal Antibodies for Imaging and Therapy", NATO ASI Series, Vol. 152, (Srivastava SC, ed.), Plenum Press, New York and London, pp. 55-73, 1988.

199. Ferrone S, Kageshita T. Human high molecular weight-melanoma associated antigen as a target for active specific immunotherapy—a phase I clinical trial with murine antiidiotypic monoclonal antibodies. J Dermatol, 15:457-465, 1988. PMID: 3074088

200. Graf LH Jr, Matsui M, Temponi M, Romano G, Rosenberg CD, Natali PG, Ferrone S. Immunological and structural profile of a 96kD human melanoma associated antigen with preferential distribution in metastases. In: "Cancer Metastasis. Biological and Biochemical Mechanisms and Clinical Aspects. Advances in Experimental Medicine and Biology", Vol. 233, (Prodi G, Liotta LA, Lollini PL, Garbisa S, Gorini S, Hellmann K, eds.) Plenum Press, New York and London, Vol. 233, pp. 341-349, 1988.

201. Kageshita T, Chen ZJ, Kekish UM, Temponi M, Romano G, Mittelman A, Ferrone S. Active specific immunotherapy of melanoma with murine antiidiotypic monoclonal antibodies elicited with syngeneic anti human high molecular weight-melanoma associated antigen monoclonal antibodies. In: "Recent Advances in Autoimmunity and Tumor Immunology", (Dammacco F, ed.), Edi-erm Wilkins, R.091404es, Milano, pp. 199-209, 1988.

202. Kageshita T, Chen ZJ, Kim JW, Kusama M, Kekish UM, Trujillo T, Temponi M, Mittelman A, Ferrone S. Murine anti-idiotypic monoclonal antibodies to syngeneic antihuman high molecular weight-melanoma associated antigen monoclonal antibodies: development, characterization and clinical applications. Pigment Cell Res (Suppl), 1:185-191, 1988. PMID: not available

203. Perosa F, Hardy MA, Guarini L, Chabot J, Dammacco F, Ferrone S. Anti-idiotypic monoclonal antibodies to anti-HLA Class II monoclonal antibodies. Potential applications in the treatment of autoimmune diseases. In: "Recent Advances in Autoimmunity and Tumor Immunology", (Dammacco F, ed.) Edi-ermes, Milano, pp. 113-130, 1988.

204. Ruiter DJ, Brocker EB, Vennegoor C, Ferrone S. Phenotypic heterogeneity of melanoma. Eur J Cancer Clin Oncol, 24:(Suppl. 2)S23-S32, 1988. PMID: not available

205. Temponi M, Romano G, D'Urso CM, Wang Z, Kekish U, Ferrone S. Profile of intercellular adhesion molecule-1 (ICAM-1) synthesized by human melanoma cell lines. Semin Oncol, 15:595-607, 1988. PMID: 3061012

206. Ahmed MA, Guarini L, Ferrone S, Fisher PB. Induction of differentiation in human melanoma cells by the combination of different classes of interferons or interferon plus mezerein. Ann NY Acad Sci, 567:328-333, 1989. PMID: not available

207. Castello G, Oka N, Addonizio JC, Ferrone S. Murine anti-HLA monoclonal antibodies: specificity and cross-reactivity with xenogeneic histocompatibility antigens. In: "Xenograft 25". Proceedings of Int. Congress, Arden House, Harriman, NY, (Hardy MA, ed.). Excerpta Medica, Amsterdam, New York, Oxford, pp. 199-205, 1989.

208. Graf LH Jr, Fagan MC, Ferrone S, Kozlowski KA, Mancino V, Rosenberg CD, Schrementi JP. Selective coamplification leads to increased representation of interspecifically transfected human genes encoding the 100K and the 96K melanoma-associated antigens. In: "Human Tumor Antigens and Specific Tumor Therapy", (Metzgar RS, Mitchell MS, eds.), Alan R. Liss, Inc., New York, pp. 35-44, 1989.

209. Graf LH Jr, Ferrone S. Human melanoma-associated antigens. In: "Human Immunogenetics. Basic Principles and Clinical Relevance", (Litwin SD, ed.) Marcel Dekker, Inc., New York and Basel, pp. 643-679, 1989.

210. Kageshita T, Temponi M, Kekish U, Chen ZJ, Kim JW, Mittelman A, Ferrone S. Human high molecular weight-melanoma associated antigen as a target for active specific immunotherapy. A phase I clinical trial with murine antiidiotypic monoclonal antibodies. In: "Molecular Probes: Technology and Medical Applications", (Albertini A, Paoletti R, Reisfeld RA, eds.). Raven Press, New York, pp. 245-260, 1989.

211. Komura A, Tokushia T, Nakagawa T, Sasase A, Ichihashi M, Ferrone S, Mishima Y. Specific killing of human melanoma cells with an efficient 10B-compound on monoclonal antibodies. Pigment Cell Res, 2:259-263, 1989. PMID: 2477835

212. Maio M, Gulwani B, Ferrone S. Differential modulation by cytokines of the gene products of the HLA-D region in melanoma cells with different metastatic potential. In: "Immunobiology of HLA", Vol. II., (Dupont B, ed.) Springer-Verlag, New York, Berlin, Heidelberg, London, Paris, Tokyo, Hong Kong, pp. 354-356, 1989.

213. Natali PG, Fawwaz R, Ruiter DJ, Bigotti A, Kageshita T, Temponi M, Ferrone S. Immunodiagnostic and immunotherapeutic applications of anti-human melanoma-associated antigen monoclonal antibodies. In: “Carcinogenesis - A comprehensive survey, Vol. 11, Skin Tumors: Experimental and Clinical Aspects”, (Conti CJ, Slaga TJ, Klein-Szanto AJP, eds.), Raven Press, Ltd., New York, Vol. 11, pp. 133-164, 1989.

214. O'Connell MJ, Chen ZJ, Yang H, Yamada M, Massaro M, Mittelman A, Ferrone S. Active specific immunotherapy with antiidiotypic antibodies in patients with solid tumors. Semin Surg Oncol, 5:441-447, 1989. PMID: 2688034

215. Perosa F, Kageshita T, Ono R, Ferrone S. Serological methods to detect anti-idiotypic antibodies. Methods Enzymol, 178:74-90, 1989. PMID: 2689842

216. Temponi M, Pupa S, Kageshita T, Ferrone S. Antiidiotypic monoclonal antibodies to quantitate and purify immunoreactive monoclonal antibodies following radiolabeling. In: "Nuclear Medicine. Trends and Possibilities in Nuclear Medicine", (Schmidt HAE, Buraggi GL, eds.), Schattauer, Futura Publishing Co., Stuttgart, Germany, pp. 582-585, 1989.

217. Turco MC, De Felice M, Yang SY, Ferrone S, Venuta S. Differential modulation by anti-HLA Class I monoclonal antibodies of T-cell proliferation induced via CD2 and CD3 pathways. In: "Immunobiology of HLA. Immunogenetics and Histocompatibility", Vol. II, (Dupont B, ed.) Springer-Verlag, New York, Berlin, Heidelberg, London, Paris, Tokyo, Hong Kong, pp. 147-150, 1989.

218. Altomonte M, Esposito G, Colizzi F, Colombatti A, Ferrone S, Maio M. Expression of leukocyte adhesion molecules on human melanoma cells. In: "Biological Agents in the Treatment of Melanoma and Other Cancers", (Hersey P, ed.), Newcastle, Australia, pp. 268-279, 1990.

219. Chen ZJ, Yang H, Mittelman A, Ferrone S. Antibodies reacting with human melanoma cells in patients immunized with murine monoclonal anti-idiotypic antibodies to syngeneic anti-HMW-MAA monoclonal antibodies. In: "Idiotype Networks in Biology and Medicine", (Osterhaus A, Uytdehaag F, eds.) Elsevier Science Publishers B.V. (Excerpta Medica), Amsterdam, New York, Oxford, pp. 157-161, 1990.

220. Chen ZJ, Yang H, O'Connell MJD, Sasase A, Mittelman A, Ferrone S. Human high molecular weight-melanoma associated antigen (HMW-MAA) mimicry by mouse antiidiotypic monoclonal antibody (MoAb) MK2-23 immunogenicity in mice and in patients with melanoma. In: "Biological Agents in the Treatment of Cancer", (Hersey P, ed.), Newcastle, Australia, pp. 344-354, 1990.

221. Chen ZJ Yang H, Yamada M, Kageshita T, Zheng Y, Bae JW, Mittelman A, Ferrone S. Murine antiidiotypic monoclonal antibodies which bear the mirror image of human high molecular weight-melanoma associated antigen (HMW-MAA). Characterization and clinical applications. In: "Cellular Immunity and the Immunotherapy of Cancer" UCLA Symposia on Molecular and Cellular Biology, (Lotze MT, Finn OJ, eds.) New Series. Wiley-Liss, Inc., New York, NY Vol. 135, pp. 351-359, 1990.

222. Clauss G, Lohmeyer J, Hamby CV, Ferrone S, Anders F. Melanoma-associated antigens in Xiphophorus Fish. In: "Human Melanoma. From Basic Research to Clinical Application", (Ferrone S, ed.). Springer-Verlag, Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong, pp. 74-86, 1990.

223. Ferrone S. Monoclonal antibodies and tumor vaccines. Curr Opinion Oncol, 2:1146-1151, 1990. PMID: 2099845 224. Hayashibe K, Mishima Y, Ferrone S. Identification of a novel melanoma-associated antigen immunogenic in

patients. In: "Biological Agents in the Treatment of Cancer", (Hersey P, ed.), Newcastle, Australia, pp. 80-87, 1990.

225. Kageshita T, Temponi M, Kekish U, Chen ZJ, Mittelman A, Matsui M, Ferrone S. Active specific and passive immunotherapy of melanoma: Clinical and experimental investigations with murine monoclonal antibodies. In: "Human Melanoma. From Basic Research to Clinical Application", (Ferrone S, ed.). Springer-Verlag, Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong, pp. 475-496, 1990.

226. Kageshita T, Yamada M, Hirai S, Yoshii A, Kimura T, Arao T, Ferrone S. Differential expression of HMW-MAA in primary and metastatic ALM lesions. In: "Biological Agents in the Treatment of Cancer", (Hersey P, ed.), Newcastle, Australia, pp. 280-291, 1990.

227. Norton FL, Shuey S, Morton DL, Mittelman A, Ferrone S, Mitchell MS, McClay E, Kohler H. Response to anti-idiotype in SCID mice reconstituted with lymphoid cells from melanoma patients. In: "Cellular Immunity and the Immunotherapy of Cancer" UCLA Symposia on Molecular and Cellular Biology, (Lotze MT, Finn OJ, eds.) New Series, Wiley-Liss, Inc. New York, NY, Vol. 135, pp. 361-369, 1990.

228. Ruiter DJ, van Muijen GNP, van Nouhuys H, Ferrone S. Immunopathology of melanoma with monoclonal antibodies. In: "Human Melanoma. From Basic Research to Clinical Application", (Ferrone S, ed.). Springer-Verlag, Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong, pp. 253-277, 1990.

229. Ferrone S. Melanoma diagnosis and therapy: New strategies with monoclonal antibodies. The Melanoma Letter, 9:1-2, 1991. PMID: not available

230. Ferrone S. Active specific immunotherapy with murine anti-idiotypic monoclonal antibodies of the high molecular weight-melanoma-associated antigen system. In: "Cutaneous Melanoma" (Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, eds.), J. B. Lippincott Company, Philadelphia, PA., pp. 552-559, 1991.

231. Graf LH Jr, Ferrone S. Molecular genetic analyses of functional melanoma-associated antigens. In: "Hereditary Malignant Melanoma" (Lynch HT, Fusaro RM, eds.), CRC Press Inc., Boca Raton, FL., pp. 87-96, 1991.

232. Houghton AN, Herlyn M, Ferrone S. Melanoma antigens. In: "Cutaneous Melanoma" (Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, eds.), J. B. Lippincott Company, Philadelphia, PA., pp. 131-144, 1991.

233. Mariani SM, Armandola EA, Ferrone S. Diversity in the fine specificity of anti-HLA-DR monoclonal antibodies elicited with syngeneic antiidiotypic monoclonal antibodies. Transplant Proc, 23:455-456, 1991. PMID: 1990583

234. Moolenaar A, Bruijn JA, Schrama E, Ferrone S, Daha MR, Zwinderman AH, Hoedemaeker PJ, van Es LA, van der Woude FJ. T-cell receptors and ICAM-1 expression in renal allografts during rejection. Transpl Int, 4:140-145, 1991. PMID: 1958278

235. Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S. MHC antigens in human melanomas. Semin Cancer Biol, 2:35-45, 1991. PMID: 1912517

236. Wang ZG, Cao Y, D'Urso C, Houghton AN, Ferrone S. Molecular abnormalities in the expression of HLA Class I-antigens by melanoma cells. Int J Cancer, 6:101-105, 1991. PMID: 2066175

237. Chen ZJ, Yang H, Liu CC, Mittelman A, Ferrone S. Association between induction of anti high molecular weight-melanoma associated antigen (HMW-MAA) immunity with mouse antiidiotypic monoclonal antibody (MoAb) MK2-23 and prolongation of survival in patients with melanoma. Pigment Cell Res, 2:113-122, 1992. PMID: 1409413

238. Cozzi E, Ferrone S. Immunotherapeutic approaches with monoclonal antibodies to immunological diseases. Rec Progr Med, 83:528-533, 1992. PMID: 1439123

239. D'Oro U, Di Rosa F, Ruggiero G, Racioppi L, Acquaviva A, Chianca R, Ferrone S, Fontana S, Zappacosta S. MHC class II molecules transduce activation signals in human T blasts. In: "HLA 1991. Proc. 11th Intl. Histocompat. Workshop Conf.", (Tsuji K, Aizawa M, Sasazuki T, eds.), Oxford University Press, Oxford, New York and Tokyo, pp. 632-635, 1992.

240. Ferrone S, Turco MC, Alfinito F, De Felice M, Tassone P, De Lorenzo F, Venuta S. Regulatory role of HLA Class I antigens in thymocyte and leukaemic T-cell proliferation. In: "Molecular Biology of Haematopoiesis," Vol. 2, Proc. Int. Conf. Molec. Biol. Haemat., Univ. Innsbruck/N.Y. Med. College, Innsbruck, Austria, 14-18, July, 1991, (Abraham NG, Konwalinka G, Marks P, Sachs L, Tavassoli M, eds.), Intercept Ltd., Andover, UK, pp. 649-660, 1992.

241. Ferrone S, Yamamura M, Grosse-Wilde H, Pouletty P. Summary of the serum-soluble HLA class I antigen component. In: "HLA 1991. Proc. 11th Intl. Histocompat. Workshop Conf.", Vol. 2. (Tsuji K, Aizawa M, Sasazuki T, eds.), Oxford University Press, Oxford, New York and Tokyo, pp. 1057-1061, 1992.

242. Kageshita T, Yamada M, Arao T, Ferrone S. Expression of high molecular weight-melanoma associated antigen (HMW-MAA) in primary ALM lesions is associated with a poor prognosis. Pigment Cell Res, 2:132-135, 1992. PMID: 1409414

243. Sakaguchi K, Koide N, Takenami T, Matsushima H, Takabatake H, Ferrone S, Tsuji T. Soluble HLA class I antigens in sera of patients with chronic hepatitis. Gastroenterol Jpn, 27:206-211, 1992. PMID: 1577226

244. Shinji T, Ferrone S. Molecular basis of the immunological similarity of the anti-HLA-DQ3 monoclonal antibody (mAb) KS13 and of the syngeneic anti-HLA-DQ3 anti-anti-idiotypic mAb S2B154. In: "HLA 1991. Proc. 11th Intl.

Histocompat. Workshop Conf.", Vol. 2, (Tsuji K, Aizawa M, Sasazuki T, eds.), Oxford University Press, Oxford, New York and Tokyo, pp. 417-419, 1992.

245. Tanabe M, Sekimata M, Ferrone S, Takiguchi M. Structure and functional characterization of monoclonal antibodies recognizing monomorphic determinants on the alpha 3 domain of HLA class I molecules. In: "HLA 1991. Proc. 11th Intl. Histocompat. Workshop Conf.", Vol. 2, (Tsuji K, Aizawa M, Sasazuki T, eds.), Oxford University Press, Oxford, New York and Tokyo, pp. 391-394, 1992.

246. Temponi M, Kekish UM, Wang Z, Ferrone S. Reactivity of monoclonal antibody TP25.99 with a determinant shared by β2-microglobulin (β2m)-associated HLA-A, -B, and -C heavy chains and β2m-free HLA-B and -C heavy chains. In: "HLA 1991. Proc. 11th Intl. Histocompat. Workshop Conf.", Vol. 2, (Tsuji K, Aizawa M, Sasazuki T, eds.), Oxford University Press, Oxford, New York and Tokyo, pp. 395-397, 1992.

247. Chen ZJ, Ferrone S. Comparison of the binding parameters to melanoma cells of antihuman high molecular weight-melanoma associated antigen (HMW-MAA) monoclonal antibodies (mAb) and syngeneic anti-anti-idiotypic (anti-anti-id) mAb. Ann NY Acad Sci, 690:398-401, 1993. PMID: 8368768

248. Ferrone S, Chen ZJ, Liu CC, Hirai S, Kageshita T, Mittelman A. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma. Pharmacol Ther, 57:259-290, 1993. PMID: 8361995

249. Ferrone S, Kageshita T, Hirai S. Active specific immunotherapy of malignant melanoma with anti-idiotypic monoclonal antibodies. J Dermatol, 20:533-539, 1993. PMID: 8227707

250. Gattoni-Celli S, Byers RH, Calorini L, Ferrone S. Organ-specific metastases in melanoma: experimental animal models. Pigment Cell Res, 6:381-384, 1993. PMID: 8146087

251. Gattoni-Celli S, Calorini L, Byers RH, Etoh T, Wang Z, Ferrone S. Abnormalities in HLA Class I antigen expression by melanoma cells: structural characterization and functional implications. J Invest Dermatol, 100:226S-230S, 1993. PMID: 8433012

252. Gattoni-Celli S, Calorini L, Simile MM, Ferrone S. Modulation by MHC Class I antigens of the biology of melanoma cells. Non-immunological mechanisms. Melanoma Res, 3:285-289, 1993. PMID: 8219762

253. Mariani SM, Armandola EA, Ferrone S. Anti-idiotypic antibodies in the HLA system. In: "The HLA System in Clinical Transplantation. Basic Concepts and Importance", (Solheim BG, Ferrone S, Moller E, eds.), Springer-Verlag, Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong, Barcelona, pp. 317-324, 1993.

254. Ferrone S. Melanoma, immune surveillance, and immunotherapy. J Clin Invest, 93:1351-1352, 1994. PMID: 8163637

255. Shoenfeld Y, Amital H, Ferrone S, Kennedy RC. Anti-idiotypes and their application under autoimmune, neoplastic, and infectious conditions. Int Arch Allergy Immunol, 105:211-223, 1994. PMID: 7920023

256. Ferrone S, Chu TM, Hellström I, Hellström KE. Tumor antigens recognized by monoclonal antibodies. In: "Biologic Therapy of Cancer", (DeVita VT Jr, Hellman S, Rosenberg SA, eds.), J.B. Lippincott Company, Philadelphia, pp. 77-86, 1995.

257. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today, 16:487-494, 1995. PMID: 7576053

258. Mittelman A, Wang X, Matsumoto K, Ferrone S. Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma, 14:175-181, 1995. PMID: 7590776

259. Puppo F, Scudeletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today, 16:124-127, 1995. PMID: 7718084

260. Ferrone S. Active specific immunotherapy of human melanoma with mouse anti-idiotypic (anti-id) monoclonal antibodies (mAb). In: Immunotherapy of Malignant Melanoma. (Leong SPL, ed.) R.G. Landes Company, pp. 73-95, 1996.

261. Hamby CV, Kageshita T, Wang Z, Liang B, Temponi M, Ferrone S. Analysis of αv/β3 integrin expression by cultured human melanoma cells. In: Melanogenesis and Malignant Melanoma: Biochemistry, Cell Biology, Molecular Biology, Pathophysiology, Diagnosis and Treatment. (Hori Y, Hearing VJ, Nakayama J, eds.) Elsevier Science, B.V. pp. 185-193, 1996.

262. Hicklin DJ, Kageshita T, Dellaratta DV, Boccaletti V, Ferrone S. Defects in HLA Class I antigen presentation machinery in melanoma cells. In: Immunology of Human Melanoma. Tumor-Host Interaction and Immunotherapy. (Maio M, ed.), IOS Press, Amsterdam, Oxford, Tokyo, Washington, DC, pp. 95-111, 1996.

263. Matsumoto K, Saida T, Ferrone S. Human HMW-MAA mimicry by anti-id mAb MK2-23 - immunogenicity in syngeneic hosts of F (ab1)2 fragments and chimeric antibody. In: Melanogenesis and Malignant Melanoma: Biochemistry, Cell Biology, Molecular Biology, Pathophysiology, Diagnosis and Treatment. (Hori Y, Hearing VJ, Nakayama J, eds.) Elsevier Science, B.V. pp. 111-118, 1996.

264. Moroi Y, Wang X, Mittelman A, Ferrone S. Active specific immunotherapy of melanoma with anti-id mAb MK2-23: clinical and experimental investigations. In: Melanogenesis and Malignant Melanoma: Biochemistry, Cell Biology, Molecular Biology, Pathophysiology, Diagnosis and Treatment. (Hori Y, Hearing VJ, Nakayama J, eds.) Elsevier Science, B.V. pp. 99-110, 1996.

265. Puppo F, Brenci S, Ghio M, Bignardi D, Contini P, Bacigalupo A, Van Lint MT, Filaci G, Scudeletti M, Ferrone S, Indiveri F. Monitoring of serum HLA Class I antigen levels in allogeneic bone marrow transplantation. In: Molecular Biology of Hematopoiesis 5. (Abraham NG, Asano S, Brittinger G, Maestroni GJM, Shadduck RK, eds.) Plenum Press, pp. 101-105, 1996.

266. Garrido F, Cabrera T, Accolla RS, Bensa JC, Bodmer W, Dohr G, Drouet M, Fauchet R, Ferrara GB, Ferrone S, Giacomini P, Kageshita T, Koopman L, Maio M, Marincola M, Mazzilli C, Morel PA, Murray A, Papasteriades CRH, Salvaneschi L, Stern PL, Ziegler A. HLA and cancer: 12th International Histocompatibility Workshop study. In: Genetic Diversity of HLA. Functional and Medical Implication. Proc. Twelfth International Histocompatibility Workshop and Conference. Vol. II. (Charron D, ed.), EDK, Sevres, France, pp. 445-452, 1997.

267. Hicklin DJ, Kageshita T, Dellaratta D, Ferrone S. Transporter associated with antigen processing (TAP) downregulation in human melanoma cells. In: Genetic Diversity of HLA. Functional and Medical Implication. Proc. Twelfth International Histocompatibility Workshop and Conference. Vol. II. (Charron D, ed.), EDK, Sevres, France, pp. 742-744, 1997.

268. Kageshita T, Hirai S, Ono T, Ferrone S. Comparison of the reactivity of frozen and formalin-fixed, paraffin-embedded sections of melanoma lesions with anti-HLA class I mAb. In: Genetic Diversity of HLA. Functional and Medical Implication. Proc. Twelfth International Histocompatibility Workshop and Conference. Vol. II. (Charron D, ed.), EDK, Sevres, France, pp. 737-739, 1997.

269. Puppo F, Indiveri F, Scudeletti M, Ferrone S. Soluble HLA antigens: new roles and uses. Immunol Today, 18:154-155, 1997. PMID: 9136450

270. Seliger B, Maeurer MJ, Ferrone S. TAP off-tumors on. Immunol Today, 18:292-299, 1997. PMID: 9190116 271. Wang X, Desai S, Noronha EJ, Mittelman A, Ferrone S. The anti-idiotypic approach to active specific

immunotherapy of malignant melanoma. In: Idiotypes in Medicine: Autoimmunity, Infection and Cancer. (Shoenfeld Y, Kennedy R, Ferrone S, eds.) Elsevier, Amsterdam, pp. 523-536, 1997.

272. Abken H, Hombach A, Reinhold U, Ferrone S. Can combined T-cell-and antibody-based immunotherapy outsmart tumor cells? Immunol Today, 19:2-5, 1998. PMID: 9465480

273. Perosa F, Luccarelli G, Neri M, De Pinto V, Ferrone S, Dammacco F. Evaluation of biotinylated cells as a source of antigens for characterization of their molecular profile. Int J Clin Lab Res, 28:246-251, 1998. PMID: 9879499

274. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today, 20:158-160, 1999. PMID: 10203710

275. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today, 5:178-186, 1999. PMID: 10203751

276. Ferrone S, Finerty JF, Jaffee EM, Nabel GJ. How much longer will tumor cells fool the immune system? Immunol Today, 21:70-72, 2000. PMID: 10712001

277. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S. Differential clinical significance of vβ3 expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. Int J Cancer (Pred Oncol), 89:153-159, 2000. PMID: 10754493

278. Kiessling R, Pawelec G, Welsh RM, Barry JD, Ferrone S. Have tumor cells learnt from microorganisms how to fool the immune system? Escape from immune surveillance of tumors and microorganisms: emerging mechanisms and shared strategies. Mol Med Today, 6:344-346, 2000. PMID: 11202973

279. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T- cell recognition: molecular mechanisms and functional significance. Adv Immunol, 74:181-273, 2000. PMID: 10605607

280. Noronha EJ, Wang X, Desai SA, Zhang D, Willers J, Ferrone S. Active specific immunotherapy of malignant diseases – Breaking tolerance to self-antigens with tumor associated antigen mimics. In: Cancer and Autoimmunity. (Shoenfeld Y, Gershwin ME, eds.) Elsevier, Amsterdam, pp. 379-395, 2000.

281. Paul P, Rouas-Freiss N, Moreau P, Cabestre FA, Menier C, Khalil-Daher I, Pangault C, Onno M, Fauchet R, Martinez-Laso J, Morales P, Villena AA, Giacomini P, Natali PG, Frumento G, Ferrara GB, McMaster M, Fisher S, Schust D, Ferrone S, Dausset J, Geraghty D, Carosella ED. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol, 61:1177-1195, 2000. PMID: 11137224

282. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today, 21:455-464, 2000. PMID: 10953098

283. Wang X, Luo W, Ferrone S. Immunotherapy of melanoma: peptide mimics of a human high molecular weight-melanoma associated antigen. Medicina (Mex), 60:48-50, 2000. PMID: 11188931

284. Ferrone S, Wang X. Active specific immunotherapy of malignant melanoma and peptide mimics of the human high-molecular-weight melanoma-associated antigen. Recent Results Cancer Res, 158:231-235, 2001. PMID: 11092050

285. Herlyn M, Ferrone S, Ronai Z, Finerty J, Pelroy R, Mohla S. Meeting Report: Melanoma Biology and Progression. Cancer Res, 61:4642-4643, 2001. PMID: 11389102

286. Wang X, Luo W, Foon KA, Ferrone S. Tumor associated antigen (TAA) mimicry and immunotherapy of malignant diseases: from anti-idiotypic antibodies to peptide mimics. Cancer Chemother Biol Response Modif, 19:309-326, 2001. PMID: 11686020

287. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine, 20(Suppl 4):A40-45, 2002. PMID: 12477427

288. Ferrone S. Changes in serum ganglioside and antibody levels in soft tissue sarcoma: are they the cause or the effect of tumor progression? Cancer J, 8:369-370, 2002. PMID: 12416893

289. Hicklin DJ, Ferrone S. HLA class I antigen loss in cancer. Sci Med, 8:86-95, 2002. 290. Noronha EJ, Wang X, Ferrone S. Isolation of human tumor-associated cell surface antigen-binding scFvs.

Methods Mol Biol, 178:227-233, 2002. PMID: 11968492 291. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant

cells. Semin Cancer Biol, 12:3-13, 2002. PMID: 11926409 292. Speiser DE, Ferrone S. The immunobiology of malignant melanoma. In: Immunology for Surgeons (Zbar AP,

Guillou PJ, Bland KI, Syrigos KN, eds.) Springer-Verlag, London, pp. 343-363, 2002. 293. Campoli M, Chang CC, Wang X, Ferrone S. HLA class I antigen-processing machinery and HLA class I antigen-

derived peptide-complex defects in tumor-cell escape. In: Cancer immunotherapy at the crossroads: how tumors evade immunity and what can be done. (Finke JH, Bukowski RM, eds.), Humana Press, Totowa, NJ, pp. 3-34, 2003.

294. Chang CC, Campoli M, Ferrone S. HLA class I defects in malignant lesions: what have we learned? Keio J Med, 52: 220-229, 2003. PMID: 14748474

295. Chang CC, Ferrone S. HLA-G in melanoma: can the current controversies be solved? Semin Cancer Biol, 13:361-369, 2003. PMID: 14708716

296. Hicklin DJ, Schrier PI, Griffioen M, Ferrone S. HLA class I antigen downregulation in malignant melanoma. In: Mechanisms of Tumor Escape from the Immune Response, (Ochoa, A.C., ed.), Taylor and Francis, England, pp.18-45, 2003.

297. Ko EC, Wang X, Ferrone S. Immunotherapy of malignant diseases: challenges and strategies. Int Arch Allergy Immunol, 132:294-309, 2003. PMID: 14707461

298. Marincola FM, Ferrone S. Immunotherapy of melanoma: the good news, the bad ones, and what to do next. Semin Cancer Biol, 13:387-389, 2003. PMID: 15001156

299. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol, 24:335-342, 2003. PMID: 12810110

300. Seliger B, Abken H, Ferrone S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol, 24:82-87, 2003. PMID: 12547505

301. Campoli M, Ferrone S. T-cell based immunotherapy of melanoma: what have we learned and how can we improve? Expert Rev Vaccines, 3:171-187, 2004. PMID: 15056043

302. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol, 24:267-296, 2004. PMID: 15588226

303. Campoli M, Chang CC, Oldford SA, Edgecombe AD, Drover S, Ferrone S. HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanism and clinical implications. “Immunology of Breast Cancer”, in “Breast

Disease” series. Wei and D.Lopez, (eds) IOS press, Amsterdam, The Netherlands, 20:105-126, 2004.

304. Chang CC, Campoli M, Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol, 16:644-650, 2004. PMID: 15342012

305. Chang CC, Campoli M, Luo W, Zhao W, Zaenker KS, Ferrone S. Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen. Potential role of nonimmunological mechanisms. Ann NY Acad Sci, 1028:340-350, 2004. PMID: 15650259

306. Ferrone S. Immunotherapy dispenses with tumor antigens. Nat Biotechnol, 22:1096-1098, 2004. PMID: 15340476

307. Mankoff SP, Brander C, Ferrone S, Marincola F. Lost in translation: obstacles to translational medicine. J Transl Med, 14:1-5, 2004. PMCID: PMC420261

308. Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, Cocco C, Ferrone S, Pistoia V. Immunogenicity of human neuroblastoma. Ann NY Acad Sci, 1028:1-12, 2004. PMID: 15650233

309. Campoli M, Ferrone S. Tumor-induced immune suppression and immune escape: mechanisms and impact on the outcome of immunotherapy of malignant diseases. In: Immunotherapy of cancer. M.L. Disis (ed.) Humana Press, Totowa, NJ., pp.263-284, 2005.

310. Campoli M, Ferrone S, Zea AH, Rodriquez PC, Ochoa AC. Mechanisms of tumor evasion. Cancer Treat Res, 123:61-88, 2005. PMID: 16211866

311. Chang CC, Campoli M, Ferrone S. Classical and non-classical HLA class I antigen and NK cell activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res, 93:189-234, 2005. PMID: 15797448

312. Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res, 33:113-133, 2005. PMID: 16234579

313. Ferrone S, Sconocchia G. A clinically relevant mouse model of human multiple myeloma? Blood, 106:388-389, 2005. PMID: not available

314. Kawano K, Ferrone S, Ioannides C. Functional Idiotopes: tumor antigen-directed expression of CD8+ T-cell epitopes nested in unique NH2-terminal VH sequence of antiidiotypic antibodies? Cancer Res, 65:6001-6004, 2005. PMID: 16024597

315. Luo W, Hsu JC, Kieber-Emmons T, Wang X, Ferrone S. Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases. Cancer Chemother Biol Response Modif, 22:769-787, 2005. PMID: 16110640

316. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res, 66:10139-10144, 2005. PMID: 16287995

317. Whiteside TL, Campoli M, Ferrone S. Tumor-induced suppression and immune escape: mechanisms and possible solutions. In: Analyzing T cell responses. How to analyze cellular immune responses against tumor associated antigens. (Nagorsen, D. and Marincola, F.M., eds.), Springer Press, Dordrecht. The Netherlands, pp. 43-81, 2005.

318. Bangia N, Ferrone S. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes? Immunol Invest, 35:485-503, 2006. PMID: 16916763

319. Brander C, Ferrone S, Marincola FM. Rewarding patient-directed research: excellence in translational medicine award. J Trans Med, 4:19-21, 2006. PMCID: PMC1468429

320. Campoli M, Ferrone S. A fresh look at an old story: revisiting HLA class II antigen expression by melanoma cells. Expert Rev Dermatol, 1:805-823, 2006. PMID: not available

321. Chang CC, Ferrone S. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Semin Cancer Biol, 16:383-392, 2006. PMID: 16931041

322. Ferris R, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen processing machinery in head and neck cancer. Clin Cancer Res, 12:3890-3895, 2006. PMID: 16818683

323. Ferrone S, Ko E. Collaboration is required for successful immunotherapy. Blood, 107:3025-3026, 2006. 324. Reynolds SR, Ferrone S, Bystryn JC. Response to: Circulating tumor cells and detection of melanoma-associated

antigen HMW-MAA in the serum of melanoma patients. J Invest Dermatol, 126:916, 2006. 325. Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral

transformation. Int J Cancer, 118:129-138, 2006. PMID: 16003759 326. Slingluff CL Jr, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res, 12:2342s-2345s,

2006. PMID: 16609056 327. Campoli M., Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27, 5869-5885, 2008.

328. Chang CC, Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother, 56:227-236, 2007. PMID: 16783578

329. Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin Am, 16:755-774, 2007. PMID: 18022543

330. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol, 17:469-479, 2007. PMCID: PMC2200630

331. Seliger B, Ferrone S. HLA class I antigen abnormalities in tumors. In: General Principles of Tumor Immunology. (Kaufman, H., and Wolchok, J., eds.) Springer Science, pp. 123-144, 2007.

332. Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med, 14:550-559, 2008. PMCID: PMC2726789

333. Campoli M, Ferrone S. Immunotherapy of malignant disease: the coming age of therapeutic monoclonal antibodies. Cancer: Principles & Practice of Oncology. (V. DeVita, S. Hellman, and S. Rosenberg Ed.) Lippincott Williams and Wilkins, New York, NY, 2009; 23:1-18.

334. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet, 373:1033-1040, 2009. PMCID: PMC2677705

335. Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Tycko B, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI 1st International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft versus tumor effects: state of the science. Biol Blood Marrow Transplant, 16:709-728, 2010. PMID: 20227509. PMCID: in process (NIHMS395047)

336. Campoli M, Ferris R, Ferrone S, Wang X. Immunotherapy of malignant disease with tumor antigen (TA)-specific monoclonal antibodies: does its therapeutic efficacy require cooperation with TA-specific CTL? Clin Cancer Res, 16:11-20, 2010. PMCID: PMC2802861

337. Campoli M, Ferrone S, Wang X. Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Can Res, 109:73-121, 2010. PMID: 21070915. PMCID: not available

338. Ferris RL, Ferrone S. Response to the letter to the editors by Ottaiano, et al.: "Cetuximab-dependent ADCC in cancer: dream or reality?" Cancer Immunol Immunother, 59:1609-1610, 2010. PMID: 20589374. PMCID: not available

339. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol, 28:4390-4399, 2010. PMCID: PMC2954137

340. Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck, 32:1412-21, 2010. PMCID: PMC2946515

341. Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favoino E, Koya Y, Campoli M, McCarthy JB, DeLeo A, Ferrone S. CSPG4 in cancer: multiple roles. Curr Mol Med, 10:419-429, 2010. PMID: 20455858. PMCID: Not available

342. Amiot L, Ferrone S, Grosse-Wilde H, and Seliger B. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci, 68:417-431, 2011. PMID: 21063893. PMCID: PMC3426238

343. Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA”, Naples, December 6th-7th 2010. J Transl Med, 9:32, 2011. PMCID: PMC3078100

344. Ferrone S. Hidden immunotherapy targets challenge dogma. Sci Transl Med, 3:99ps38, 2011. PMID: 21900591. PMC3426280

345. Whiteside T, Ferrone S. For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res, 18:2417-2419, 2012. PMID: 22442060. PMCID: PMC3426232

346. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin, 62(5):309-335, 2012. PMID: 22576456. PMCID: PMC3445708

347. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stronek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the “Melanoma Research: A Bridge from Naples to the World”,






http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ferris%20RL%22%5BAuthor%5D











Napoli, December 5th-6th, 2011. J Transl Med, 10:83, 2012. PMCID: PMC3390271 348. Fauci JM, Straughn JM Jr, Ferrone S, Buchsbaum DJ. A review of B7-H3 and B7-H4 immune molecules and their

role in ovarian cancer. Gynecol Oncol, 127:420-425, 2012. PMID: 22910694. PMCID: not available. 349. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit NK cell

functions—letter. Cancer Res, 72:5428-5429, 2012. PMID: 23047870. PMCID: no available. 350. Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabro L, Cascinelli N, Cesano A, Del Vecchio M,

Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research. Meeting report from the "melanoma bridge. Napoli, december 2nd-4th 2012". J Transl Med. 11:137, 2013. PMID: 23731854. PMCID: 3681569.

351. Ferrone S. A tribute to Edgardo Carosella on the occasion of the 6th International Conference on HLA-G held in Paris, France, July 9-11, 2012. Hum Immunol. 74:405, 2013. PMID: 23232062.

352. Loustau M, Wiendl H, Ferrone S, Carosella ED. HLA-G 2012 conference: the 15-year milestone update. Tissue Antigens. 81:127-136, 2013. PMID: 23347068.

353. Scarpati GD, Fusciello C, Sabbatino F, Ferrone S, Caponigro F, Perri F, Carlomagno C, Pepe S. Multidisciplinary approach to patient with malignant melanoma. Anticancer Agents Med Chem. 1;13:887-900, 2013. PMID: 23272971.

354. Wang, Y., Sabbatino, F., Yu, L., Favoino, E., Wang X., Ligorio, M., Ferrone, S., Schwab, J.H., Ferrone C.R. Tumor antigen-specific monoclonal antibody-based immunotherapy, cancer initiating cells and disease recurrence. in Resistance to immunotherapeutic antibodies in cancer. (Bonavida, B. Ed). Springer Science+Business Media, New York. pp. 25-48. 2013.

355. Whiteside TL, Ferrone S. IGKC and prognosis in breast cancer--response to Schmidt. Clin Cancer Res. 19:305, 2013. PMID: 23231949.

356. Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabro L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". Journal of translational medicine. 11:137, 2013. PMID: 23695963.

357. Sabbatino F, Wang Y, Wang X, Ferrone S, Ferrone CR. Emerging BRAF inhibitors for melanoma. Expert Opin Emerg Drugs. 18:431-43, 2013. PMID: 24073999.

358. Wang, X, Wang, Y, Sabbatino F, Deleo, A.B., Ferrone, S. Role of HLA class I antigen, antigen processing machinery and tumor antigen levels in T cell recognition of cancer initiating cells. Hum Immunol. Accepted pending revisions.

359. Wang Y, Sabbatino F, Wang X, Ferrone S. Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma. Methods Mol Biol. 1102:523-35, 2014. PMID: 24258997.

360. Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther. 7:203-209, 2014. PMID: 24570590.

361. Sabbatino F, Wang Y, Wang X, Schwab JH, Ferrone S, Ferrone CR. Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer initiating cells in solid tumors. Semin Oncol. 41:685-99, 2014. PMID: 25440613.

362. Ferrone S. Therapeutic monoclonal antibodies: introduction. Semin Oncol. 41:556-8, 2014. PMID: 25440602 363. Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S,

Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med. 13:374, 2015. PMID: 26619946

364. Wang Y, Geldres C, Ferrone S, Dotti G. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. Expert Opin Ther Targets. 19:1339-50, 2015. PMID: 26190756.

365. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 14:313, 2016. PMID: 27846884.

366. Concha-Benavente F, Srivastava R, Ferrone S, Ferris RL. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. Oral Oncol. 58:52-8, 2016. PMID: 27264839.

367. Maio M, Bertocci E, Fazio C, Chiarucci C, Cutaia O, Scala E, Gicobini G, Lofiego MF, Fonsatti E, Maccalli C, Nicolay HJ, Parmiani G, NIBIT. “Cancer Bio-Immunotherapy in Siena”: Thirteenth meeting of the netwrok italiano per la bioterapia dei tumori (NIBIT), Siena, Italy, October 8-10, 2015. Cancer Immunol Immunother. 63:1423-1431, 2016. PMID: 27619513

368. Caratelli S, Sconocchia T, Arriga R, Coppola A, Lanzilli G, Lauro D, Venditti A, Del Principe MI, Buccisano F, Maurillo L, Ferrone S, Sconocchia G. FCy chimeric receptor-engineered T Cells: methodology, advantages, limitations and clinical relevance. Front Immunol. 8:457, 2017. PMID: 28496440

369. Maccalli C, Parmiani G, Ferrone S. Immunomodulating and immunoresistance properties of cancer-initiating cells: implications for the clinical success of immunotherapy. Immunol Invest. 46:221-238, 2017. PMID:28287848

370. Seliger B, Kloor M, Ferrone S. HLA class II antigen-processing pathway in tumors: molecular defects and clinical relevance. Oncoimmunology 6:2, 2017. PMID 28344859

BOOKS EDITED 1. Ferrone, S., Curtoni, E. and Gorini, S. HLA antigens in clinical medicine and biology. Garland STPM Press, New

York & London, 1979. 2. Ferrone, S., Gorini, S., Herberman, R.B. and Reisfeld, R.A. Current trends in tumor immunology. Garland STPM

Press, New York & London, 1979. 3. Reisfeld, R.A. and Ferrone, S. Current trends in histocompatibility. Plenum Press, New York & London, 1981. 4. Reisfeld, R.A. and Ferrone, S. Melanoma antigens and antibodies. Plenum Press, New York & London, 1981. 5. Ferrone, S. and David, C. Ia antigens. CRC Press, Inc., Boca Raton, Florida, 1982. 6. Ferrone, S. and Solheim, B. HLA typing: Methodology and clinical aspects. CRC Press, Inc. Boca Raton, Florida,

1982. 7. Ruiter, D.J., Weevaart, K. and Ferrone, S. Cutaneous melanoma and precursors lesions. Wijhoff, The Hague,

1984. 8. Koprowski, H., Ferrone, S. and Albertini, A. Biotechnology in Diagnostics. Elseviers Science Publishers,

Amsterdam - New York - Oxford, 1985. 9. Ferrone, S. and Dierich, M.P. The Handbook of Monoclonal Antibodies. Applications in Biology and Medicine:

Noyes Publications, Park Ridge, N.J., 1985. 10. Solheim, B.G., Möller, E. and Ferrone, S. HLA class II antigens. A comprehensive review of structure and

function. Springer-Verlag, Berlin, Heidelberg, New York, Tokyo, 1986. 11. Ferrone, S. Human melanoma. From basic research to clinical application. Springer-Verlag, Berlin, Heidelberg,

New York, London, Paris, Tokyo, Hong Kong, 1990. 12. Solheim, B.G., Ferrone, S. and Möller, E. The HLA system in clinical transplantation. Basic Concepts and

Importance. Springer-Verlag, Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong, Barcelona and Budapest, 1993.

13. Bystryn, J.C., Ferrone, S. and Livingston, P. Specific immunotherapy of cancer with vaccines. Ann. NY Acad. Sci. 690, 1-401, 1993.

14. Ferrone, S. (Guest Ed.). The Melanoma Letter. The Skin Cancer Foundation. New York, NY Vol. 13:3, 1995. 15. Shoenfeld, Y., Kennedy, R.C. and Ferrone, S. Idiotypes in Medicine: Autoimmunity, Infection and Cancer. Elsevier,

Amsterdam, The Netherlands, 1997. 16. Ferrone, S. (Guest Ed.). Tumor escape mechanisms. Semin. Cancer Biol: 12:1-86, 2002.

17. Ferrone, S. and Marincola, F.M. (Guest Eds.). Immunotherapy of melanoma. Semin. Cancer Biol: 13:387-480, 2003.

18. Bankert, R.B. and Ferrone, S. (Guest Eds.). Tumor microenvironments and immunoregulatory networks. Immunol. Invest. 35:251-503, 2006.

19. Ferrone, S. (Guest Ed.). Tumor antigen-specific monoclonal antibody-based immunotherapy. Semin Oncol. 2014. 41, .

Narrative Report

I am a tumor immunologist who has applied and is applying basic science to address clinically relevant questions. I have focused my research program on two distinct, but complementary areas. One has characterized at the cellular and molecular level the escape mechanisms utilized by tumor cells to avoid recognition and destruction by the host’s immune system. I have used this information to design strategies to counteract the immune escape mechanisms utilized by tumor cells. The other research area has aimed at developing and implementing combinatorial tumor antigen-specific antibody-based immunotherapeutic strategies which target both differentiated tumor cells and cancer initiating cells. Both research areas have benefitted from a large panel of monoclonal antibodies (some of which with a unique specificity) which I have developed over the years. Furthermore throughout my career I have trained more than 40 PhD graduate students and post-doctoral fellows; most of them have established a successful independent research program in Academic Institutions. Lastly for at least 30 years I have served on Study Sections of NIH, VA, ACS and private Foundations either on a permanent basis or as an ad hoc reviewer. For many years I have spent 50% of my time in research, 20% in teaching and 30% in administration. More recently I have increased my time in research to 70% and reduced my time in administration to 10%.

In research I have characterized the molecular basis of escape mechanisms utilized by tumor cells to escape destruction. I have especially emphasized the role in the clinical course of malignant diseases of structural and functional abnormalities of HLA class I antigen processing machinery components frequently present in malignant cells and their negative impact on the response to T cell-based immunotherapy. My studies have greatly benefited from a unique panel of monoclonal antibodies I have developed over the years. In addition utilizing the hybridoma technology I have identified several clinically relevant tumor antigens. I have characterized their structural profile, their role in the biology of tumor cells and their usefulness as targets of antibody-based immunotherapy. Two of the identified tumor antigens, CSPG4 and Grp94, have been found to meet the criteria to be utilized as targets of antibody-based immunotherapy, because of their high expression on malignant cells, including cancer initiating cells in various types of malignant diseases, and their restricted distribution in normal tissues. Utilizing CSPG4- and Grp94-specific monoclonal antibodies, I have developed combinatorial strategies which are effective in eliminating not only differentiated cancer cells, but also cancer initiating cells in malignancies such as melanoma, triple negative breast cancer and pancreatic ductal adenocarcinoma. By collaborating with pharmaceutical companies and biotechnology companies I am in the process of moving to a clinical setting the unique monoclonal antibodies I have developed.

I am continuing to mentor medical students and postdoctoral fellows. I train them not only in designing a sound research project and performing well controlled experiments, but also in writing competitive fellowship and grant applications, in presenting seminars in a clear and crisp way and in teaching.

curriculum vitae - a.i.l.m.a.g · 2017-08-22 · curriculum vitae date prepared: march 27, 2017...

Documents